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CHAPTER 1 
INTRODUCTION 
Monoclonal B cell proliferative disorders, when at the differentiation 
stage of a plasma cell, are often able to produce large quantities of an 
inununoglobulin (Ig) product. These monoclonal or homogenous Ig 
components (H-Ig), also called paraproteins or M-components, become 
detectable in the serum (section 1.1). The monoclonal bands in the ganuna-
region of the serum protein spectrum has given the name to these B-cell 
proliferative disorders: monoclonal ganunopathies (MO) [1]. This 
heterogenous group of serologically diagnosed disorders include a wide 
variety of benign and malignant B-cell proliferations (section 1.2). 
1.1 Detection of H-Ig components 
Routine assessment of serum protein spectrum abnormalities in 
hospital and research laboratories is based on electrophoretic techniques. As 
early as in 1939, Tiselius and Kabat used free boundary electrophoresis for 
the detection of H-Ig [2]. A major improvement of this technique was the 
agar-gel electrophoresis on microscope slides, developed by Wieme in 1959 
[3,4]. The increased resolving power of his technique enabled him, for the 
first time, to separate normal human serum into at least 9 fractions: one pre-
albumin, one albumin, one ",,-globulin, two "'2-globulins, three Il-globulins 
and a continuous spectrum of or-globulins. In a slightly modified form, this 
technique has been used in this thesis to screen for the presence of H-Ig in the 
sera. It has a detection limit for H-Ig of about 1001'g/ml. Even more sensitive 
techniques are needed in experimental settings. Usually a protein blotting 
technique is used, called immunoblotting. The procedure starts with the agar-
gel electrophoresis followed by a protein transfer step to a membrane carrier. 
The Ig spectrum is further analyzed on this membrane, using specific 
antibodies or antigens. The detection limit of this technique can be as low as 
0.5 to 1 I'g/ml [5]. 
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1.2 Classification of monoclonal ganllnopathies 
Several attempts have been made to classify the MG. Based on their 
possible origin and/or pathogenesis, Radl [6,7] described four major 
categories of MG (see chapter 2.1, table I). 
CategOlY 1: B-cell malignancies [8]. These include multiple myeloma (MM) , 
Waldenstrom's macroglobulinaemia (WM), (extra-)medullary plasmacytoma, 
light chain disease, heavy chain disease, B-cell chronic lymphocytic leukemia 
(B-CLL) and lymphoma. These disorders are frequently accompanied by the 
occurrence of Bence-Jones proteins (Ig light-chain complexes) in the urine. 
The incidences of these B-cell malignancies increase with age. 
CategOlY 2: B-cell benign tumor. This common B-cell proliferative disorder is 
also known as benign monoclonal gammopathy (BMG) or idiopathic 
paraproteinemia (IP). Like the disorders of the first category, the incidence of 
BMG increases with age. Many authors regard this entity as an early stage in 
the development of myeloma [8,9]. This is understandable from the viewpoint 
that in the early phase of the malignant disease diagnostic parameters may be 
lacking. The single use of the H-Ig level as a tumor marker is than insufficient 
to discriminate between benign and malignant disorders. In this phase it is 
good practice to use the term monoclonal ganlll10pathy of undetermined 
significance (MGUS). Experimental and clinical data, however, show that 
BMG may remain stable during many years without progression to 
malignancy [10-14]. 
CategOlY 3: MG due to immunodeficiency with T-cell / B-cell imbalance. This 
group includes rare primary immunodeficiency syndromes (Wiskott-Aldrich, 
Nezelof, DiGeorge, and SCID) [15], as well as secondary inll11Une 
disturbances due to aging, immunosuppressive treatment [16], viral infections, 
malignancies of the inllnune system other than from B-cell origin [17], or 
carcinomas [18], and the reconstitution phase after bone marrow 
transplantation [19-22]. 
CategOlY 4: MG due to particular antigenic stimulation, as is seen in response 
to certain haptens and polysaccharides, and in some autoimmune disorders. 
Categories 3 and 4 represent generally disorders with low levels of H-Ig that 
are transient in time. This is in contrast to categories I and 2, with high levels 
of persistent H-Ig. 
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1.3 Animal model of age-related monoclonal gannnopathies 
Although a large amount of clinical data is available on MG of 
neoplastic origin (categories 1 and 2), there is still not much known about the 
exact etiology of these B-cell proliferative disorders. The possible relationship 
among the different disorders, the location and the stage in the differentiation 
pathway of the B-cell at the moment of the neoplastic transformation, and the 
causes of this transformation are among the questions that asked for a suitable 
animal model. 
It turned out that not only aging humans developed malignant MG 
and, about a 100 times more frequent, BMG [23-25], but also aging 
laboratory animals: monkeys [26], dogs, rabbits, rats, and mice. A 
particularly useful mouse strain is the C57BLlKaLwRij mouse [27-34]. Aging 
mice of this strain develop spontaneously various monoclonal B-cell 
proliferative disorders, which are indistinguishable from those that occur in 
humans. The vast majority of MG are BMG (about 80%), while about 1 % of 
the mice older than two years develop MM or WM. 
A BMG in these mice usually becomes manifest by an H-Ig in the 
serum that is detectable for at least 6 months and mostly until the death of the 
mouse. The concentration of the H-Ig reflects the size of the plasma cell clone 
in the bone marrow (BM) and the spleen, and is usually less than 4 mg/ml. As 
in the human situation, the concentration of the other Ig in the spectrum is not 
affected and the level of the H-Ig is non-progressive. 
Occasionally, a rapid progressive H-Ig develops in an old C57BL 
mouse, often with concentrations of more than 10 mg/ml. Histopathological 
examination of the bone and BM shows often the typical picture of MM. x-
ray analysis of the skeleton of these mice can even show the typical osteolytic 
bone lesions of MM. 
The first intriguing information from this mouse model came from 
transplantation experiments [35]. After transplantation of BMG clones into 
young syngeneic mice these recipient mice developed the same H-Ig as the 
donor mice. This result indicated that BMG represents an intrinsic B-cell 
abnormality that leads to continued proliferation of the plasma cell clone. 
Within the young recipient mice, the BMG clones maintained their non-
progressive character. However, the engraftment or "take" frequency in 
subsequent transplantations of the same BMG clone decreases, and 
propagation of a BMG clone for more than three or four generations was 
never achieved. This is in sharp contrast with the results of mouse MM and 
WM. Both are continuously transplantable, with a take frequency of 
approximately 100% and a progressive development of a paraproteinemia. The 
latter always caused the marked shortened survival-times of the affected mice. 
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Thus, although BMG, MM, and WM cell clones proliferate after 
transplantation, BMG cells are not immortal, while those of the B-cell 
malignancies are. 
The immortal character of the C57BLlKaLwRij mouse MM and WM 
resulted in a rich myeloma- and macroglobulinemia cell bank with BM cells, 
spleen cells and cells from lymph nodes of the mice that were engrafted with 
earlier generations of the malignant mouse MG. This so-called 5T series of 
mouse B-cell tumors is therefore easily accessible for research purposes. 
1.4 Introduction to the experimental work 
B-cel/ lineages 
The first part of this thesis addresses the question whether B-cell 
lineages are differentially involved in the development of age-related 
monoclonal B-cell proliferative disorders. The T-cell differentiation antigen 
CD5 has been found on B-cells in the peritoneal and thoracal cavities. 
Demonstrated by adoptive transfer experiments, these B-cells comprise a 
separate compartment of self-replenishing B-cells: the B-1 lineage [36-38]. An 
introduction to the B-cell subsets in the peritoneal cavity will be given in 
Chapter 2.1. This short overview of the B-1 cell phenotype and other cell 
characteristics also addresses the question whether the B-1 cells have a 
distinctive role in the development of MG. Although CD5 expression has been 
found on the malignant cells of B-CLL in humans and in certain mouse B-cell 
lymphomas and cell lines [39], no information was available on the lineage 
origin of the more mature B-cell proliferative disorders (BMG, MM, WM). 
Two experimental approaches have been used to investigate the latter question. 
First, a life-long follow-up study of ",K-transgenic Sp6 mice [40] was 
started. In these mice, peripheral B-cells expressed exclusively the transgenic 
IgM of ,,' allotype. Only a small proportion of B-cells showed endogenous "b_ 
allotype expression; these B-cells possessed a B-1 phenotype, were especially 
enriched in the peritoneal cavity, and could not fully reconstitute endogenous 
IgM-positive B-cells in irradiated recipient mice. Therefore it was concluded 
that the B-1 cells in these transgenic mice were the producers of endogenous 
Ig isotypes [41]. Determination of the isotype (and allotype in case of IgM) of 
the H-Ig that developed during aging should give insight into the involvement 
of the B-1 cell lineage in the development of MG. This study is described in 
Chapter 2.2. 
Second, we used IgH allotype-congenic C57BL mouse chimeras in 
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order to be able to evaluate the H-Ig that originated from the B-1 cell lineage 
separately. Lethally irradiated mice were reconstituted with BM cells and IgH 
allotype congenic peritoneal wash cells. The peritoneal cells provided for the 
B-1 cells [42-45]. The H-Ig of aging C57BL mice originating from the B-1 
cell lineage in the peritoneal cavity could be discriminated from the BM 
derived B-2 cell Ig product by allotype difference, and is described in detail in 
Chapter 2.3. 
C/ona! dominance of specific antibody responses 
Inullunization of mice with carbohydrates or certain other antigens 
with a limited number of different antigenic determinants frequently elicits an 
antibody response that shows markedly restricted heterogeneity [46]. Using 
isoelectric focussing (TEF), the specific antibodies can be divided into discrete 
bands, the so-called spectrotypes or clonotypes. This is a sensitive technique 
to show clonality at the protein level [47]. The spectrotype of the highest 
concentration is thus regarded as the dominant clone. Furthermore, recurrent 
spectrotype patterns between individuals might indicate a favourable and 
therefore dominant antibody response. 
Since clonal dominance seems to be a physiological phenomenon in 
antibody responses, the question arises whether a control mechanism is 
present, and if so, does disruption or impairment of this control mechanism 
facilitate the development of even bigger dominant B-cell clones? The Ig 
secreted by these bigger clones might than become detectable in the serum as 
a transient H-Ig or even a persistent one. 
We investigated the effects of age, genetic background (CBA and 
C57BL mouse strains), and impaired T-cell system (neonatal thymectomy) on 
the levels and the heterogeneity of the specific antibody response to 
dinitrophenylated human serum albumin (DNP-HSA). The individual 
parameters have been shown to be involved in the development of MG: 
persistent H-Ig is age-related, and aging C57BL strains are especially sensitive 
to development of MG, whei'eas CBA mice have a low incidence of these B-
cell proliferative disorders (section 1.3). Furthermore, a normally functioning 
T-cell system is essential for the generation of a normal heterogenous Ig 
spectrum [16,48-51]. Whether the idiosyncrasy of an individual to respond to 
an antigen with a restricted set of clonotypes correlates with the tendency to 
develop MG is studied in Chapter 3. 
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imlllunosuppressive treatment and the incidence of MG 
The number of patients that are treated with inmlUnosuppressive drugs 
for a prolonged time increases steadily. This treatment is especially indicated 
after solid organ transplantation and in some autoillUllune disorders. Short 
term evaluation studies have shown a markedly increased incidence of 
Iymphoproliferative disorders, most of them B-ce11 neoplasms associated with 
Epstein-Barr virus (EBV) [52-54]. Terminal differentiation to plasma cells in 
these B-ce11 malignancies is rare, and is only published as case reports 
[reviewed in 55]. Information on the late effects in life-long treated individuals 
is scarce. Preliminary data suggested that the increased frequencies of MM 
and BMG in kidney recipients were more related to the higher age of the 
individual than to the duration of the immunosuppressive treatment [16]. 
In Chapter 4 we report a study of two widely used treatment protocols 
(azathioprine/prednisolone and Cyclosporin A/prednisolone) applied to young 
(4 to 5 months old) and adult (14 months old) C57BLIKaLwRij mice. The aim 
of this study was to investigate the influence of long-term maintenance 
immunosuppressive treatment on the incidence of age-associated monoclonal 
gammopathies: MM, WM, and BMG. Extensive postmortem histopathological 
examination of the mice was required for the definitive diagnosis and the 
evaluation of other pathological effects of the treatment protocols. 
immunoglobulin VH gene sequence analysis of spollfaneous lIIouse MG 
The specificity of an Ig-molecule for an antigen is made up by three 
complementarity-determining regions (CDR) in the variable (V) regions of the 
heavy (H) and light (L) chains. Each B-cell expresses a single and unique 
combination of these CDR that in total forms the Ig repertoire of an 
individual. The V -regions are responsible for binding of the antigen, while the 
constant (C) regions determine the isotype or (sub)c1ass, i.e. K and A light 
chains, and (in the mouse) fl., 0, 'YI, 'Y2a, 'Y2b, 'Y3, E, and a heavy chains. At 
the molecular level, V -regions of the L-chains are encoded by two gene 
segments: the VL (variable) genes and the JL (joining) genes. V-regions of H-
chains are encoded by VII' DH (diversity), and JH genes. The germ line VH and 
V L genes each encode two of the CDR, while the third (CDR3) is generated 
when the forementioned gene segments are rearranged. 
Several mechanisms contribute to the diversity of antibodies, such as 
many different genes of the V-, D-, and J-families, junctional diversity by 
imprecise joining of the individual gene segments and random insertion of 
nucleotides, combination of the H- and L-chains in the complete Ig molecule, 
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and somatic hypermutation. Antigen-driven somatic mutation in the germinal 
centers and subsequent clonal selection results in the production of Ig with 
higher affinity for the antigen [56-61]. 
These mechanisms that generate antibody diversity act in subsequent 
steps of the B-cell differentiation pathway. Thus the presence of somatic 
mutations tells about a fonner encounter of the antigen. Sequence analysis of 
V -regions of MM Ig in humans showed that there were replacement mutations 
clustered in CDR regions in either V H or V L [62-64]. This can be regarded as 
evidence for antigen selection of the corresponding myeloma cell clone. 
Intraclonal variation was not detected in human MM, indicating that the 
malignant plasma cells are no longer able to accumulate further mutations. 
However, a proportion of cases of MGUS (quite often they turn out to be a 
BMG) did show intraclonal variation and therefore these tumor cells may still 
be under the influence of the somatic mutation mechanism [63]. 
In Chapter 5 we report the sequences of Ig V H genes of spontaneously 
developed mouse MM (5T2, 5T7, 5Tl3, 5Tl4, 5T33) and WM (5TlO, 5Tl6) 
lines, and of one biclonal BMG. Their sequences were analyzed in comparison 
with human disease counterparts in order to reveal the role of antigenic 
selection of the precursor cells of MG in the C57BLlKaLwRij mouse model. 
Furthermore, the intraclonal variation of the mouse tumors could be studied. 
Information on these subjects should give insight into whether the mouse MG 
model is equivalent to human age-related MG. 
1.5 Aim of the experimental worl{ 
In Chapter 2 the question is addressed whether the B-1 and B-2 cell 
lineages are differentially involved in the development of age-related 
monoclonal B-cell proliferative disorders. Two experimental approaches have 
been used. First, a life-long follow-up study of !',K-transgenic mice was 
started. B-1 cells in these mice were the producers of endogenous Ig isotypes, 
and therefore MG originating from the B-1 cells produce endogenous Ig. 
Second, we used IgH allotype-congenic C57BL mouse chimeras. The H-Ig of 
aging C57BL mice originating from the B-1 cell lineage in the peritoneal 
cavity could be discriminated from the BM derived B-2 cell Ig product by 
allotype difference. 
In Chapter 3 we investigated the effects of age, genetic background, 
and impaired T-cell system on the levels and the heterogeneity of the specific 
antibody response to dinitrophenylated human serum albumin (DNP-HSA). 
In Chapter 4 we investigated the influence of long-term maintenance 
immunosuppressive treatment on the incidence of age-associated monoclonal 
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gammopathies: MM, WM, and BMG. 
In Chapter 5 we report the sequences of Ig V H genes of spontaneously 
developed mouse MM, WM, and of one biclonal BMG. Their sequences were 
analyzed in order to reveal the role of antigenic selection of the precursor 
cells of MG in the C57BLlKaLwRij mouse model, and to give insight into 
whether the mouse MG model in this respect is equivalent to human age-
related MG. 
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B-CELL LINEAGE INVOLVEMENT IN AGE-RELATED 
MONOCLONAL B-CELL PROLIFERATIVE DISORDERS' 
C. van Al'keI 1.', J. Radl ' 
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2. Department of Immunology and Infectious Diseases, TNO-Prevention alld Health, 
Leiden, The Netherlands. 
SUMMARY 
The B-1 or B-2 lineage ongm of monoclonal B-cell proliferative 
disorders is of interest but calmot easily be studied directly in humans; 
however, this is possible in experimental animal models that became available 
only recently. A short review of the literature relevant to such a study 
involves some recent data on the four major categories of monoclonal 
gammopathies (MG) , on the phenotypes, biological features and on the 
behavior of the two B-cell lineages. Two examples of suitable experimental 
approaches are given. 
INTRODUCTION 
The inmlUne system in aging individuals changes in several aspects. 
Thymus involution, appearance of CD8+ T-cell clones of restricted 
heterogeneity in peripheral blood (PB) [1,2] and, with respect to the B-cell 
system, restriction of inmlUnoglobulin (lg) heterogeneity and appearance of 
monoclonal Ig components (M-lg) in the serum are the most remarkable 
phenomena appearing in the aging immune system [3,4]. To what extent these 
changes reflect a decline in the inullune function is not exactly known, but it 
seems plausible that the increased levels of autoantibodies, higher incidences 
of infections and lymphoid neoplasias in aging individuals are consequences of 
the hampering inunune system. 
* Published in: Aging: Immunol Infect Dis 1994,5:173-183. 
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Recent findings indicated the existence of different B-cell lineages, 
designated B-1 and B-2 cells (reviewed in 5 and 6). In order to understand 
better the mechanisms by which the age-related monoclonal B-eell 
proliferative disorders develop, the cell origin of individual B-cell neoplasias 
became of interest. In this short review, we will focus on age-related 
monoclonal B-cell proliferative disorders and the possible pathogenetic role of 
B-cell subsets. 
B-CELL PROLIFERATIVE DISORDERS: MONOCLONAL GAMMO-
PATIDES 
An antigenic stimulation in healthy individuals initiates the activation 
of several B-cell clones, all specifically reactive to different antigenic 
determinants or epitopes. In this process often a dominance of one or a few B-
cell clones occurs. The homogenous antibody component in the serum, 
produced by such relatively small dominant clones (less than 107 cells) can be 
detected only by very sensitive techniques, such as antigen-specific 
inununoblotting [7]. The sum of these homogenous antibody components 
usually gives a heterogenous (polyclonal) pattern, and no abnormal 
homogenous Ig components are detected by routine laboratory teclmiques. 
However, some autoinunune processes or T-cell independent antigenic 
stimulation on a certain genetic background may lead to a larger clonal 
expansion with a concentration of the monoclonal Ig in the serum of more 
than 0.5 mglml (category 4, Table 1). In these conditions, no intrinsic B- and 
T-cell defects have been detected [3]. 
Some T-cell dysfunctions and inununodeficiencies frequently give rise 
to larger monoclonal B cell expansions. An impaired T-cell regulation seems 
to be typical for aging of the immune system. Iatrogenic inununosuppression 
may cause a comparable T/B cell imbalance and subsequently give rise to a 
high incidence of MO [8]. Furthermore, MO of this category (category 3, 
table 1) can be observed in children and adults with some primary and 
secondary immunodeficiencies [9, lO] and following bone marrow 
transplantation (BMT) [11]. Similar changes may appear within the T-cell 
system. In this respect, two recent findings of the restriction of the 
heterogeneity of the peripheral CD8 + T cell pool in aging mice and humans 
are of special interest [1,2]. MO that develop by these two mechanisms 
represent in general transient proliferative disorders of normal B cells, in 
contrast to the next two categories of autonomous, neoplastic proliferative 
disorders. 
Benign monoclonal ganmlOpathy (BMO) (category 2, table 1) is a 
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monoclonal proliferation of mature plasma cells without malignant 
characteristics of multiple myeloma, with production of a M-Jg of usually less 
than 2.5 mg/ml in man. Genetic susceptibility, T-cell dysfunction and long-
lasting thymus dependent antigenic stimulation, all contribute to the genesis of 
this essentially benign and age-related proliferative disorder [reviewed in 
3,4,12 and 13]. 
Malignant forms of MG are about 100 times less frequent than BMG. 
To this category (category 1, table 1) belong multiple myeloma (MM), 
(extramedullary) plasmacytomas, Waldenstrom's macroglobulinemia and some 
other non-Hodgkin lymphomas, heavy and light chain disease [3,4,15]. B-cell 
tumors, usually without a distinct monoclonal immunoglobulin serum com-
Table 1. Four major categories of monoclonal gauullopathies. 
Category 
1. B-ceJl malignancies a 
2. B-celI benign proliferations a 
3. Immunodeticiency with TIE 
illllllUlle system imbalance 
4. Homogenous antibody response 
a. 
b. 
Condition 
mUltiple myeloma (MM), 
Waldenstrom's macroglobulinemia 
plasmacytoma, lymphoma, B-eLL, 
heavy and light chain disease 
benign monoclonal gammopathy (BMG) 
a. 
b. 
c. 
d. 
primary: Wiskott-Aldrich, Nezelof-, 
D iGeorg e-s ynd roilles 
secondary: 
1. due to aging a 
2. immunosuppressive treatment 
3. immune system malignancies other 
than of B-cell origin 
4. acquired, viral, idiopathic 
reconstitution of the immune system 
after bone marrow transplantation 
(SClD, aplastic anemia) 
early ontogenesis with excessive 
antigenic stimulation 
Due to particular antigenic stimulation 
a. excess stimulation with 
polysaccharides, hap lens 
h. autoimmune disorders 
, Categorics I, 2, and 3bl are age-related (together 90% of all MG). 
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ponent, are leukemias and lymphomas. Within these groups we can distinguish 
a rapid growing and aggressive group of tumors, e.g. B-cell acute 
lymphocytic leukemia (B-ALL) and Burkitt's lymphoma, and more indolent, 
low grade tumor forms, e.g. B-cell chronic lymphocytic leukemia (B-CLL, 
which is the most conmlon B-cell tumor in humans) and follicular lymphomas. 
Animal //lodel of MG 
Animal models have been developed to facilitate the study of B-cell 
neoplasia development in vivo [16-18]. The aging CS7BLlKaLwRij mouse 
appeared to offer an excellent model of B-cell proliferative disorders, strongly 
resembling those of human origin [13-1S]. These mice spontaneously develop 
in a high frequency BMG and follicular center cell lymphomas and, less 
frequently like in the human situation, typical MM and WM. In this model, it 
was shown that BMG did not represent a premalignant condition of MM or 
WM. By transplantation of BM or spleen cells to unmanipulated recipient 
mice, the BMG clone could be propagated for maximally three to four 
generations and with decreasing take frequency. This is in contrast to 
malignant forms, which can be propagated indefinitely. Thus, the clonogenic 
cell of BMG differs substantially from that of B-ce1l malignancies by 
remaining mortal. 
B-CELL LINEAGES 
Initiated by the discovery of Ly-l + B-cells in mice and CDS+ B-cells 
in humans the search for the pathophysiological role of this CDS+ B-cell 
subset in the immune system became of interest [S,6,19-21]. The majority of 
data were obtained from ill vivo and in vitro experiments, performed in mice. 
According to phenotype, two B-cell subsets can be distinguished: B-1 
(with B-la and B-lb subpopulations) and B-2 cells (table 2) [22]. This 
nomenclature implies a different origin of these B-cell subsets. However, this 
is still a matter for discussion because some authors believe that antigenic 
stimulation and subsequent selection of cells are responsible for the dichotomy 
of B-cell subsets (for excellent discussion, see references 23 and 24). 
The B-1 cells are preferentially located in the coelomic cavities - the 
peritoneal and thoracal cavities - between which there is a free migration of 
cells [2S]. No other preferential localization is known. Thymic B cells have a 
B-1 cell phenotype [26], but are probably not of B-1 origin [27]. In low 
frequencies, B-1 cells are resident in the spleen. It is not known whether there 
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is a migrational route via peripheral blood (PB) to or from other organs, 
especially the bone marrow, although in some autoinunune diseases, such as 
primary Sjogren's Syndrome and rheumatoid arthritis [28], increased 
frequencies of these cells can be detected in PB, as is also obvious in 
autoinunune NZB mice [29]. Their role in pathogenesis is not clear, however. 
Adoptive transfer studies, performed by various research groups, of 
embryonic splanchnopleura and fetal omentum in lethally irradiated or SCID 
recipient mice revealed that in these organs only B-1 cell precursors are 
present. Fetal liver reconstitutes both the B-1 and B-2 cell population, but 
adult bone marrow can only fully reconstitute the B-2 cell population [19-
21,30,31]. These findings form the basis of the lineage theory, which implies 
that B-1 and B-2 cells are derived from different precursor cells, located in 
adult life in different organs and tissues [23]. 
B-cells of the B-2 lineage are readily available for investigation 
because they are abundant in bone marrow, spleen and peripheral blood. Most 
of the scientific data concerning B-cells in general are related to these cells. 
Less is known about the B-1 lineage, on which we focus in the next section. 
Characteristics of the B-cell lineages 
The biological function of the CD5 and CDllb membrane markers of 
the B-1 cell population is unknown. CD II b belongs to the family of adhesion 
molecules and it is very likely that this property is also preserved in B-1 cells. 
CD5 is associated with the inununoglobulin receptor [32], the membrane 
bound IgM-IgodJl (CD79a/CD79b) complex, and may very well act, in 
conjunction with its ligand CD72 [33], as a modifier of intracellular signals 
after antigen binding by the IgM receptor [34,35]. 
Various ill vitro experiments showed that CD5- B cells can be induced 
to express CD5 (by phorbolmyristateacetate (PMA) [36], anti-IgM [37] or 
Staphylococcus allrells Cowan strain I antigen [38] activation), but whether 
this is a functional and lasting expression is unknown. Zupo et al. found that 
only a distinct subset of human tonsillar CD5- B-cells could be induced to 
express CD5 by PMA and that these cells coexpress the activation marker 
CD38. This was prevented by T cell contact alone or by rIL-4 [39]. These 
inducible CD5 + B-cells may be the human analogues of the murine B-lb cells 
[40], 
In B-2 cells, the mechanism of somatic mutation is responsible for so 
called affinity maturation. The B-1 cell population is characterized by a 
restricted usage of VII inunulloglobulin genes, with a relative resistance to 
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Table 2. B cell phenotypes in B-1 and B-2 nomenclature 
B cell types/lineages 
Markers B-Ia B-Ib B-2 
sIgM +++ +++ + 
sIgD + + +++ 
CDS (Ly-I) + 
CDllb (Mac-I,,)" + + 
IL-SR + + ± 
CDn + + ++ 
CD4SR (B220) + + ++ 
a Splenic B-1 cells are CDllb-negative. 
somatic mutations as compared to B-2 cells [41-43]. Thus, it is not surprising 
that the antigenic specificity of B-1 cells is also restricted and biased to 
usually polyreactive activity, with low affinity against autoantigens and 
bacterial antigens. In addition to the production of multispecific Ig, a 
relatively large amount of IL-lO is secreted by peritoneal B-1 cells [44]. This 
suggests their regulatory role by inhibiting T HI reactions. Furthermore, IL-lO 
probably functions as an autocrine growth factor for B-1 cells, as anti-ILIO 
treatment selectively depleted the B-1 cell population in the peritoneal cavity 
[45]. 
Focussing on the physiological behavior of B-1 cells during life, it 
becomes apparent that their representation in the total B-cell pool shows two 
peaks. During fetal life and perinatally, the proportion of B-1 cells is 
relatively high, decreasing thereafter because of the expansion of the B-2 cell 
pool, which will remain the largest population of B cells throughout life [46]. 
However, in aging mice, the peritoneal B-1 cell population expands, whereas 
the V H gene usage becomes more restricted. These emerging B-1 clones can 
even be detected in the spleen [29]. This is illustrated also by the observation 
of a selective increase in the phosphory1choline specific B cells in aging mice, 
which is a typical B-1 cell specificity [47], although no B-1 cell data were 
collected in that study [48]. Recently, it appeared that sex-associated 
phenomena may play an important part in the homeostasis of this cell 
population. It was found that B-1 cells decreased in aged male mice and 
increased in aged female mice. B-1 cell responsiveness to mitogens and 
antigens is probably decreased in all aged mice [49,50]. 
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INVOLVEMENT OF B-CELL LINEAGES IN DEVELOPMENT OF MG 
The lineage origin of some B-cell neoplasias is known, e.g., the B-1 
cell origin of CD5+ B-CLL and the B-2 cell origin of follicnlar-center cell 
lymphoma. However, the lineage origin of the majority of B-cell proliferative 
disorders, inclnding disorders that give rise to MG, is unknown. Different 
mechanisms may be responsible for abnormal clonal restrictions and 
expansions within B-cell populations. Most likely, multiple causes should be 
considered. 
1. Because of a limited number of B-1 precursor cells and no 
supplementation by BM resident precursors, the B-1 cell pool becomes 
c10nally restricted in time. This also implies that no significant number of 
somatic mutations occurs in the descendants of these long-living precursors, 
and that some clones are able to outgrow all others, or that most clones 
disappear and the remaining cells have to fill in the cellular gap by expanding 
(not for any other purpose) their cell number. The feedback regulatory 
mechanisms play an important role in the homeostasis of the B-1 cell 
population [51]. Independence from the BM of the B-1 cell population and 
longevity of their precursors in coelomic cavities, clonal restriction, and clonal 
expansion increasing with age all may subsequently lead to an increased 
chance of neoplastic transformation [29]. 
2. Repeated or prolonged antigenic stimulation throughout life may be 
a good reason for clonal expansions of both B-1 and B-2 cells. In that case, 
c10nality may have a purpose. It is possible that autoantigens playa major role 
in this process in the case of B-1 cells, as is suggested by the production of 
large amounts of natural (auto)antibodies. However, autoantigens are present 
in abundance during the whole lifetime, whereas the B-1 cell clones become 
enlarged, but restricted in number, during aging only. Other unknown 
antigenic stimulations, possibly initiated at the respiratory and gastrointestinal 
mucosa, may be more important in inducing clonal expansions. A recent study 
by Murakami et al. showed in an autoantibody transgenic mouse model that 
orally administered LPS activated B-1 cells in the lamina propria of the gut, as 
well as in the peritoneal cavity. Systemic injection of LPS did not result in B-
I cell activation [52]. These findings imply that these B-1 cells readily migrate 
between both locations. The work of Kroese et al. leads to similar conclusions 
[53]. Together with the B-2 cells in Peyer's patches, the B-1 cells in the 
lamina propria take part in gut-associated lymphoid tissue (GALT) and 
possibly also in bronchus-associated lymphoid tissue (BALT). Their exact 
function in mucosal innnune reactions have to be elucidated. Results of 
experiments in C57BLlKa mice suggest that memory B-cells (the B-2 lineage) 
are involved in the development of BMG and MM. 
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3. In addition to these mechanisms, insufficient T-cell help may 
reduce the numbers of responding B-cell clones, and on the other hand, loss 
of T-cell suppression would allow excessive expansions of B-cell clones that 
did respond to certain (antigenic) stimuli. This mechanism may act especially 
in MG of B-2 cell origin because of the fact that in most B-2 responses T-cell 
help and control plays a major role. Responses of B-1 cells (e.g., to 
polysaccharides) may not need such a T-cell interference. 
Independent of the mechanisms that are responsible for the 
development of B-cell proliferative disorders, the antigenic specificity and 
structural properties of M-Ig may be helpful in defining subgroups of B-cell 
neoplasias. 
1. B-cell neoplasias with relatively few somatic mutations, as seen in 
CD5+ B-CLL, Burkitt's lymphoma, WM, and some BMG. Most of the M-Ig 
with known antibody specificity were shown to be autoantibodies [16,54-56]. 
These tumors may very well be of B-1 cell origin. 
2. B cell neoplasias with antigen-selected somatic mutations in V H 
immunoglobulin genes (as in MM, CD5- B-CLL, hairy cell leukemia and 
possibly some BMG) [28,54,55, 57], or with ongoing somatic mutations as in 
follicular lymphomas. Most likely these tumors originate from B-2 cells. 
An additional point should be considered. The CD5 expression alone 
on B-cell neoplasias must be interpreted carefully because it is not known 
whether neoplastic transformation can induce or inhibit the expression of 
CDS. However, in addition to other B-1 cell characteristics, such as antigenic 
specificity of secreted Ig and VII gene family usage and mutational status of 
the complementarity determining regions (CDR), the expression of CDS and 
CDllb can help to reveal the origin of B-cell tumors [28,41,54,55]. 
EXPERIMENTAL APPROACHES 
To test whether B-1 or B-2 cells give rise to certain B-cell 
proliferative disorders with different frequency and characteristics, a murine 
model can be helpful. Allotype congenic chimeras, in which bone marrow-
derived B-2 cells and peritoneal cavity resident B-1 cells are of different IgH 
allotype, enable the study of the two separate B-cell lineages in the same 
animal [58]. Alternatively, fJ.-K transgenic Sp6 mice can be used as an 
experimental model. In these mice, B-2 cells express only the transgenic IgM 
on their cell membranes, while B-1 cells coexpress endogenous IgM molecules 
[59]. The M54 fJ. heavy-chain transgenic mouse model has been studied for the 
development of age-related MG by Gueret ef al., and showed a profound 
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effect of the transgene on the development of M-Ig, which were always of 
endogenous origin [60]. However, results from transgenic model experiments 
have to be interpreted carefully because the entire B-cell system may have 
been altered. In those animals, e.g., the peripheral B-cell number is 
remarkably reduced [62,63]. 
Elucidating the lineage origin of MG may help to better understand 
the mechanisms of their development, to improve the differential diagnosis of 
the underlying disorders, and possibly to provide us with new means of 
treatment of the health- or life-threatening forms of MG. 
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SUMMARY 
Monoclonal gammopathies (MG) are monoclonal proliferative 
disorders of B cells at the differentiation stage of Ig production. They can be 
detected in the semm, either as transient or as persistent homogenous Ig 
components (H-Ig). The exact phenotype, localization, and cell lineage origin 
of the precursor cells of MG are unknown. In the !"K-inununoglobulin (Sp6) 
transgenic (Tg) mice a small proportion of B cells still can produce 
endogenous IgM. It has been shown, by virtue of their phenotype and 
localization, and in adoptive transfer experiments, that these cells are of B-1 
cell origin. We studied aging !"K Tg mice for their ability to develop MG. It 
can be assumed that MG, producing an Ig of endogenous isotype, originated 
from the B-1 cells. 
The Tg mice showed a stable expression of the transgene during 
aging. Male Tg mice survived 20 weeks shorter than Iittermate control mice. 
This could be attributed to more intercurrent acute inflammatory diseases in 
Tg mice. In the Tg mice Ig serum levels were decreased as compared to 
controls, except for IgG2b and IgM. The MG in Tg mice showed a later onset 
and a lower frequency than those in Iittermate control mice. The 10% of B 
cells that were able to produce endogenous Ig led to the development of MG 
in a frequency that was half the number of MG found in normal littermates. 
None of the MG in Tg mice produced an Ig of the Tg origin and therefore it 
can be concluded that they originated from B-1 cells. These results show that, 
in the presence of a genetic susceptibility to develop MG, B-1 cells in mice 
are frequently involved as precursor cells of transient monoclonal expansions 
of B cell clones as well as of neoplastic B cell proliferative disorders. 
* Part of Ihis chapter was published in Eur J Immullol 1997,27:2436-2440. 
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INTRODUCTION 
The competence of the immune system is greatly affected by aging of 
the individual. Changes in both Band T cell systems are responsible for the 
age-related increase in levels of autoantibodies, higher incidences of infections 
and the development of various neoplastic diseases. One of the most striking 
manifestations of aging of the inunune system is the development of excessive 
monoclonal B cell proliferations [I]. They are often detectable in the sera by 
electrophoresis as homogenous or monoclonal inununoglobulin (H-Ig) 
components, therefore designated as monoclonal gal11l11opathies (MG). 
Transient MG often accompany imbalances between the Band T cell systems. 
Persistent MG can either be benign or malignant and both categories are age-
related neoplastic proliferative disorders of inmmnoglobulin (Ig) producing 
plasma cells, mainly localized in the bone marrow (BM). Benign monoclonal 
ganunopathies (BMG) are much more frequent than the malignant MG, i.e. 
mUltiple myeloma, Waldenstrom's macroglobulinemia and (extra-)medullary 
plasmacytoma. Influences of T cell function, antigenic stimulation and genetic 
background on MG development have been reported earlier in mice as well as 
in man [2,3,4]. The question which cell becomes the target for the events 
leading to the development of benign and malignant B cell proliferation 
disorders may be cmcial for both the correct diagnosis and for timely efficient 
treatment of the malignant forms. 
Based on cell surface phenotype, anatomical localization, function and 
origin, B cells in mice can be divided into two lineages: the predominantly in 
thoracal and peritoneal cavities localized B-1 cells, expressing the CD 11 b 
molecule (B-lb cells), often in conjunction with CDS expression (B-la cells), 
and the conventional, bone marrow derived B-2 cells, which express neither 
CD11b, nor CDS. B-1 cells appear early in foetal life and migrate to the 
peritoneal and pleural cavity, where they maintain themselves as a self-
renewing IgM-positive population. B-2 cells arise later and are continuously 
renewed by newly formed bone marrow precursor cells [5]. 
We used for the first time ul11l1anipulated aging ",K-transgenic Sp6 
mice [6] on C57BL background to investigate the incidence of MG in aging 
Tg mice and the B cell lineage origin in the development of MG. It was 
shown by Kroese et al. [7] that the majority of B cells in the periphery and in 
the BM of B6-Sp6 mice expressed exclusively transgenic IgM, bearing the ,,' 
allotype. However, a small proportion of B cells (about 10% of spleen cells) 
showed endogenous IgM ("b) expression, usually concomitant with transgenic 
IgM. These cells possessed a B-1 phenotype: expression of CD11b, low levels 
of (endogenous) IgD, and most cells also expressed CDS. Furthermore, they 
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were especially enriched in the peritoneal cavity. BM of the transgenic (Tg) 
mice could not fully reconstitute endogenous IgM positive B cells in irradiated 
recipients. From this experiment it was concluded that endogenous isotypes in 
Sp6 mice were produced by B-1 cells. We therefore assumed that B cell 
proliferative disorders arising from the B-1 cell population in these aging Tg 
mice would result in an H-Ig of endogenous isotype. 
We found a stable expression of the trans gene throughout the life-span 
of the Tg mice. SelUm Ig levels were lower in Tg mice than in Iittermate 
(LM) controls. The frequency of H-Ig components in the serum of Tg mice 
was half of that in LM controls and they developed at a later age. These H-Ig 
were of endogenous isotypes and none of these produced the Tg fl' allotype. 
Our findings suggest that the B-1 cell lineage can be responsible for at least a 
part of the MG in mice. 
MATERIALS AND METHODS 
iUice 
Sp6 transgenic male mice on C57BL/6 background (designated B6-Sp6) were 
originally provided by Dr M.e.Lamers (Max Planck Institute for hnmullobiology, Freiburg, 
Germany). They were backcrossed once with C57BLIKaLwRij female mice from the breeding 
stock of TNO-Prevention and Health, Leiden, The Netherlands and kept under conventional 
conditions in the animal housing of the Department of Histology and Cell Biology. University 
of Groningen. After one year they were transferred to the animal facilities of the Erasmus 
University Rotterdam and kept in isolators under positive pressure isolation. 
The It.K-transgene originates from the BALBJc (Igh-a allotype) derived Sp6 
hybridoma. which produces an antibody that specitically binds to TNP (6]. Backcrossing all 
C57BL Igh-b allotype background facilitated the detection of the transgenic IgM (lgh-6a) by 
allotype specific anti-IgM antibodies. 
The C57BL/KaLwRij mouse strain has been established as a suitable animal model for 
research on MG, based on the relatively high frequency of spontaneously developing MG of all 
categories at old age (8]. The one time backcross of the Sp6-B6 mice with the C57BLIKaLwRij 
mice was useful to introduce at least some of the genetically determined characteristics t()r 
susceptibility to the development of MG. 
The Tg phenotype was identified by ELISA, using coated DNP-BSA as the relevant 
antigen for transgenic IgM. Binding of Tg encoded antibody was revealed by goat anti-mouse 
(GaM) IgM conjugated to alkaline phosphatase (Southern Biotechnology Associates, 
Birmingham, AL). Control mice were LM of the Tg animals. Every 2-3 months a small blood 
sample was taken from the tail veins of 58 unmanipulated Tg mice (35 male, 23 female) and 68 
LM (37 male, 31 female), starting at the age of 3.7-10.5 months and continued till the end of 
their lives. Seriously ill or moribund animals were terminated by carbon dioxide inhalation and 
submitted to necropsy. Microbiological evaluation of the animals showed no deviations from the 
established flora during the experiment. 
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Histopathological examinatioll 
Complete necropsy and histopathological examination was performed on 36 LM 
controls (24 males, 12 females) and 28 Tg mice (21 males, 7 females) according to a standard 
protocol [9]. All tissues were fixed with B5-fixative. The sections were stained with 
hcmatoxilin-phloxin-saffron. Examination of the sections was carried out without prior 
knowledge of the genetic constitution of the mice that corresponded to the tissue sections. 
Ig-isotype ELISA 
Microwell plates with high binding affinity (Greiner, Alphen aan de Rijn, The 
Netherlands) were coated overnight at 4 °C with 50 pi of diluted GaM-IgGI, GaM-IgG2a, 
GaM-IgG2b, GaM-IgG3, GaM-IgA, or GaM-IgM (7S-Ig fractions, Nordic Immunological 
Laboratories, Tilburg, The Netherlands) at a concentration of 10 Itg/ml. The plates were 
washed six times with PBS, containing 0.05% Tween~20 (polyoxyethylene-sorbitan-
monolaurate; Sigma, St.Louis, MO) (PBS-Tw), using the Scanwasher 300 version A (Skatron 
Instruments, Costar Europe Ltd, Badhoevedorp, The Netherlands). The wells were blocked 
with 300 pi PBS-Tw with 0.5% BSA (PBS-Tw-BSA; Fraction V, Sigma, St.Louis, MO) for 30 
minutes at room temperature and washed again. Fifty Id of diluted samples and standards in 
PBS-Tw-BSA were added to each well and the plates were incubated for 2 hours at room 
temperature. On each plate three subsequent dilutions of a commercially available calibrated 
normal mouse serum (Nordic Immunological Laboratories) were treated as samples to serve as 
a positive isotype-specific control. After washing, 50 It! of a 1 :250 dilution of alkaline 
phosphatase (AP) conjugated GaM-IgA~IgG-IgM (Kirkegaard & Perry Laboratories, Mutacon 
B.V., Leimuiden, The Netherlands) were added to the wells. The plates were incubated for I 
hour at room temperature. After washing the wells, 50 It! of a substrate solution (p-
nitrophenylphosphate 1 mg/ml in aiM diethanolamine, 0.05 M MgCI2 buffer (pH 9.8» was 
added to the wells and incubated for approximately 40 minutes at 37 °C. The absorbance was 
read at 405 lUll using a Bio-Rad Model 3550 Microplate Reader (Bio-Rad, Veenendaal, The 
Netherlands). The IgM-aliotypes were measured using plates coated with RS3.1 and MB86 
monoclonal mouse-ami-mouse Igh-6a and Igh-6b, respectively (kindly donated by dr 
A.Colitinho, Institut Pasteur, Paris), and GaM-IgM-AP (Kirkegaard & Perry Labs.) as a 
detecting antibody. 
Two serum pools, one from CBA mice (Igh-a) and one from C57BL mice (lgh-b), 
were calibrated to be used as secondary allotype- and isotype-specific standards. Therefore 
aftinity-chromatography purified mouse paraproteins of appropriate isotype and allotype were 
used as primary standards. The protein concentrations of the primary standards were measured 
using the Bio-Rad Protein-assay (Bio-Rad) and subsequently used to construct a standard curve 
for calibration of the standard sera. Concentrations of the individual sample dilutions were 
calculated using the calibrated standard serum. To minimize variability we analyzed the sera 
derived from a single mouse on the same plate. Per isotype all samples were tested on the same 
day. 
Detection of homogenolls Ig-compouellts 
Sera were investigated for the presence of H-Ig by a slightly modified high resolution 
agar electrophoresis according to Wieme [10,11]. Briefly, 8.2 x 8.2-em glass plates were 
covered with 12 011 of 0.9% Agar Noble (Difco, Detroit, MI) in IEP buffer, pH 8.6, containing 
10 mM 5.5'-diethylbarbituric acid and 50 mM sodium barbital (Merck, Darmstadt, Germany). 
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Each slit was filled with 4 f!1 of serum. Electrophoresis was perFormed at 190 V and 80 mA for 
15 min with the agar plate completely submerged in petroleulll ether (40-60 °C; BDH, Poole, 
U.K.) to prevent overheating of the gel. The proteins in the gels were fixated by 30 min 
soaking in a glacial acetic acid and methanol mixture (1: 10). The gels were dried, covered with 
wet tilter paper, in a stove at 60°C, and colored with Amido Black IThiazine Red in fixating 
solution for direct assessment of the serum protein spectrum. 
Electrophoresis of the sera in dilutions I :50 and 1: 100 were used for the 
immullobiotting of H-Jg. Serum proteins were transferred from the agar by diffusion under 
pressure for 30 min onto polyvinylidene difluoride (PVDF) membranes (lmmobilon; Millipore, 
Bedford, MA). Unoccupied protein binding sides on the blots were then blocked with PBS-
0.05% Tw-I % BSA (Boseral DEM; Organon Tecnica, Oss, The Netherlands) by incubating 60 
min at room temperature. After 90 min incubation with peroxidase conjugated isotype specitic 
antibodies and subsequent washing, the blots were stained with a freshly prepared substrate 
solution of 0.02% (w/v) 3,3'-diaminobenzidine tertahydrochloride (DAB; Sigma, St.Louis, 
MO) and 0.03% (v/v) hydrogen peroxide (perhydrol; 30% H20 2, Merck, Darmstadt, Germany) 
in PBS-Tw. The enzymatic reaction was stopped after 10 min by rinsing the blots in distilled 
water. 
Since IgD is normally not detectable in the sera of mice [12], we first screened 
undiluted sera using the Ouchterlony immunoprecipitation technique in agar plates. As a 
positive control we used ascites from the TEPC1017 plasmacytoma line. Positive sera were 
subsequently tested in dilutions by immunoblotting. 
An H-Ig component was defined as a narrow band in agar electrophoresis, contirmed 
by the detection of a band of the same mobility by immullobiotting wilh isotype specitic anti-Ig 
antiserum conjugates. 
Antibodies for itlllllltlloblottillg 
Peroxidase-labelled polyclonal GaM isotype-specific conjugates (Nordic 
Immunological Laboratories) were used for characterisation of H-Ig by immunoblotting in the 
following dilutions: GaM-IgGI-PO 1:10.000, GaM-IgG2a-PO I: 10.000, GaM-IgG2b-PO 
1:5000, GaM-IgG3-PO 1:5000, GaM-IgA-PO 1:10.000, GaM-IgM-PO 1:5000, GaM-IgD-PO 
I :7500. For determination of the H-Ig light chains, peroxidase conjugated polyclonal sheep 
anti-mollse (ShaM) kappa and ShaM lambda were used in 1 :4000 and 1: 10.000 dilutions, 
respectively. 
To discriminate between transgenic IgM of a-allotype and the endogenous IgM of b-
allotype, we used RS3.I-biotin anti-Igh-6a and MB86-biotin anli-Igh-6b conjugates (kind gifts 
from dr A.Coutinho, Illstitut Pasteur, Paris) in immunoblouing experiments, both in 1 :5000 
dilution. A second-step avidin-peroxidase (Calbiochem Co., La Jolla, CA) 1:1000 incubation 
was used to allow for detection with DAB substrate. 
Classificatioll of MG 
Electrophoresis and immullobioiting data were assessed in combination with the 
clinical features of mice with H-Ig to allow for classification of MG into the categories as 
described by Radl [1,8]. Briefly, the following categories were distinguished: in category I, the 
H-Ig showed a progressive development within two months, reaching paraprotein concentrations 
of more than 5 mg/ml (often more than 10 mg/ml). This pattern is typical for multiple 
myeloma. An H-Ig was classified as belonging to category 2 when the concentration of the 
paraprotein remained below 4 mg/ml and persisted for at least six months before the animal 
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died of other causes. This pattern is typical for BMG, i.e. benign neoplasias. Category 3 
comprised transient H-Ig components, usually of low concentration. H-Ig that appeared shortly 
before death were considered unclassifiable. The first two categories represent neoplastic B cell 
disorders in which an intrinsic B cell defect is present. This is illustrated by the fact that MG of 
both categories arC transplantable into congenic recipients. The third category of transient H-Ig 
components often accompanies an imbalance between Band T cell systems. 
Statistical methods 
Survival curves were estimated by the method of Kaplan-Meier with differences 
assessed by the logrank test. Proportions were compared by chi-square analysis, using Yates 
continuity correction, or Fisher's Exact test when a number was smaller than 5. ELISA-data 
were log transformed and analyzed by ANOVA and Mann-Whitney-U tests. P-valucs smaller 
than 0.05 were considered statistically significant. 
RESULTS 
Survival analysis 
Survival probability curves of Tg and LM mice were constructed 
according to the method of Kaplan-Meier (Fig. lA). The SO% survival times 
were 96.S weeks for Tg mice and 108 weeks for LM controls. The life-span 
of Tg mice was significantly (P < .02) shorter than that of LM, both sexes 
taken together. Male LM mice lived significantly longer than females 
(P < .001) (Fig. 1B and C). Previously it has been shown for inbred CS7BL 
strains that males lived longer than females [9), similar to our findings in our 
control group. In the Tg mice there was no apparent difference in survival 
time between the sexes and both sexes lived as long as female LM mice. In 
other words: only male Tg mice had a reduced (20 weeks) life-span as 
compared to their LM male controls (P < .001). 
Histopathology 
The histopathological diagnoses are given in table 1 with a summary 
in table lao No significant differences between Tg and LM mice were 
observed with the exception of the relatively high incidence of histiocytic 
sarcoma in LM mice and the absence of such lesions in Tg mice (P=0.0088). 
Compared to historical data [9) the relatively high incidence of acute 
inflanmlatory lesions in LM as well as in Tg mice was remarkable. Such 
intercurrent disease would interrupt the development of aging pathology (e.g. 
neoplastic, chronic inflammatory and various degenerative lesions), decrease 
the number of lesions per mouse and increase the proportion of acute 
inflammatory lesions in Tg mice. As can be deduced from table la, a trend in 
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Figure 1. A. Survival probability curves of WK Sp6 transgenic mice (Tg: _ ) and littermate 
controls (LM: - - - ). both sexes taken together. B. Survival probability curves of male P.-K Sp6 
Tg mice and LM controls. C. The same for female mice. The logrank test was used to assess 
the differences between the curves. Corresponding P-values are given. The horizontal ( ..... ) 
line is the 50% survival value. 
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Table 1. Survey of neoplastic and non-neoplastic lesions in aged p,K Tg mice and littermate 
controls. 
LM mice Tg mice 
00 99 00 99 
I. Neoplastic lesions 
Follicle center cell lymphoma (FCC) 7/24 ,) 5/ll 8/20 217 
Malignant lymphoma NOS b) 5/24 O/ll 4/20 117 
Multiple myeloma c) 1124 0112 0/21 117 
Histiocytic sarcoma d) 7123 5/ll 0/21 017 
Hemangioma or hemangiosarcoma 5/24 2111 5/21 217 
Total other neoplastic lesions 5/24 2111 6/21 017 
II. Hyperplastic lesions 
Fibro-osseous hyperplasia 0/24 2/12 1121 217 
Lymphoid hyperplasia 1124 2/ll 0120 017 
Bone marrow plasma cell hyperplasia 9/24 2112 5121 017 
idem, including pleomorphism 2/24 4112 4/21 117 
Extramedullary haemopoiesis 8123 5/11 7/20 317 
Total other hyperplasia 2/24 1111 1/21 117 
III. Non-neoplastic lesions: 
- Acute inflamlllatory 
Parodontitis 2117 0/3 0117 0/3 
Incisor dysplasia + intlammation 8117 0/3 6117 0/3 
Acute lymphadenitis 2/24 0111 2120 217 
Skin erosion / ulceration 2116 117 3116 3/5 
Subcutaneous abscesses 1116 0/6 3/16 0/5 
Otitis media I rhinitis 3/8 0/1 4/9 3/3 
Total other acute inflammatory 10124 3/11 12/21 417 
Chronic inflammatory; 
Polyarteritis 2/24 3/11 1121 017 
Sialoadenitis 2/22 1/11 2/21 017 
Eosinophilic macrophage pneumonia 6124 0/10 4120 217 
Total other chronic intlammatory 7124 0/11 2/21 117 
IV. Various other non-neoplastic lesions 
Incisor dysplasia 6117 3/3 8/17 113 
Amyloidosis (localised) 12/24 1/11 10/21 217 
Hydronephrosis 5/21 1/9 2/21 0/5 
Renal tubular atrophy + dilatation 5/21 0/9 5/21 2/5 
Total other non-neoplastic lesions 19/24 9/11 10/21 317 
a) Number of diagnoses per relevant necropsy. 
b) NOS: not otherwise specitied. 
c) Diagnosis by histopathological and serological findings. 
d) LM mice compared to Tg mice: two-sided P-value = 0.0088, both sexes together. 
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Table 1a. Total number of lesions in necropsy material of Tg and LM male mice. 
Diagnostic category 
Neoplastic lesions 
Hyperplastic lesios 
AClite intlammation 
Chronic intlammation 
Various other non-neoplastic lesions 
Total lesions per mouse 
Ll\'1 male mice 
(n=24) 
11 (lesions) 
30 
22 
28 
17 
47 
144 
ratio 
1.25 
0.92 
1.17 
0.71 
1.95 
6.0 
Tg male mice 
(n=21) 
11 (lesions) ratio 
23 1.10 
18 0.86 
30 1.43 
9 0.43 
35 1.67 
115 5.5 
47 
this direction is indeed present. This favours the explanation of the decreased 
survival of male Tg mice to be due to a decreased resistance to acute 
inflanunatory disease. There were no differences detected between the two 
sexes except for a higher incidence of localized amyloidosis (mainly in the 
stomach) in the male mice (P = 0.016, Tg and LM together). 
JlIIlIIlllloglobulin levels during aging 
The fully rearranged p.,K-transgene resulted in a relatively high 
concentration of selUm IgM of Tg origin, and a suppression of the levels of 
the endogenous isotypes in young Tg mice [13]. We quantitated the serum 
concentrations of the predominant Ig isotypes in aging Tg and LM mice of 
both sexes; Tg-mice; n = 16 males, n = 17 females; LM-mice: n = 10 males, 
and n = 10 females. All selected groups had the same age distribution and none 
of the mice showed an H-Ig in agar electrophoresis. From each mouse a small 
blood sample was taken from the tail vein at 3 to 6 consecutive time points. 
The data were ordered according to age by using 7 age cohorts of 15 weeks 
duration (Fig.2). Neither in the Tg group, nor in the LM control group 
differences were observed between the two sexes (data not shown). Therefore 
we analyzed the data of both sexes together. 
The mean isotype concentrations in the sera of the Tg mice were 
lower than those in the LM group, except for IgG2b (during their entire life) 
and for total IgM (in the first year of their life) (Fig. 2, table 2). The effects 
of aging on the Ig isotype levels in Tg mice were similar as in LM controls: a 
decreasing amount of IgG2b (P=0.0016 in the Tg mice, P=0.0051 in the LM 
mice; table 2), and a marginal increase in total IgM. The decrease in Tg mice 
Figure 2. Immunoglobulin isotype levels (mean ± SD) during aging in Tg (black columns and dashed regression lines) and LM mice (open columns 
and poimed regression line). For analysis of data. see table 2. 
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Table 2. Comparison of Ig-Ievels in Tg and LM mice during aging. Log transformed data were analyzed by ANOVA and Mann-Whitney-U tests. 
Age cohorts (weeks) 
[sotype 16-30 31-45 46-60 61-75 76-90 91-105 106-120 
IgGl: 7111 .) 2!126 20/23 26117 10/3 18113 10/3 
2-sided P-value 0.007 0.002 0.03 0.01 0.004 0.05 NS 
Linear trend - LM: P< .0001 Tg:NS 
IgGZa: 7113 22/34 20/29 26/22 12119 18!l3 12/4 
2-sided P-value <.0001 < .0001 < .0001 <.0001 < .0001 <.0001 <.0001 
Linear trend - LM: NS Tg: NS 
IgGZb: 9112 22/33 24/32 25/24 15119 16117 7/5 
2-sided P-value NS NS NS NS NS NS NS 
Linear trend - LM: P=.0051 Tg: P=.0016 
IgG3: 6!l2 20/30 17/26 23/20 12/21 12116 8/4 
2-sided P-value < .0001 < .0001 < .0001 < .0001 0.0007 0.0007 0.0315 
Linear trend - LM: NS Tg: NS 
IgA: 3113 20/31 19/27 24/22 13/18 15113 8/3 
2-sided P-value 0.005 <.0001 <.0002 < .0001 0.007 0.034 NS 
Linear trend - LM: P= .0073 Tg; NS 
IgM: 6112 18/35 17/29 25/24 15/20 17/15 12/3 
2-sided P-value NS NS NS 0.01 0.004 0.0006 NS 
Linear trend - LM: P= .0099 Tg: NS 
a) Number of mice analyzed (LM I Tg). 
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of the IgG I levels with aging was not significant due to the large range of the 
results. As previously described [6,13], IgM was the predominant isotype in 
the serum of Tg mice. The low levels of IgG2a and IgG3 were mainly 
responsible for the low IgG levels in Tg mice at all ages tested. 
Stable expressioll of the IgM-K trallsgelle durillg agillg 
The transgenic IgM (Igh-6a) and the endogenous IgM (Igh-6b) levels 
were also quantitated by ELISA (Fig. 3). At old age, the transgenic IgM was 
still produced in at least the same amount as in young Tg mice. We found that 
the cumulative amounts of both IgM allotype concentrations was lower than 
the amount measured by the total IgM-isotype ELISA. This observation was 
reported earlier by Grandien et of. [14] and can be ascribed to the production 
of "mixed" pentamers in Sp6-Tg mice [13,15], with approximately five times 
as much transgenic IgM (Igh-6a) as compared to endogenous IgM (Igh-6b). 
Although the results of the IgM allotype ELISA might not accurately represent 
the quantitative amounts that are actually present in Tg mice, they showed the 
same effect of aging as the results of the total IgM ELISA. 
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Figure 3. Concentration (mean ± SD) of transgenic IgM, Igh-6a (open columns and dashed 
regression line) and endogenous JgM, Igh-6b (black columns and pointed regression line) in 
serum of Tg mice during aging. 
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Frequency of MG-categories 
The H-Ig were classified into the three categories as described (Table 
3). No differences were observed between Tg and LM mice for the 
frequencies of multiple myeloma, transient MG and unclassifiable MG. The 
diagnosis of multiple myeloma was based on histopathology, confirming the 
serological data. The only one myeloma which developed in a Tg mouse 
produced IgG2b-kappa, the only one myeloma in a LM mouse produced 
IgG I-kappa. The aging Tg mice showed half as many MG as the LM (P = 
0.0016), mainly because of a four times lower incidence of BMG (P=0.0007) 
in the Tg mice. 
The cumulative frequency of the first appearance of the H-Ig in the sera 
of the mice is shown in Fig. 4. The Tg mice developed H-Ig significantly 
later (P<O.OOI) than the LM mice. At their 50% survival age, 25% of the Tg 
mice had an H-Ig in the serum, in contrast to 66% of the LM mice. 
Up to the age of approximately 80 weeks, the LM mice showed an 
enhanced increase of H-Ig components as compared to the Tg mice. In this 
period, the increase of MG in Tg mice was also enhanced as compared to the 
time-period after 80 weeks. After this age, the slopes of the curves were 
essentially parallel, meaning that from this age on there was an equal 
influence of age on the appearance of H-Ig in Tg and LM mice. 
Table 3. Cumulative frequency of MG-categories in aging Tg and LM mice. 
Tg (N~5S) LM (N~6S) 
Category of MG II / % a) n I % 
I. Multiple myeloma 1 (1.7) 1 (1.5) 
II. Benign MG 6 (10.3) hi 26 (3S.2) 
Ill. Transient MG 5 (S.6) 11 (16.2) 
Unclassitiable 10 (17.2) S (I1.S) 
Total MG 22 (37.9) 01 46 (67.6) 
a) Number and percentage of mice that developed MG of the designated category. 
b) Two-sided P-value ~ 0.0007. 
c) Two-sided P-value = 0.0016. 
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Figure 4. Cumulative representation of the incidence of all H-Ig components in Tg (squares) 
and LM mice (circles). 
H-Ig isotype distribution 
The H-Ig isotype distribution as determined by immunoblotting (Table 
4) did not show statistically significant differences between Tg and LM mice. 
The mean age of the mice in table 4 was 27 months (range = 22.6 - 28.6 
months). At this age 27% of the Tg mice showed an H-Ig compared to 67% 
of the LM. The Tg mice had developed significantly less H-Ig components 
(Fisher's Exact two-tailed, P=O.028) at this age than LM mice. It is 
remarkable that none of the Tg mice developed an H-Ig producing the Tg Igh-
6a allotype. A double H-Ig was detected by agar electrophoresis in 6 Tg mice 
(10.3%) and in 12 LM (17.6%) within the entire follow-up period. 
There were H-Ig components that stained for several isotypes in 
inullunoblotting. Because goat anti-mouse antisera were used for detection of 
the H-Ig on the blots, these H-Ig were carefully checked for specificity for 
goat IgG. Therefore, after blotting, the PVDF membranes were incubated 
with biotinylated normal goat IgG (protein G purified), diluted in blocking 
solution. A subsequent incubation with avidin-peroxidase allowed for staining 
of the blots with DAB substrate as described. None of these H-Ig showed anti-
goat specificity (not shown). Thus a rheumatoid factor-like activity of these H-
Ig could not be proved and we designated them as multireactive Ig (MR). In 
the Tg group, a MR could be detected in two (11.8%) of the mice, whereas in 
the LM group six (15%) of the mice had a MR. 
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Lambda light -chain usage was apparently not increased since in both 
groups only 1 H-Ig gave a positive reaction with ShaM-A-PO in itmnunoblot. 
Persistent H-Ig of the IgD isotype were detected in low frequencies in 
both groups [Tg: 5.1 % (n=39); LM: 7.7% (n=52); p>O.05]. The mice 
tested for IgD were 7 months younger than the mice tested in table 4. 
Table 4. Isotype distribution of H-Ig components in aged WK Tg mice and LM controls. 
H-Ig Tg(N~17) LM (N~26) 
isotype a n (%) b n (%) 
IgGI 6 (35.3) 7 (17.5) 
IgG2a 2 (11.8) 9 (22.5) 
IgG2b 4 (23.5) 6 (15) 
IgG3 2 (11.8) 3 (7.5) 
IgM (Igh-6b) I (5.9) 9 (22.5) 
IgM (Igh-6a) 0 , 
IgA 0 0 
MRd 2 (11.8) 6 (15) 
a Isotype distribution of H-Ig components was determined by immunoblouing, using GaM 
isotype-specific peroxidase conjugates. 
b Number and percentage of total number of H-Ig components per group. 
e LM mice do not have IgM (Igh-6a). 
d Multireactive H-Jg, showing multiple staining in immunoblotting. 
DISCUSSION 
The exact phenotype, localization and B cell lineage ongm of the 
neoplastic precursor cells of MG are unknown. Unlike most B cell chronic 
lymphocytic leukemias (B-CLL) in humans, there is no constitutive expression 
of CD5 on the cell surface of neoplastic B cells from MG, making it difficult 
to speculate about the cell lineage origin of these B cell proliferative 
disorders. Data on this, however, are needed to discriminate early stages of 
benign and malignant B cell proliferative disorders and may be crucial for the 
timely efficient treatment of the malignant forms. In this respect the possible 
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origin of MG from either B-1 or B-2 cells is of interest. While B-CLL and 
some cases of Waldenstrom's macroglobulinemia were shown to develop from 
the B-1 cell, experiments with mouse multiple myeloma and BMG indicated 
the possibility that the target cell is a memory cell, possibly of the B-2 cell 
lineage. Our results demonstrated that both these neoplastic disorders can also 
stem from the B-1 cell. 
Although the transgenic mouse model we used does not reflect a normal 
inunune system, it still has some advantages that are crucial for this study. 
Firstly, the B-1 cell population could be studied without being dependent on 
cell surface markers. The expression of markers specific for the B-1 lineage 
(CD5 and CDllb) might be affected by the growth deregulating processes that 
occur during neoplastic transformation. Furthermore, B cell proliferative 
disorders do not express these markers at the end-stage of their differentiation. 
The presence of an Ig transgene can result in dowmegulation of the Tg 
expression or even in total shut down of Tg transcription [16,17]. This would 
result in normalization of the serum Ig isotype levels at old age. This was not 
the case in this animal model, in which the mice had a stable level of Igh-6a 
during their entire life-span. Effects of aging on the B cell system as reflected 
by the isotype levels were approximately the same in Tg and LM mice. Even 
after more than two years normal Ig levels in the sera of the Tg mice were not 
reached and the relative humoral immunodeficiency remained present in the 
old mice. 
During aging, the T cell compartment also shows diminished capacities 
and this, acting together with the already inflicted B cell compartment, could 
very well have an influence on age-associated pathology in Tg mice. 
However, histological examination of about half of the LM and Tg mice did 
not reveal specific lesions which could be ascribed to the Tg status. Type and 
incidence of lesions were similar to that of historical data [9], with the 
exception of a clearly higher incidence of acute inflannnatory lesions in both 
groups, due to conventional housing of the mice, and of the absence of 
histiocytic sarcomas in Tg mice. 
The observed difference between the life-spans of male Tg and LM 
mice was marginal considering that antibody responses to T-cell independent 
antigens, many of which are bacterially related, were almost absent and the 
response to T-cell dependent antigens was retarded [13] in the Sp6-B6 mice. 
Furthermore, the degenerate specificity of the Sp6 antibody [18] did not result 
in manifest autoinunune diseases, reflecting ample compensatory mechanisms 
and a functional T cell system. From the histopathological examination of 
necropsy material it can be concluded that the presence of the Ig transgene 
itself is not a stimulating factor for neoplastic transformation in general. 
The interpretation of the electrophoresis and i11l11lunoblotting data was 
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not complicated by a monoclonal band of Tg IgM, probably due to the 
secretion of "mixed" IgM pentamers, as was suggested earlier [13,15]. 
Although the Tg IgM-kappa is principally a monoclonal Ig, the introduction of 
the Ig transgene in B cells resulted, at least in a sUbpopulation of B cells, in 
the appearance of double-Ig producers. Various, probably random, amounts of 
endogenous and Tg IgM molecules in the secreted IgM pentamers, together 
with the possibility for combination of the Tg p.-chain with endogenous light-
chains, prevented the appearance of a monoclonal band in serum 
electrophoresis and rather resulted in a more diffuse electrophoretic pattern. 
We purified Tg IgM (lgh-6a) from pooled Tg sera by affinity 
chromatography and compared the differentiated carbohydrate residue content 
with purified IgM from LM pooled sera and purified IgM paraproteins of both 
allotypes (unpublished data). Differences in carbohydrate content between the 
samples were minimal (analysis performed by Dr.M.Tomana, University of 
Alabama, Birmingham, AL). Therefore the absence of a consistent H-Ig of Tg 
origin in serum agar electrophoresis could not be attributed to differences in 
post -translational modification of the transgenic and endogenous p.-chains. 
Others have shown that the B cell compartment responsible for 
endogenous Ig production is extensively activated in these mice [14,19]. In the 
Sp6-Tg mice the Ig specificity development was clearly shifted to the 
population of B cells that is still able to form a near-to-normal Ig repertoire 
[20], in this case the B-1 cells. Still, the transgenes expressing B cells are 
functioning properly after encountering the relevant antigen TNP [21]. 
Certain specific conditions may be necessary to allow for excessive 
proliferation of B cell clones, such as an extensive antigenic activation or, like 
in this model, a relative B-2 cell immunodeficiency that leads to compensatory 
activation of the B-1 cells. Because the development of MG of B-2 cell origin 
seems to be suppressed by the presence of an Ig transgene coding for an 
irrelevant specificity, it can be reasoned that antigenic specificity and 
activation of a B cell might be a competent contributing factor in MG 
development. In this respect it would be interesting to know whether Sp6-Tg 
mice, after repeated il1ll11unization with TNP-conjugates, develop IgM 
paraproteins with TNP specificity. 
In Tg mice about 10% of splenic B cells express endogenous Ig [7]. 
During aging the frequency of MG in Tg mice is about 50% of that in LM 
mice. This suggests that there is a five fold higher contribution of endogenous 
Ig producing B-1 cells to the formation of MG in Tg mice than in LM mice. 
It has been shown in non-transgenic mice that peritoneal B-1 cells can 
become clonally restricted during aging [22]. More studies need to be done to 
find out whether these B-1 cell clones are the producers of a paraprotein. 
The results of this study are in accordance only with some points from a 
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similar study on MG development in M54 Tg mice [23]. In M54 mice the 
transgene encodes for a Jl-heavy chain only, derived from a NP-specific IgM 
producing hybridoma. The authors did not find H-Ig of transgenic origin, 
which is analogous with our observations in the Sp6 Tg mice. In contrast to 
our findings in Sp6 mice, only transient H-Ig of endogenous isotype were 
found and all of low concentration. The frequency of those monoclonal 
components was higher in Tg mice than in LM controls, most of them using 
lambda light-chains. The differences in results of these two studies can in part 
be explained by the difference in mouse strains and their genetic backgronnd 
and age, in microbiological status, and in the use of different transgenes. 
Recently Gueret et al published a study on MG development in C57BLlXid 
mice [24]. The Xid mutation resulted in a deficient B-1 cell population. No H-
Ig were detected in the Xid-mice against a 50% incidence in control mice. 
Unfortunately, these mice did not live long enough to develop full-blown MG 
of neoplastic origin. Still, this observation also suggests a role for the mouse 
B-1 cell lineage in the pathogenesis of age-related B cell proliferative 
disorders. 
The exact function of the B-1 cells is still unknown. Their localization 
in the coelomic cavities, together with intestinal IgA plasma cells derived from 
the B-1 cells, emphasizes their role in mucosal inununity [5,7,25,26,27). 
ExcesSive and prolonged antigenic stimulation is not unconunon in this 
enviromnent. For example, bacterial cell walls contain LPS-like substances 
that are potent polyclonal B cell stimulators. It was shown that orally fed LPS 
was able to stimulate the B-1 cell population but not the B-2 cells [28). When 
the B-1 cells become clonally restricted with increasing age [22], in the 
presence of genetic susceptibility to MG development, an H-Ig may become 
detectable in the serum. 
In conclusion, we have shown that the B-1 lineage contributes to the 
development of monoclonal ganunopathies in mice. Studies of gene 
abnormalities in the B cell clones involved in MG development and the 
determination of the H-Ig specificities will be useful in further explaining the 
origin of these B cell proliferative disorders. 
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IgH ALLOTYPE-CONGENIC MOUSE CHIMERAS REVEAL 
INVOLVEMENT OF THE B-1 CELL LINEAGE IN THE 
DEVELOPMENT OF BENIGN MONOCLONAL IgM 
GAMMOPATHY 
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SUMMARY 
Plasma cell proliferative disorders present themselves by homogenous, 
monoclonal immunoglobulins (H-Ig) in the serum. Cells of the neoplastic 
representatives of these monoclonal ganmlOpathies (MG), such as multiple 
myeloma (MM) , Waldenstrom's macroglobulinemia (WM) and benign 
monoclonal gammopathy (BMG) , are mainly located in the bone marrow, 
spleen and lymph nodes. Still, it is not clear what the exact phenotype, 
localization, and cell lineage origin is of the precursor cells of MG. 
Knowledge of the B-cell lineage origin might be helpful for correct diagnosis 
and timely efficient treatment of malignant forms of MG. 
We used Ig allotype-congenic mouse chimeras to determine the cell 
lineage origin of MG. Using this model, the H-Ig of aging C57BL mice 
originating from the B-1 cells in the peritoneal cavity could be discriminated 
from the bone marrow derived B-2 cell Ig product by allotype difference. 
Due to late effects of the total body irradiation (9.5 Gy), the life-span of 
the chimeras was reduced and consequently the number of H-Ig detected in 
this study was less than expected. The determination of the IgM-allotypes of 
H-Ig in aged chimeras revealed that most of these H-Ig originated from B-1 
cells. These MG could be classified as BMG and transient MG. In the 
chimeras (n= 166) we detected only one multiple myeloma, with an allotype 
corresponding with the BM donor. 
This study indicates that age-related monoclonal B-cell proliferative 
disorders in genetically susceptible mice can originate from the BM as well as 
from the peritoneal cavity, involving the B-1 cell population. 
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INTRODUCTION 
Monoclonal B cell proliferative disorders at the differentiation stage of a 
plasma cell synthesize monoclonal immunoglobulins that are detectable in the 
serum as homogenous Ig components (H-Ig). Therefore they are designated 
monoclonal ganmlOpathies (MG). Using biological and pathogenetic 
characteristics, Radl divided MG into four categories [1,2]. Clinically the 
most important MG are those of the neoplastic categories. They develop due 
to intrinsic B cell disorders, resulting in either a benign MG (BMG) or in a 
malignant plasma cell neoplasia, such as multiple myeloma (MM), (extra-) 
medullary plasmacytoma, or Waldenstrom's macroglobulinemia. The 
development of these B cell proliferative disorders is age-related. Monoclonal 
ganunopathies of other categories are mainly the result of imbalances between 
Band T cell functions, such as during inununosuppressive treatment, or as a 
result of a homogenous antibody response after excessive antigenic 
stimulation. Influences of genetic background, T cell function impairment and 
antigenic stimulation on the development of MG have been reported earlier in 
humans as well as in laboratory animals [2,3,4]. The C57BLIKaLwRij mouse 
strain proved to be a suitable model for studying MG, since aging mice of this 
strain develop spontaneously MG of all categories [5,6]. 
The phenotype of the neoplastic MG precursor cells is not known. In 
mice two B cell lineages can be distinguished [7,8]. The B-1 cells constitute a 
self-replenishing population of B cells in the peritoneal and thoracic cavities. 
The conventional B cells are bone marrow derived, and are called B-2 cells. 
Unlike mature B cells, plasma cells do not express the lineage markers CD5 
or CDllb that are characteristic of the B-1 lineage. The precise function of 
the B-1 cells is not known, but they may playa role in mucosal defence and 
in various autoinunune phenomena [9]. lt has been shown in mice that with 
aging the B-1 cell population becomes increasingly clonally restricted [10]. 
This phenomenon might also account for a relatively high chance of neoplastic 
transformation within these cells. Therefore they form a pool of potential 
precursor cells of MG. 
We used allotype congenic mouse chimeras to study the B cell lineage 
origin of MG in aging C57BL mice. A long-term follow-up study was 
performed in lethally irradiated mice that were reconstituted with bone 
marrow (BM) cells and IgH allotype congenic peritoneal wash cells. The cells 
from the peritoneal washes provided the precursors of the B-1 cell population. 
The BM cells gave rise to the B-2 cells [11]. The cellular origin of the H-Ig 
that developed at old age in these chimeras could thus be determined by Ig-
allotyping of the H-Ig component in the serum. 
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We were able to show that some of the H-Ig that were detected in the 
old chimeras, were derived from peritoneal B cells. These MG could only 
have developed from the B-1 cell lineage, since the peritoneal wash cells in 
adult mice do not provide for B-2 stem cells. 
MATERIALS AND METHODS 
Illice and cell trausfer 
C57BL/6 (Ighh) and C57BL.Igha mice from the breeding stock of the Department of 
Immunology of the Erasmus University in Rotterdam were maintained under clean conventional 
conditions. Recipient mice received a single dose of 9.5 Gy total body irradiation, 24 hours 
prior to cell transfer. Only female recipient mice (aged 5 months) were used. The donor mice 
were of the same age. Peritoneal cells were washed out of the peritoneal cavities (PerC) of the 
donor mice with 10 ml ice-cold balanced salt solution (BSS). BM cells were prepared by 
tlushing the femur and tibia with BSS. Transfer of PerC cells was performed by Lp. injection 
of 3x106 PerC cells in 250 JlI BSS. Transfer of BM cells was performed by i.v. injection of 
2xlO' BM cells in 0.5 ml BSS. 
We used three groups of irradiated recipient mice: one group of 63 C57BL.lgh~ mice 
received only Ighl> BM cells; 57 C57BL.lgh~ mice received Igh~ BM cells and Ighl> PerC cells; 
46 C57BL/6 mice received Ighl> BM cells and Igha PerC cells. Groups of 33 un irradiated aging 
mice of both strains were used as control mice. The mice were allowed to live out their Iife-
spans. Seriously ill or moribund mice were submitted to necropsy according to a standard 
protocol [12J. 
Antibodies 
PUI·it1ed polyclonal goat anti-mouse (7S fractions) IgG 1, IgG2a, IgG2b, IgG3, IgM, and 
IgA (Nordic Immunological Laboratories, Tilburg, The Netherlands) were used in the ELISA 
as capture antibodies. Peroxidase conjugates of the same antibodies were used in the 
immunoblots for determining the isotype of the H-Ig. Detection of IgM-allotypes by 
immunoblotling was done with biotin conjugated RS3.1 mouse anti-ll1ouse-Igh6a and MB86 
mouse anti-mouse~Igh6b (kindly donated by Dr.A.Colitinho). Biotinylated mouse anti-mouse 
Ighlb, clone 145-3.1 (Nordic Immunological Laboratories) was used to determine IgG2al> 
allotype positive H-Ig. Because the total IgG2a (a and b allotype together) was also determined, 
H-Ig that were negative in the Ighlb detecting immunoblolting experiments had to be of Ighla 
allotype. 
Detection lIlld characterization of H-Ig 
Every three months a small blood sample was taken from the tail veins of the mice. The 
undiluted serum was used for high resolution serum electrophoresis in agar 0.9% (Difco, 
Detroit, MI) as described previously [13]. The H-Ig detection limit of this technique was JOO 
Itg per Ill!. To determine the heavy-chain and light-chain isotypes of the H-Ig we used 
immunoblotting on PVDP membranes (Immobilon; Millipore, Bedfort, MA) as described 
previously [13]. The same method was used for allotype detection of H-Ig. Since B-1 cells 
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produce relatively large amounts of IgM, we optimized H-Ig allotype detection of Igh6a and 
Igh6b (lgM allotypes). Additionally, the Ighlb (lgG2ah) allotype was determined. 
ELISA 
Briefly, 96-well round-bottom microliter plates (Greiner, Alphen aId Rijn, The 
Netherlands) were coated with purified goat anti-mouse isotype antibodies (10 pg/ml in PBS, 50 
It! per well) overnight at 4°C. After blocking the residual sites with PBS-Tween-20/5% BSA, 
the serum samples were added in appropriate dilutions and incubated at room temperature for 2 
hours. After washing the plates with PBS-Tween the plates were incubated with alkaline-
phosphatase (AP) conjugated goat anti-mouse IgG, -A, and -M (KPL, Gaithersburg, MD, USA) 
for one hour at room temperature. After washing and final incubation with substrate solution 
(p-nitrophenylphosphate lmg/ml in a 1M diethanolamine, 0.05 M MgCl2 buffer, pH 9.8) the 
absorbance was read by 405 lUll using a BioRad Model 3550 Microplate Reader (BioRad, 
Veenendaai, The Netherlands). For detection of IgM allotypes, the RS3.1 mouse anti-mouse 
Igh6a (a kind gift of DLA.Coutinho, Institut Pasteur, Paris) and the AF6-78 mouse anti-mouse 
Igh6b (Phanningen, San Diego, CA) antibodies were used as a coating. After incubation with 
appropriate serum dilutions, AP conjugated goat anti-mouse IgM (KPL) allowed for specific 
IgM detection. The assays were standardized with affinity-purified mouse monoclonal 
antibodies of appropriate isotype and allotype. 
Statistical allalysis 
Survival-curves were constructed according to the method of Kaplan-Meier and 
differences were assessed by the logrank test. ELISA data were log-transformed and analyzed 
by ANOVA. Frequencies were analyzed by Fisher's Exact Test. A P-value smaller than 0.05 
was considered statistically significant. 
RESULTS 
SUl'vival 
All groups that received total body irradiation (9.5 Gy) died 
significantly earlier (P < .001) than the two control groups (fig. 1). C57BLf6 
recipient mice that received Ighb-BM cells and Igh'-PerC cells had the shortest 
life-span (P < .001). C57BL.Igh' mice that received only Ighb-BM cells lived 
shorter than C57BL.Igh' mice that received Igh'-BM cells and Ighb-PerC cells 
(P< .001). The two control groups had equal survival characteristics. Survival 
of the irradiated mice did not improve markedly when the dosage of radiation 
was decreased to 8.5 Gy, but a dose of 10 Gy significantly further reduced the 
life-span of the treated mice (data not shown). The cause of death was not 
unsuccessful cell transfer, as this would have caused death at a much earlier 
time point. Necropsies of the mice which died spontaneously or were killed 
when moribund revealed that the decreased survival was due to severe late 
renal damage, caused by the irradiation. The renal changes were dominated by 
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Figure 1. Kaplan-Meier survival curves of the allotype-congenic radiation chimeras and control 
groups. The age at which the irradiation and cell transfers took place is indicated by an arrow. 
The horizontal dotted line is the 50% survival reference line. (A) C57BL/6 recipient mice of 
Igh" BM cells and Igh' PerC cells (n=46); (B) C57BL.lgh' recipient mice of Igh' BM cells 
(n=63);(C) C57BL. Igh'recipient mice of Igh' BM cells and Igh" PerC cells (n=57); (D) 
unirradiated C57BLl6 mice (n=33); (E) unirradiated C57BL.lgh' mice (n=33). 
severe endothelial damage leading to fibrinoid change of many arterioles and 
small arteries. Additionally, plugging of the lumen of arterioles and 
glomerular capillaries by fibrin thrombi resulted in extensive mesangiolysis 
and ischemic glomerular changes. 
Similar subendothelial fibrinoid changes were sporadically seen also in 
small arteries elsewhere in the body. These, however, did not result in severe 
organ damage as seen in the kidneys. The low incidence of other life-limiting 
or age-related diseases, such as malignant lymphomas or amyloidosis, 
indicated that the steep decline of the survival curve was due to a single 
intercurrent fatal disease, i. e. renal damage. Consequently the mice did not 
live long enough to develop the various categories of MG in an incidence that 
is seen in untreated aging C57BL mice. 
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Ig isotype concelltrations during aging 
Individual serum isotype concentrations are of interest in relation to the 
isotype distribution of the H-Ig. The dominant isotypes usually represent the 
majority of the H-Ig. The serum concentrations of Ig isotypes were 
determined in 12 to 22 mice of each group by a double sandwich ELISA (fig. 
2) at four consecutive time points (ranging from 3 months till 12 months after 
irradiation and cell transfer). 
As for the group of C57BL.Igh' mice that received only BM of Ighb 
allotype, most of the Ig isotypes were lower in concentration than in the 
C57BL.Igh' control group. Only the total IgM concentration was higher than 
in the control group (P< .001). 
The C57BL.Igh' mice that received BM of Igh' allotype and PerC cells 
of Ighb allotype had lower levels of IgG 1 and IgA than the C57BL.Igh' control 
mice (P < .00l), but higher levels of total IgM (significant at the last three 
time points). The IgG2a and IgG2b levels in this group were significantly 
lower than in the control group at the first time point, that was 3 months after 
transfer (P< .001). Later in life the levels of these isotypes in this group 
equalled that of the control group. 
The other group of allotype chimeras, C57BLl6 (lghb) mice that 
received Ighb BM and Igh' PerC cells, had equal levels of IgG1, IgG2a 
(except at 3 months: P< .05), IgG2b, IgG3 (except at 3 months: P< .01), and 
total IgM compared to the C57BLl6 control group. At 3 and 6 months after 
cell transfer the IgA levels were lower than in the control group (P < .01). 
Comparison of the control groups showed that C57BLl6 mice had 
higher levels of IgG2a (P < .05), and slightly higher levels of IgM 
(significantly so at 6 and 9 months after cell transfer; P < .05 and P < .01, 
respectively). 
Although satisfying in immunoblotting experiments, the MB86 
monoclonal mouse anti-mouse Igh6b antibody did not work out well in the 
ELISA. We therefore tested the AF6-78 mouse anti-mouse Igh6b 
(Phanningen) as a coating antibody (10 I'g/ml), which gave reproducible and 
specific results in ELISA. 
The results of the Igh6a and Igh6b ELISA showed that about 25 % to 
50 % of the serum IgM originated from the donor peritoneal B cells in both 
groups that received BM and PerC cells (fig. 3). 
Frequency and classification of H-Ig development 
Figure 4 shows the cumulative frequency of H-Ig development in 
allotype congenic chimeras and control mice. The incidences of H-Ig in unir-
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Figure 2. Serum Ig isotype concentrations during aging of allotype~congenic radiation chimeras 
and age-matched controls. The groups are indicated by (a) C57BL.lgha recipient mice of Igh" 
BM cells; (Il) C57BL.lgh' recipient mice of Igh' BM cells and Igh' PerC cells; (c) C57BLl6 
recipient mice of Igh" BM cells and Igha PerC cells; Cd) unirradiated C57BL,lgha mice; (e) 
unirradiated C57BL/6 mice. 
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Figure 3. Serum Igh6a and Igh6b (IgM-alJotypes) concentrations during aging of allotype-
congenic radiation chimeras. The open bars represent the group of C57BL.Igha mice that 
received Igh' BM cells and Igh' PerC cells; the black bars represent the group of C57BLl6 
mice that received Ighh BM cells and Igha PerC cells. 
radiated control mice were consistently higher in the C57BLl6 (lghb) mice 
than in the age-matched C57BL.Igh' mice, but only after 19 months this 
difference was statistically significant (two-sided P-value = 0.01). The 
allotype chimeras approximately followed the frequencies of their original BM 
allotype. However, 12 months after cell transfer all irradiated groups showed 
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Figure 4. Incidence of H-Ig in the experimental and control groups during aging. (0) 
C57BL.lgh' control mice; (II) C57BLl6 control mice; (,) C57BL.lgh' recipient mice of Igh' 
BM cells; (0) C57BL.lgh' recipient mice of Igh' BM cells and Igh' PerC cells; (e) C57BLl6 
recipient mice of Ighh BM cel1s and Igh" PerC cells. 
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an enhanced frequency of H-Ig development as compared to the control mice 
of the same age. This time-point was just before the initiation of the relatively 
fast extinction of the irradiated mice, caused by fatal renal damage. We 
therefore concluded that later than 12 months after lethal irradiation the 
experimental groups could not be compared any more to the control groups. 
Table 1 lists the various serologically determined categories of the H-Ig. 
The data that are shown here were collected up to one year after cell transfer. 
C57BLl6 control mice showed a higher incidence (P< .05) of total H-Ig than 
C57BL.Igh' control mice, but there was no significant difference in the 
incidences of the individual categories. 
The C57BL.Igh' mice that received only Ighb BM cells developed less 
total H-Ig (P= .0033), BMG (P= .004) and multiple H-Ig (P= .05) than the 
C57BLl6 control group. 
The C57BL.Igh' mice that received Igh' BM and Ighb PerC cells showed 
the same incidences of H-Ig categories as did the C57BL.Igh' control group. 
The C57BLl6 mice that received Ighb BM and Igh' PerC developed less BMG 
(P= .02) and multiple H-Ig (P= .03) than the C57BLl6 control group. 
Isotype distribution of the H-Ig 
The isotype distribution of the H-Ig in the aged groups is shown in table 
2. Comparison with the control groups showed a higher incidence of H-Ig of 
the IgG2a isotype in the C57BLl6 mice (P=0.05). This observation is in 
accordance with the higher serum levels of IgG2a in this group (fig 2). In 
analogy, the C57BL.Igh' mice that received Ighb BM cells developed more H-
Ig of the IgM isotype than the control groups (13.8 % vs 3 % and 0 %), but 
these numbers were just not significantly different. Overall, the incidences of 
H-Ig of the IgM isotype were higher in the irradiated groups than in the 
control groups. 
Allotype distribution of the H-Ig 
Most H-Ig in C57BLl6 mice were of the IgG2a isotype. A substantial 
part of the weak H-Ig were IgM. Therefore we determined the frequencies of 
Ighl and Igh6 a- and b-allotypes of the H-Ig one year after irradiation and cell 
transfer (Table 2). At this time point the majority of the mice was still alive 
and the incidence of H-Ig had reached a maximum in the irradiated mice. The 
presence of both allotypes of IgM in every recipient mouse during their entire 
life span indicated successful transfer of BM cells as well as of PerC cells. 
We did not find H -Ig of the IgG2a isotype that originated from the PerC 
cell transfer. The pronounced H-Ig of Igla allotype that was found in a single 
Table L Classification of the H-Ig in aging allotype congenic C57BL chimeras. The follow-up time was one year after transfer of cells. 
Recipient mouse strain Unmanipulated controls 
C57BL.Igh" C57BLl6 C57BL.Igh" C57BLl6 
Transferred cells Ighb-BM Ighll-BM + Ighb-PerC Ighh-BM + Ighll-PerC none none 
Total number of mice 63 57 46 33 33 
Mice with H-Ig (%) a) 16 (25.4) b) 16 (2S.1) 25 (54.4) 10 (30.3) g) 19(57.6) 
I. Multiple myeloma o (0) 1 (6.3) 0(0) o (0) 0(0) 
IT. Benign MG 1 (6.3) 0) 7 (43.S) 4 (16) 0) 4 (40) 10(52.6) 
ill. Transient MG 10 (62.5) 3 (IS.S) 7 (2S) 5 (50) 7 (36.S) 
Unclassifiable S (50) 5 (31.3) 14 (56) 2 (20) 4 (21.1) 
Multiple H-Ig 1 (6.3) d) 2 (12.5) 4 (16) 0 o (0) 7 (36.S) 
a) The number of mice with H-Ig is the 100% reference value for the percentages of the subsequent categories of MG. Cumulative percentages of all 
categories of MG can be more than 100% due to the possible presence of (multiple) transient MG and the occurrence of other MG in the same mouse; 
b) P=0.0033; c) P=0.004; d) P=0.05; e) P=0.02; f) P=0.03; g) P< .05; all P-values were calculated in comparison to the C57BLl6 control group. 
Table 2. Isotype distribution of H-Ig components in the sera of aged allotype chimeras. The sera were taken at the age of 17 months ± 2 weeks. i.e. 
one year after lethal irradiation and cell transfer. 
Recipient mouse strain Unmanipulated controls 
C57BL.lgh' C57BLl6 C57BL.Igh' C57BLl6 
Transferred cells Igbb-BM Igba-BM + Igbb-PerC Igbb-BM + IghJ-PerC none none 
Number of tested mice 58 51 21 33 33 
Isotype 
IgG1 1 (1.7) " 3 (5.9) 0 1 (3.0) 2 (6.0) 
IgG2b 1 (1.7) 1 (2.0) 0 4 (12.1) 2 (6.0) 
IgG3 2 (3.4) 2 (3.9) 2 (9.5) 2 (6.0) 1 (3.0) 
IgA 0 0 0 0 1 (3.0) 
IgG2a ' (Ighla) 0 1 (2.0) 0 1 (3.0) 
IgG2a' (Ighlb) 1 (1.7) 0 1 (4.8) 7 (21.2) 
IgM' (Igh6a) 7 (12.!) 2 (3.9) 3 (14.3) 1 (3.0) 
IgM b (Igh6b) 1 (1.7) 6 (11.8) 1 (4.8) 0 
a) absolute and relative number (% between brackets) of H-Ig components 
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mouse in the C57BL.lgh' group that received Igh' BM and Ighb PerC cells 
turned out to be a multiple myeloma. Because of its Igh' allotype, this 
multiple myeloma could be identified as originating from B-2 cells in the BM. 
In the irradiated groups H-Ig of Igh6a and Igh6b were found, 
indicating that H-Ig of the IgM isotype could originate from BM cells as well 
as from PerC cells, with a higher incidence of the latter. The C57BL.lgh' 
mice that received only Ighb BM cells were still able to develop H-Ig of Igh6a 
and Igh6b allotypes. 
DISCUSSION 
Malignant representatives of age-associated MG, mUltiple myeloma 
and Waldenstrom's macroglobulinemia, consist of expanding plasma cell 
clones that produce large quantities of H-Ig (paraprotein). These malignant 
plasma cells expand in the BM, spleen andlor lymph nodes. However, this 
category of MG is much less connnon than the BMG, with a 100 times higher 
incidence in C57BL mice, and the transient MG. Although it is sometimes 
possible to find the relatively small benign plasma cell clone in the BM, it is 
not clear where the excessive monoclonal B cell proliferation originated, what 
the exact phenotype is of the B cells and what the cell lineage origin is. 
Information about these parameters might enable us to discriminate in an early 
phase between malignant and benign MG and could therefore be necessary for 
correct diagnosis and timely treatment. 
In mice it has been shown that roughly two populations of B cells can 
be distinguished by their phenotype and localization [7, 8, 11, 14). In adult 
mice, the 8-1 cells are exclusively derived from precursor cells in the 
peritoneal cavity, probably residing in the omentum [15, 16). The B-2 cells 
originate from the 8M. Based on this dichotomy we generated different types 
of IgH allotype chimeras [11) for long-term follow-up of the Ig spectrum. 
This enabled us to determine the cell lineage origin of the MG by detection of 
the allotype of the H-Ig component. 
While a somewhat decreased median survival time due to an increased 
incidence of a variety of tumors and of non-neoplastic lesions, among which 
some late renal damage, was envisaged due to the irradiation of the mice [17, 
18). the severely reduced survival as observed in our experimental groups was 
unexpected. Also the histopathological aspect of the renal lesions was 
extraordinary. Usually after total body irradiation (TBI) late renal damage is 
limited to mainly the glomeruli; lesions of tubuli and especially of arterioles 
and small arteries are rare [18, 19). Strain differences in survival time after 
TBI have been described (18) and it could be that the abnormal subendothelial 
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fibrin transudation and the formation of fibrin thrombi is due to an 
exceptionally high radiosensitivity of the substrains used in our experiments. 
Consequently, the number of H-Ig detected in this study was less than 
expected. Table 1 shows that one year after lethal irradiation and cell transfer 
the chimeras had developed about the same number of the various MG 
categories as the control groups. However, the two control groups lived much 
longer after this time point than the chimeras and developed still more H-Ig, 
as is shown in figure 3. The Ig isotype levels in the sera of the chimeras were 
slightly affected. 
The two mouse strains used in these experiments did not develop 
equal numbers of MG, as appears from table I. The C57BL.Igh' mice, 
whether in the control group or in the allotype-chimera groups, had less H-Ig 
than their Ighb counterparts, the C57BLl6 mice. This difference between the 
two strains was not extended to the individual frequencies of the various MG 
categories. However, the time point of our observations, i.e. one year after 
irradiation, might be responsible for the latter, as mentioned before. The 
allotype related difference in development of MG was observed previously in 
the individual mouse strains [20], as well as in C57BLlKaLwRij and 
CBA/BrARij radiation chimeras [21] and in (C57BLlLiARij x CBA/BrARij) 
Fl mice [22]. 
The determination of the IgM-aliotypes of H-Ig in aged chimeras 
revealed that most of these H-Ig originated from PerC cells (11.8% - 14.3% 
of total H-Ig). This holds even true for the group of C57BL.Igh' mice that 
received only BM cells of Ighb allotype: in this cohort we detected 7 H-Ig of 
Igh6a allotype. This was only possible when some of the original Igh' 
precursor cells survived the irradiation. Whether these precursor cells resided 
in the PerC or in the BM is uncertain. Before starting the experiment we 
confirmed in a pilot study that the dose of 9.5 Gy was lethal to the mice. 
However, it has been shown that B-1 precursor cells are more radioresistant 
than their B-2 cell counterparts [14]. This means that there might have been 
some viable Igh' B-1 precursor cells left in the PerC of this group of mice 
after irradiation. These B-1 cell precursors could reconstitute the PerC of 
these mice, because they did not receive unirradiated, and thus viable, 
peritoneal wash cells. 
The frequency of PerC derived IgM positive H-Ig was inversely 
related to the serum concentration of the PerC derived IgM allotype (fig. 3). 
This phenomenon might reflect the clonal restriction of the PerC derived B-1 
cells, which increases with age [10]. 
Besides producing large quantities of IgM natural antibodies [23], B-1 
cells are known to provide the lamina propria of the gut with IgA producing 
plasma cells [24]. It is possible to detect IgA allotypes in the serum; however, 
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none of the chimeras in this study developed an H-Ig of IgA allotype. The fact 
that we did not detect IgG2a positive H-Ig derived from the peritoneal cells 
reflects the small amount of IgG2a produced by these B-1 cells. 
Our observation that monoclonal IgM producing MG can originate 
from B-1 cells does not answer the question whether these excessive 
proliferations are induced by antigen or whether they are merely a result of 
the restricted "natural" repertoire of the B-1 cells at old age [10]. We have 
shown previously that the B-1 cell lineage contributes to the development of 
MG in genetically susceptible mice [25]. Because we detected only benign 
IgM producing MG of B-1 cell origin, it is speculative that malignant IgM 
producing MG, as in Waldenstrom's macroglobulinemia, can originate from 
the B-1 cell population in C57BL mice. Whether human Waldenstrom's 
macroglobulinemia, (extra-)medullary plasmacytoma, BMG, and transient MG 
can be manifestations of plasma cell clones of B-1 cell origin, remains to be 
investigated. 
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CHAPTER 3 
FREQUENCY OF CLONAL DOMINANCE IN THE 
SPECIFIC ANTIBODY RESPONSE TO DNP-HSA IN CBA 
AND C57BL MICE REFLECTS THEIR SUSCEPTIBILITY 
TO AGE-ASSOCIATED DEVELOPMENT OF 
MONOCLONAL GAMMOPATHIES • 
C. van Al'kel l ", F.J.M. Nooij I, A.J. van del' Sluijs-Gelling', J. Radl' 
1. Department of ImlJlullological alld Infectious Diseases, TNO Prevention alld Health, Leiden; 
2. Department of Immunology, Erasmus University Rotterdam, Rotterdam; 3. Nordic 
Imlllullological Laboratories, Tilburg, The Netherlands. 
SUMMARY 
The effects of age, genetic background and neonatal thymectomy on 
the levels and the heterogeneity of the specific antibody response were 
investigated in an experimental mouse model. Both intact and neonatally 
thymectomized (NTx) C57BLIKaLwRij (C57BL) and CBA/BrARij (CBA) 
mice were immunized at the age of 3 ("young") or 22 months ("old"). Highly 
sensitive antigen-specific immunoblotting techniques (ABL) , in combination 
with agar-electrophoresis and isoelectric focusing (IEF) , were used to 
investigate total specific antibody levels, the number of responding antigen-
specific clonotypes, and the dominance of responding B cell clones in the 
antibody response against dinitrophenylated human serum albumin. After 
inullunization, the specific antibody levels progressively increased in all 
experimental groups with the exception of old C57BL mice. All mice 
responded with a specific polyclonal heterogenous response. In addition, some 
mice showed a clonal dominance of antibody-producing cells, as is reflected in 
the appearance of distinct homogenous antibody components (H-Ab) in the 
sera. This clonal dominance was scarce in CBA mice but frequent in C57BL 
mice. Age at time of immunization and NTx had little if any additive effect on 
the incidence of H-Ab in either mouse strain. All dominant clones showed 
different electrophoretic mobility, indicating the proliferation of various 
clonotypes and not a strain-specific dominance of one clone. In old C57BL 
mice the specific antibody response was more restricted in heterogeneity as is 
illustrated by more visible spectrotype bands in IEF and subsequent ABL. 
* Published in: Clin Immunol Immunopathol 1997,83:272-280. 
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Hence, in old C57BL mice smaller amounts of specific antibodies were 
produced by fewer clones. Still the incidence of H-Ab in this group was the 
same as in the group of young C57BL mice. This indicates that at old age the 
responding B cell clones are more prone to becoming clonally dominant in 
C57BL mice. This tendency correlates with the high incidence of 
~pontaneously developing monoclonal gammopathies in aging C57BL mice. 
INTRODUCTION 
The diversity of antibody responses strongly depends on the available 
B-cell repertoire in the adult individual. The selection of responding 
clonotypes is therefore not only antigen dependent, but also under genetic 
control with a major role for the variable heavy- and light-chain immuno-
globulin (Ig) genes, followed by the ability to express the corresponding 
clonotypes before and after antigenic stimulation [I]. Furthermore, T-B cell 
interactions affect the quantity and quality of the antibody response. 
Long-term effects of these modifying factors become more pronounced 
during aging [2]. Although the overall Ig levels do not decrease with age, a 
progressively increasing variation of the Ig levels is a characteristic finding in 
aging humans as well as in many laboratory animals [3,4]. The occurrence of 
less heterogenous antibodies with respect to isotype, affinity and idiotype at 
old age were described previously [5-8]. Electrophoretic and immunodiffusion 
teclllliques applied on sera of very old people demonstrated a common 
deviation of the Ig spectrum, namely an Ig pattern of restricted heterogeneity, 
often accompanied by transient or persistent homogenous Ig components (H-
Ig) [9]. These conditions are clinically classified as monoclonal ganllllopathies 
(MG). Three categories of MG are age-associated: 1) B cell malignancy, 2) B 
cell benign neoplasia, benign MG, and 3) transient MG reflecting an 
inllllunodeficiency due to T < B cell imbalance [10]. 
It is not exactly known why and how these B cell proliferative 
disorders develop but it has been demonstrated that the clonotypes responsible 
for the development of H-Ig could have been selected by antigen at a much 
earlier time in the life of man [11] as well as of mice from the 
C57BLlKaLwRij strain. Although antigen-specific antibody levels declined 
gradually with aging in DNP-HSA immunized mice, they still developed age-
associated MG with antibody activity to DNP [12,13]. In other words, some 
memory B cells eventually evolved for yet unknown reasons into clones of a 
sufficient size to make the H-Ig detectable in the sera, or became a target for 
an oncogenic event. 
We studied the capacity of the inllllune system to recruit the available 
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antigen-specific clonotypes directly after inul1unization. The phenomenon of 
clonal dominance in antigen-specific antibody formation was of special interest 
because it can illustrate the intrinsic characteristics of a certain mouse strain to 
allow for 'overshooting' of B cell clones. If this relation exists, it might help 
to explain the susceptibility of the different mouse strains to develop an age-
associated MG. 
Here we investigated the effects of aging, genetic background, and 
impaired T cell system (using neonatal thymectomy) on the antibody response 
to DNP-HSA, with special attention to antibody levels, heterogeneity of the 
antibody response, and the appearance of H-Ab. We used two different inbred 
mouse strains: the C57BL/KaLwRij, which has a high incidence of 
spontaneously developing age-related MG, and the CBA/BrARij, which in 
contrast shows a low incidence of these B cell proliferative disorders [14]. 
Sensitive inul1unoblotting techniques allowed for the detection of antigen 
specific homogenous IgM, IgG and IgA of about 0.005 I'g/ml. 
MATERIALS AND METHODS 
l\/ice 
C57BL/KaLwRij and CBAfBrARij mice were bred and maintained under conventional 
conditions in the mouse colonies of the REP Institutes TNO in Rijswijk (presently TNO-PG, 
Dept. of Immunological and Infectious Diseases, Lciden, The Netherlands), All mice received 
pelleted food (Hope Farms, Woerden, The Netherlands) and acidified water (pH 3-4) ad 
libitum. 
Experime1ltal groups 
Eight experimental groups were selected, each consisting of 25 mice at the start of the 
experiment: Two mouse strains, C57BLIKaLwRij (C57BL) and CBA/BrARij (eBA) mice; two 
age groups, young-adult mice immunized at the age of 2-3 months ("young") and mice 
immunized at the age of 22 months ("old"); they were used either intact or neonatally 
thymectomized ("NTx") according to Roubinian as described previously [15,16]. The mice 
were allowed to live out their life-spans. The 50% survival was 27 and 29 months for intact 
C57BL and CBA mice, respectively, and 25 months for mice of the NTx groups of both 
strains. Postmortem microscopic examination of serial sections of the anterior mediastinum of 
NTx mice revealed complete removal of thymic tissues. 
Antigens 
A hapten-carrier complex of DNP-HSA was chosen as immunogen. DNP is a hapten 
with a limited number of epitopes and the immune response to DNP-HSA should thus result in 
a relatively limited number of clones producing antibodies to DNP. Human serum albumin 
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(Nordic, Tilburg, The Netherlands) was cottiugated to a level of ± 12 DNP molecules per 
protein molecule according to Good et al. [17J and stored in small aliquots at -20 oe until use. 
Immunizatio1l procedure 
Mice of the experimental groups received an intraperitoneal (i.p.) injection once a 
month (tour times in total) containing 50 I'g DNP-HSA in 50 I" phosphate-buffered saline 
(PBS) and 50 Itl Freund's adjuvant (complete for the first two immunizations and incomplete 
for the latter two). Control mice, 25 for each experimental group, received only 50 ,ttl PBS and 
50 It! Freund's adjuvant. Prior to the first, two weeks after each consecutive immunization, and 
regularly each third month thereafter until death, small blood samples were taken from their tail 
veins and the sera were inmlediately analyzed and/or stored at -20°C for later use. One young 
and four old NTx C57BL mice, and five old NTx CBA mice died of natural causes during the 
immunization period, but none of the mice died due to the immunization procedure. 
Preparatioll of h'allsfer membranes 
Because polyvinylidene difluoride membranes (Immobilon PVDF; 0.45 ltm pore size, 
Millipore, Etten-Leur, The Netherlands) are hydrophobic, they were pre-wetted first with 
methanol and then with distilled water. Subsequently, they were incubated with 30 {tg/ml DNP-
HSA in a 0.5 M NaHCOJ buffer solution (pH 8.0) per em2, for at least 2 hours at room 
temperature [18]. Since DNP is light sensitive, membranes were coated in the dark. To prevent 
nonspecific binding to the PVDF membrane, unoccupied protein binding sites were blocked 
with 1 % bovine serum albumin (Boseral DEM; Organon Technika, Oss, The Netherlands) in 
PBS, containing 0.05% Tween-20 (PBS-BSA-T) during 1 h at room temperature. Any 
undesired detachment of the antigen during subsequent treatment was prevented by "fixating" 
the membrane with a 2.5% glutardialdehyde solution in a 0.2 M sodium acetate buffer (pH 5.0) 
for 15 min. 
As a negative control for non-specific binding of proteins to the membrane, a serum 
pool of non-immunized C57BL/KaLwRij mice was used. Since this normal mouse serum 
(NMS) had a natural antibody activity against DNP (NMSDNP), the NMS was purified by 
affinity-chromatography using a DNP-binding column (NMSDNP"). After blotting, reactivity of 
NMSDNP- could be demonstrated only below a 11200 dilution, reflecting non-specitic binding of 
proteins (data not shown). Thus, antibody activity of serum diluted 11200 and in higher 
dilutions was considered specific. 
Quantification of fhe alltigell~specific antibody response 
The specific antibody response was quantitated by an antigen-specific dot-
immunobinding assay (ADIDA), modified from Hawkes et al. [19] and Jol-Van der Zijde et al. 
[20]. The antigen-coated Immobilon PVDF membrane was rinsed with PBS, transferred to a 
dot-blot tiltration apparatus (Bio-Rad, Richmond, CA) and washed with 150 Id 0.05% Tween 
20 in PBS (PBS-T) per application well. Sera from the experimental animals were serially 
diluted two-told (range 1140,000 to 11320,000) in PBS-BSA-T and 50 I" of sample was spOiled 
onto the membrane. When the samples had completely soaked into the membrane (30 min 
without vacuum), they were washed under vacuum with 150 ld PBS-T per well. The blot was 
then removed ti"om the apparatus and shortly rinsed again, followed by incubation of 
peroxidase-conjugated rabbit-anti-mouse-Ig (RaM-Ig-PO; Dakopaus, GloStlllP, Denmark) and 
subsequent coloring reaction to reveal the antigen-specific antibodies that bound to the 
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membrane. 
Semi-quantitative determination of the antibody levels was performed with a 
reflectance densitometer (TR-944. MacBeth, Newburgh, NY) and expressed as relative OD 
values based on comparison with a standard curve obtained with a serum pool of selected young 
C57BL mice which were repeatedly immunized with DNP-HSA and reached high levels of 
corresponding antibodies. 
Wieme electrophoresis (W) 
High resolution agar gel electrophoresis according (0 Wieme [21J was modified and 
carried out as described previously [22]. Each slit was filled with 3 ~I of serum, diluted 1/500 
and 111000 in PBS. The detection limit of H-Ig in sera after total protein staining of the gels 
was 0.1 mg/ml. When performing immunoblotting techniques, this limit was considerably 
lower [22]. 
lsoelectric jocusillg (IEF) 
IEF was performed in a 0.5 mill thick 0.8% agarose gel, pH 3-10 (Agarose IEF, 
Pharmacia-LKB, Uppsala, Sweden), as described in detail elsewhere [22]. Each slot of the 
application strip was filled with 5 Itl of serum sample, diluted 11200 in PBS. 
Alltigen-specific immulloblottillg (ABL) 
After \V or TEF, antigen-specific antibodies were transferred from the gel onto the 
antigen-coated membrane by diffusion under pressure. The membrane was rinsed in PBS, laid 
on the gel and covered with three layers of wet and seven layers of dry Whatman No. 3 MM 
chromatography paper. A weight of 100 g was placed on a glass plate on top of the paper 
stack. After 30 min, the blot was removed from the gel and rinsed shortly with PBS. The 
detection limit of antigen specific H-Ig using this technique was 0.005 J(g per ml, as reported 
previously by Nooij et al. [22J. 
Specific color reactioll 
The blots were incubated with peroxidase-labeled polyclonal rabbit anti-mouse-Ig 
(RaM-Ig-PO, Dakopatts, Glostrup, Denmark), diluted 112500. for 2 hours at room temperature. 
After intensive washing with PBS-To they were incubated with substrate solution. A specific 
color reaction was developed for 10 min in the dark with a freshly prepared solution of 0.02% 
(w/v) 3,3'-diaminobenzidine tetrahyorochloride (DAB; Sigma, St. Louis, MO) and 0.03% (v/v) 
hydrogen peroxide in PBS-To Finally. the blots were rinsed in distilled water to stop the 
enzymatic reaction, dried and stored in the dark to prevent bleaching. 
Statistical methods 
Comparison of frequencies between two groups was performed by Student's !-test, if 
applicable. or the Mann-Whitney-U test. Proportions were compared by Fisher's Exact test or 
by chi-square analysis, using Yates continuity correction, when the observed frequencies were 
higher than 5. P values smaller than 0.05 were considered statistically significant. 
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RESULTS 
Levels of DNP-HSA-specific alltibodies after successive immullizatiolls 
The specific antibody response was quantitated in selUm samples taken 
prior t6 the first immunization with DNP-HSA and two weeks after each of 
the consecutive immunizations (Figure 1). As tested by double radial 
immunodiffusion with DNP-HSA and DNP-ovalbumin conjugates, each 
responding serum reacted with both antigens, but not with unconjugated HSA. 
The pre-immune sera from all groups already contained some antibody activity 
against DNP-HSA, while the negative control (NMSDNP-) did not. Kinetics of 
the antibody response after immunization were similar for the young CBA, 
young C57BL and the old CBA mice. After the first inmlUnization, the 
response was low, but the response rapidly increased after successive immuni-
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Figure 1. Determination of specific antibody levels by ADIBA after successive immunizations 
with DNP·HSA. Serum samples were taken prior to the first immunization and two weeks after 
each of the consecutive immunizations. Results are shown for young CBA (A), young C57BL 
(B), old CBA (C) and old C57BL (D) mice. Groups of normal intact mice are indicated by a 
solid line and NTx groups by an intermitting line. Results are in arbitrary units relative to a 
standard serum pool from mice after repeated immunization with DNP~HSA and are the mean 
and S.D. of 25 mice per group. 
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zations. The kinetic pattern of the specific antibody response was aberrant in 
old C57BL mice as compared to the other groups: mean antibody levels rose 
gradually, but reached a low-level plateau after the third immunization. Both 
in intact and in NTx treated old C57BL mice these maximum levels were 
significantly lower than for young C57BL mice (P<0.001). It should be noted 
that the standard deviation was significantly higher in the old intact C57BL 
group than in the old NTx C57BL (P=0.01) or in the young intact C57BL 
mice (P < 0.01), indicating a high individual variation within this group. There 
were no significant differences in maximum levels of specific antibodies 
between intact and NTx-treated mice in any of the four experimental groups 
(Figure 1). 
Heterogelleity of the DNP-HSA-speci!ic alltibodies as tested by W + ABL 
The heterogeneity pattern of DNP-HSA-specific antibodies was 
determined at regular intervals using W + ABL. Immunizations with DNP-
HSA induced a heterogenous antibody response against the antigen in mice of 
all experimental groups, which was reflected by a smear pattern on the W + 
ABL blots. The antibody response reached its maximum after the last 
immunization and gradually subsided during the following months. The 
electrophoretic patterns in the sera from the C57BL and CBA mice were 
distinct: sera from the C57BL mice had the maximum of their antibodies in 
the cathodic gamma-2 region, while this was in the more anodic gamma-1 
region for the CBA mice. 
In addition to the heterogenous antibody pattern, some sera showed 
products from antigen-reactive dominant clones, as reflected by the presence 
of one (example shown in Figure 2) or, less frequently, two DNP-HSA-
specific H-Ab components on the W + ABL blots. These H-Ab were of 
different mobility in different individual mice and had rather variable kinetics: 
they could be persistent (i.e. detectable for more than 6 months) or, in the 
majority of cases, transient. The fact that the levels of all specific antibodies, 
including the dominantly produced H-Ab, gradually decreased after the peak 
response illustrated that these components were regulated in the same way as 
the other specific antibody-producing clones. Because most of them were not 
visible on Wieme agar electrophoresis, we can deduce that their concentration 
was below 100 f'g/ml. The frequency of these specific H-Ab components was 
determined at the peak of the antibody response, i. e. after 4 successive 
immunizations. Results for the sera from the intact mice and the NTx mice are 
presented in Table 1. 
H-Ab in the sera from intact CBA mice were found in low numbers 
(8 %), both in young- and old-immunized animals. In intact C57BL mice, the 
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Figure 2. An example of a dominant H-Ab response to DNP-HSA in the serum of a young 
C57BL Illouse (M2), as detected by W + ABL (W ABL) 011 DNP-HSA coated PVDF 
membranes. A heterogenous response is illustrated by the serum of another C57BL mouse 
(M3). Preimmune serum of the mouse M2 served as a negative control (Ml). The application 
site is indicated by an arrow, anodic site by +. AU sera were tested at dilutions 11500 and 
1Il000. 
picture was quite different: in 56% and 48% of the young- and old-inmmnized 
animals, respectively, H-Ab could be shown at or around the peak of the 
antibody response. No new H-Ab arose after the peak response (i.e. not until 
very old age [12]), as was shown by a follow-up of all mice for their entire 
life-span. In a few old mice, an H-Ab reactive with DNP-HSA could already 
be demonstrated in preinullune serum. 
In NTx CBA mice, antigen-specific H-Ab were found in 16% of the 
young- and in 30% of the old-immunized animals. In NTx C57BL mice, this 
frequency was higher: 54 % and 52 % for the young- and the old-immunized 
mice, respectively. In the pre-inullune sera of NTx mice, H-Ab with activity 
against DNP-HSA could be demonstrated in three C57BL mice and one CBA 
mouse to be immunized at old age (21 months), but in none of the animals to 
be inullunized at young age. 
The above data show that the incidence of DNP-HSA-specific H-Ab 
was much higher in the C57BL mice than ill the CBA mice. This was 
measured at the peak of the antibody response where the two strains did not 
show significant differences in total levels of antigen-specific antibodies, with 
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Table 1. Homogenous antibody components (H-Ab) with DNP-HSA specificity in pre-immune 
and immune sera as detected by agar electrophoresis 0v) with subsequent antigen-specific 
immunoblotting (ABL). The imIllune sera were analyzed at the peak of the antibody response, 
i.e. after 4 successive immunisations. 
CBA 
young 
A. Intact mice 
Number of tested mice 25 
Mice with pre-immune H-Ab (n (%» 0(0) 
H-Ab after 4 immunizations (n (%» 2 (8) 
B. Neonatally-thymectomized (NTx) mice 
Number of tested mice 25 
Mice with pre-immune H-Ab (n (%» o (0) 
H-Ab after 4 immunizations (n (%» 4 (16) 
old 
25 
o (0) 
2 (8) 
20 
1 (5) 
6 (30) 
C57BL 
young 
25 
o (0) 
14 (56)" 
24 
0(0) 
13 (54), 
old 
25 
1 (4) 
12(48)' 
21 
3 (14) 
11(52)" 
a Two-sided P-value = 0.0006 as given by Fisher's exact test when compared to the 
group of young intact CBA mice. 
b Two~sided P~value = 0.0036 as given by Fisher's exact test when compared to the 
group of old intact eBA mice. 
c Two-sided P-value = 0.0072 as given by Fisher's exact test when compared to the 
group of young thymectomized eBA mice. 
d Two-sided P-value = 0.2 as given by Fisher's exact test when compared to the group 
of old thymectomized eBA mice. 
exception of the old C57BL group. This group responded with significantly 
lower levels of anti-DNP antibodies. Nevertheless they developed an equal 
incidence of DNP-HSA-specific H-Ig, as did the young C57BL group. 
Neonatal thymectomy did not result in a clear change in the incidence 
of DNP-HSA-specific H-Ab, although the NTx CBA groups showed a 
tendency to develop relatively more of these components in the serum than the 
intact CBA mice (16% to 30% vs. 8%). The generally highly significant 
differences between intact CBA and C57BL mice disappeared in the old 
thymectomized mice (Table 1). 
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Heterogeneity of DNP-HSA-specific alltibodies as tested by IEF + ABL 
The heterogeneity of the antibody response against DNP-HSA was 
examined further in sera taken at the peak of the response from the groups of 
intact, unthymectomized mice. They were tested for spectrotype bands at 
optimal dilutions by isoelectric focusing. For young C57BL, young CBA and 
old CBA mice, these dilutions were 11250, 11500 and 111000. Since the 
antibody response was quantitatively much lower in the old C57BL mice, 
optimal dilutions for this group were 1110, 1130 and 11100. Individual 
spectrotypes in sera from each experimental group are illustrated in Fig. 3. 
On average, the anti-DNP antibodies in the sera from C57BL mice, making 
up the spectrotype pattern, had an electric charge in a more basic pH range 
than those of CBA mice. In the sera illustrated, no H-Ab were detected using 
W + ABL, only a heterogenous antibody response was demonstrated (data not 
shown). Unlike the W + ABL teclmique, the heterogenous antibody pattern 
after IEF + ABL was represented by a pattern of small discrete bands on a 
smear background. In Table 2 the mean number of detectable spectrotype 
bands for each experimental group is presented. The number of bands was 
determined in 11-23 sera taken at the peak of the antibody response against 
DNP-HSA. Young CBA and young C57BL mice showed on average the 
same number of bands. The difference between young and old CBA was not 
statistically significant (p=0.0547). The spectrotype of old C57BL mice 
showed significantly more bands than old and young CBA and young C57BL 
mice (Figure 3 and Table 2). 
Table 2. Comparison of antigen-specific spectrotype bands in immune sera of intact mice as 
detected by lEF + ABL. • 
Experimental group bands a two-sided P~yalue 
Young CBA (n=23) 15.0 ± 0.7 , , 
I n.s. I 
Young C57BL (n=lI) 13.3 ± 0.8 .J , I p=.0547 
I I 
Old CBA (n =23) 17.1 ± 0.8 , Ip<·OOI .J 
Ip<·OOI I 
Old C57BL (11 = 13) 26.6 ± 1.6 .J .J 
* Note: The sera used in this experiment did not show H-Ab components. 
~ The number of bands (mean ± SE) as determined in sera taken at the peak of the antibody 
response against DNP-HSA. 
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Figure 3. Illustration of antigenHspecific spectrotypes in sera from 4 individual mice. each of a 
different experimental group. All mice had been immunized with DNP-HSA. Analysis was 
performed by IEF + ABL (pH 3-10) of sera taken at the peak of the antibody response. The 
application site is indicated by an arrow. For each experimental group, 3 serum dilutions were 
chosen that were optimal for counting the number of antigen-specific spectrotype bands. Note 
that sera of old C57BL mice were far less diluted than sera of the other groups. The application 
site is indicated by an arrow. 
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DISCUSSION 
Using an experimental mouse model, three parameters were under 
study which may influence the heterogeneity of the DNP-HSA-specific 
antibody response after antigenic stimulation: age at time of immunization, the 
genetic background and neonatal thymectomy. As an inmlUnogen, a hapten-
carrier complex of dinitrophenylated human selUm albumin (DNP-HSA) was 
chosen. DNP is a hapten with a limited number of epitopes and the immune 
response to DNP-HSA should thus result in a relatively limited number of 
clones producing antibodies to DNP. Furthermore, the DNP-specific precursor 
cell frequency in the spleens of non-immune CBA and C57BL mice is about 
the same [1], which allows us to compare the spectra of generated specific 
antibodies in the two strains, but which does not tell us anything about the 
total available repertoire of clonotypes. Total specific antibody levels, number 
of antigen-specific clonotypes and dominance of responding B cell clones were 
studied in detail. 
Pre-umnune sera from a few old mice already contained DNP-HSA-
reactive antibodies, some of which even were homogenous (H-Ab). The 
frequency of such H-Ab increased with age and was slightly higher in 
neonatally thymectomized mice. Nothing is known about their origin. It might 
be that they are cross-reactive antibodies, in the induction of which regulatory 
T cells are thought to be active via the idiotype-anti-idiotype network [23,24]. 
The specific antibody response to DNP-HSA after four successive 
immunizations showed similar kinetics in CBA and C57BL mice. Only C57BL 
mice immunized at old age generated lower levels of specific antibodies than 
the other groups, reflecting a deterioration of the immune system due to a 
more pronounced aging process in the C57BL mice [25,26]. Neonatal 
thymectomy did not result in lower antibody levels, probably because this 
intervention does not completely prevent T cell development; it only results in 
a moderately impaired T cell system in adult life. In addition, part of the 
DNP-specific antibody response might be T-cell independent. 
Although total specific antibody levels were the same in CBA and 
young C57BL mice, the latter group demonstrated a much higher frequency of 
H-Ab at the peak of the antibody response regardless of NTx treatment. On 
the other hand, old C57BL mice responded with lower levels of antibodies to 
DNP-HSA, but developed the same incidence of H-Ab as did the young 
C57BL mice. This illustrates that the detection of dominant clones in the 
antibody response to DNP-HSA was not dependent on the total serum anti-
DNP antibody levels in these two strains. The electrophoretic mobility of the 
detected H-Ab components differred from mouse to mouse, indicating the 
proliferation of different clones and not a strain-dependent dominance of one 
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clone. This peculiar homogenous response of C57BL mice has already been 
noted by Takiguchi et 01. [27] and adds new insight to earlier observations of 
high incidence of H-Ig, regardless their specificity [25]. 
The sensitive IEF + ABL immunoblotting technique (detection limit 
for H-Ab 670 ng/ml; [22]) was used to visualize the products of specific 
antibody-producing clones and to gain an insight into the heterogeneity of 
their response. The evaluation of the analyses is not easy. The banding pattern 
(spectrotype), using an appropriate pI range and proper dilutions, consists of a 
smear with superimposed tiny bands. It should be kept in mind that none of 
the sera used for this analysis contained an H-Ab component, as was 
demonstrated by W + ABL, a teclmique with a higher sensitivity for H-Ab 
than IEF + ABL [22]. It can therefore be safely assumed that the banding 
pattern found here does not reflect one or more H-Ab in the strict sense of the 
word, but the products of several "more prominent" clones. For the CBA and 
the young C57BL mice the same dilutions of the tested sera could be used to 
generate comparable conditions. However, since the antibody response was 
quantitatively much lower in the old C57BL mice than in the other groups 
(see ADIBA analysis), a different set of dilutions had to be used to yield a 
comparable banding pattern in the sera from this group. When sera from the 
old C57BL mice were analyzed at the optimal dilutions as found for the CBA 
mice, no smear or banding pattern was seen at all. The other way round, 
when sera from the CBA mice were analyzed at the optimal dilutions as found 
for the C57BL mice, only a very dark smear without any banding was visible 
(data not shown). 
We believe it is legitimate to use the number of bands to gain an 
insight in the heterogeneity of the antigen-specific antibody response [18]. The 
more bands are detected on top of the smear, the less heterogenous is the 
response and the more of the prominent clones become visible. The age at 
time of inununization had a profound effect on the number of spectrotype 
bands as seen in the old C57BL mice. Thus not only the total generated 
amount of specific antibodies was diminished in old C57BL mice, but the 
specific antibody response was also more restricted in heterogeneity as 
illustrated by more visible spectrotype bands in IEF and subsequent ABL. 
Hence, in old C57BL mice smaller amounts of specific antibodies were 
produced by fewer clones. Still the incidence of H-Ab, a marker of clonal 
dominance in the specific antibody response, in this group was the same as in 
the group of young C57BL mice. This indicates that at old age the responding 
B cell clones are more susceptible to become clonally dominant in C57BL 
mice. 
Young CBA mice resembled very much young C57BL mice in their 
response to DNP-HSA. They showed similar total specific antibody levels as 
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well as an equal number of spectrotype bands. The only difference between 
these groups was a higher incidence of H-Ab in young C57BL mice. This 
observation stresses the importance of other factors than an impaired T cell 
system or age at time of immunization in the development of clonal antibody 
responses, which was also illustrated previously by the fact that clonality of 
the antibody response was not dependent on the presence of antigen-specific 
T-helper cells [28). Probably strain dependent, genetically defined factors 
account for the high tendency of C57BL mice to develop clonal dominance in 
antigen specific antibody responses. This tendency correlates with the high 
incidence of spontaneously developing monoclonal ganunopathies in aging 
C57BL mice [14,25). Nooij et al. were able to find MG with antibody-
specificity for the antigen (DNP-HSA) used for inununization at young age. 
Deducing from spectrotype characteristics, the majority of these spontaneously 
appearing H-Ig at old age were "new" but some obviously originated from 
previously expanded dominant clones [12). 
Thus, although the mechanism accounting for the high frequency of 
clonal dominance at the peak of the antibody response in C57BL mice might 
also be responsible for the high tendency to develop a deregulated clonal B 
cell proliferation that results in MG, this mechanism is not restricted to certain 
clonotypes. It rather might be a random process, hitting one of the 
'overshooting' B cell clones that respond to the corresponding antigen. The 
results of this study show that this mechanism is already present at young age 
in C57BL mice, but is almost absent in CBA mice. 
It is not likely that the development of a B cell clone into a benign or 
malignant MG is triggered by antigen alone, but external and internal antigens 
may contribute to this process by starting the development of clonal 
expansions of memory-B cells that may escape control of the inunune system. 
Although the T cell system is not an important factor in the initiation of 
clonality of the antibody response, it certainly plays an important role in the 
progression into bigger clones and subsequent development of MG [16,29-31). 
The biological significance of dominant clones in antibody responses, 
observed in some animals but not in others within the same inbred strain, is 
speculative and remains to be elucidated. 
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SUMMARY 
Persons undergoing maintenance immunosuppressive treatment (MIST) 
were shown to be at increased risk for the development of early malignancies, 
often of cells of the inunune system, Very little is known about the late effects 
of MIST. Some clinical studies indicated an age-related increase in the 
incidence of plasma cell disorders, in particular in that of multiple myeloma 
(MM). In the present study the influence of MIST on the development of 
monoclonal B-cell proliferative disorders, monoclonal ganullopathies (MO), 
was studied in an animal model, the C57BL/KaLwRij mouse. This strain is 
known for its susceptibility to develop with aging MO similar to those in 
humans. Two widely used inununosuppressive treatment protocols in humans 
(azathioprine/prednisolone and Cyclosporin A/prednisolone) were tested in 
young and adult mice. Both regimens were shown to increase tenfold the 
incidence of spontaneous MM. Unexpectedly, the same high incidence of MM 
and in addition the development of a life-shortening lymphoblastic lymphoma 
were found in a high frequency in the control group that received Cremophor 
EL only, i.e. the solvent of Cyclosporin A. Repeated experiments with an 
other lot of Cremophor showed a sixfold increased frequency of MM but no 
lymphoblastic lymphoma. With respect to the life-span and the incidence of 
hemopoietic neoplasms the least harmful drugs for MIST appeared to be 
azathioprine/prednisolone. The results of the experiments in this C57BLI 
KaLwRij mouse model give a warning for increased incidence of MM in 
susceptible aging individuals and address a question whether Cremophore EL 
is a safe solvent for Cyclosporin A. 
* Published in: Clin Immunol Immunopathol 1996,79:155-162. 
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INTRODUCTION 
The number of individuals undergoing maintenance inmlUno-
suppressive treatment (MIST) for long periods of time (i.e. recipients of organ 
transplants, some patients with autoimmune disorders) grows steadily. Short 
term evaluation studies suggest that they are at markedly increased risk for the 
development of malignancies, often of lymphoid origin [1-4]. The majority of 
these post-transplant lymphoproliferative diseases are B-cell non-Hodgkin 
lymphomas and are usually EBV related. Malignancies of B cells in a more 
mature stage are rare [5]. Little is known about the late effects of MIST. In 
some older studies the late effects of selected inununosuppressants on 
immunocompetence were studied [6-8]; however, any information on the late 
effects of more recently introduced inmlUnosuppressants is scarce [9]. Our 
own studies performed in man [10] indicated that age-related 
immunodeficiency, which gradually develops in individuals with genetically 
determined different speed, may substantially be accelerated and potentiated 
by MIST. We hypothesize that MIST will eventually lead in susceptible 
individuals to a more frequent development of benign and malignant 
proliferative disorders, mainly of B-cells. 
The aim of this study was to test this hypothesis. Because a follow-up 
investigation needs to involve the whole life-span of an individual a suitable 
animal model is necessary. The aging mice of the C57BLIKaLwRij strain 
offer an appropriate experimental model for such a study because these mice 
spontaneously develop in a high frequency monoclonal B-cell proliferative 
disorders that are similar to those in humans [11-13]. Two widely used 
immunosuppressive treatment protocols: azathioprine/prednisolone and 
Cyclosporin A (CsA)/prednisolone were tested in young as well as in late 
adult mice. Both regimens were shown to increase the frequency of 
spontaneous multiple myeloma (MM) in mice of this strain. Control 
experiments using Cremophore EL, the solvent of CsA, showed the same 
incidence of MM and indicated strong adverse effects of this preparation. 
MATERIALS AND METHODS 
il1ice 
SPF derived female C57BLIKaLwRij mice from the colony of the TNO Institute for 
Experimental Gerontology in Rijswijk (presently TNO-Prevention and Health, Leiden, The 
Netherlands) were maintained under clean conventional conditions. Detailed information on 
husbandry. health status, survival data, and age-related pathology of the strain has been 
published previously [14]. A complete necropsy was done on mice within two hours of death or 
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immediately following euthanasia of moribund animals. Histological examination of 
representative samples of all relevant tissues was performed according to a standard protocol. 
Ultrastructural examination by electron microscopy was performed on bone marrow samples in 
mice suspected of having multiple myeloma. 
Young adult (4 to 5 months old) and late adult (14 months old) mice of the 
C57BLIKaLwRij strain were first immunized with a purified human IgGI-lambda paraprotein 
(KAT), Each mouse received intraperitoneally 50 fig of the protein dissolved in 0.1 ml 
phosphate buffered saline (PBS) and emulsified with 0.1 ml of complete Freunds adjuvant and 
boosted after 4 weeks with the same amount of protein dissolved in incomplete Freunds 
adjuvant/PBS (1:1). The immunization was used to obtain an additional marker for the 
detection of some H~Ig that were expected to develop with aging. Immunization by itself, using 
protein antigens and Freund's adjuvant or adjuvant alone, does not lead to the increased 
incidence of multiple myeloma as shown in our previous experiments [11,15]. 
One month later, the mice were submitted to MIST by intraperitoneal route because 
administration per os did not guarantee an equal intake of the drugs. The mice received 
azathioprine (The Wellcome Foundation Ltd., London, UK) and prednisolone (prednisolone 
sodiumsuccinate, N.V. Organon, Oss, The Netherlands): Group A (young mice: n= 50, adult 
mice: n= 50), or Cyclosporin A (kindly donated by Sandoz AG, Basel, Switzerland) and 
prednisolone: Group B (young mice: n= 50, adult mice: n= 47). These drugs were given 
twice a week in doses corresponding to those used in human MIST as calculated according to 
Freireich et al. [16]. The dosage schedule was: Azathioprine, first five doses 0.9 mg each per 
mouse and further 0.4 mg/mouse; CsA, first six doses 3.4 mg each per mouse and further 0.72 
mg/mouse; prednisolone: first dose of 0.6 mg/mouse, six following doses of 0.3 mg/mouse and 
further 0.12 mg/mouse, continued over the whole remaining life~spans of the mice. The 
average total doses received per mouse were: MIST from the age of late adult: 27.3 mg of 
azathioprine and 9.0 mg of prednisolone, 47.5 mg of CsA and 6.8 mg of prednisolone; MIST 
started at young age: 53.6 mg of azathioprine and 17.6 mg of prednisolone, 117.4 mg of CsA 
and 17.9 mg of prednisolone. 
Control groups consisted of mice receiving the solvent of the corresponding drug 
twice a week only, i.e., 0.25 ml PBS for azathioprine (Group D, young mice: n= 28, adult 
mice: 11= 30) and the solvent for CsA, Cremophor EL (Sigma Chemical Company, St. Louis, 
USA; lot 97F0246), 160 mg in 0.25 ml of 10% ethanol and saline (Group C, young mice: n= 
51, adult mice: n~ 48). 
Due to unexpected results in group C, several additional experiments were performed 
to test the Cremophor EL influence. They, however, could only be performed with an other, 
more recent Cremophor EL, lot 70H0361. Mice of group CRt (11= 15) received, 
intraperitoneally, a dose of Cremophore EL (in 0.25 1111) four times higher (650 mg) than those 
of group C in the first experiment: The same dose was given to mice of the group CR2 (n = 
15) but once a week. Groups CR3 (n= 15) and CR4 (n= 15) represented the same conditions 
as group C in the tirst experiment; however, only mice of group CR4 were immunized with the 
human IgGl~lambda paraprotein before starting MIST. Control mice were injected 
intraperitoneally with 0.25 1111 PBS/lO% ethanol solution, either once a month (group Kl) or 
once a week (group K2). All mice in the second experiment were approximately 6 months of 
age at the start of the experiment. 
Detection of homogellolls immunoglobulill components 
Blood samples were taken every 2 months and the sera were tested for the presence of 
homogenous immunoglobulin components (H~Ig) by high resolution electrophoresis and 
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immunoelectrophoresis [17]. The appearance of H-Ig in the sera of individual mice was 
tentatively c1assilied according to the foHowing criteria [12]: (1) H-Ig which progressively 
develop within 2 months and reach levels above 5 mg/rnl. This pattern is typical for MM 
spontaneously appearing in this mouse strain at the frequency of about 0.5%. (2) Distinct H-Ig 
with a concentration below 4 mg/ml, which persist for at least 6 months and can be detected till 
the death of the animals. This pattern is typical for benign monoclonal gammopathy (BMG), a 
benign neoplasia of B cells, which is frequent in the C57BL/Ka mice. (3) Transient H-Ig 
components, usually of a low concentration, appearing for a limited period of time. These H-Ig 
were described as resulting from insufficient control of T-cell function in various 
immunodeficiencies with preserved B-cell function (including the immunodeficiency due to 
aging of the immune system). (4) H-Ig components which appeared shortly before the death of 
the mice were considered unclassifiable. 
The potential specificity of H-Ig to the human IgGJ-lambda protein used for the 
immunization of the mice was tested by antigen specific immunoblotting as described previously 
[17]. 
Statistical allalysis 
Survival curves were estimated by the method of Kaplan-Meier with differences 
assessed by the logrank test. Proportions were compared by chi-square analysis, using Yates 
continuity correction, or Fisher's exact test when a number was smaller than 5. P-values 
smaller than 0.05 were considered statistically significant. 
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Figure 1. Survival curves of experimental and control mice. Start of immunosuppressive 
treatment is indicated by arrows. The upper and lower graphs represent the groups of young 
adult and the late groups of adult mice, respectively. A 50% survival line is shown in both 
graphs. Experiments with young groups A and D were terminated at 121 weeks. 
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Table 1. Survival analysis of C57BLIKaLwRij mice submitted to two maintenance 
immunosuppressive treatments. 
Group A: 
azathioprine/prednisolone a 
Group B: 
Cyclosporin A/prednisolone 
Group C: 
Cremophor ELIlO% ethanol ~ 
Compared to PBS-control group D; 
Mice 
(n) 
young (50) 
old (50) 
young (47) 
old (50) 
young (48) 
old (51) 
x' 
0.2023 
0.4685 
15.4782 b 
4.2164 • 
2.0002 b 
2.7998 • 
25.06 
11.8466 
b Compared to Cremophore EL/lO% ethanol control group C. 
RESULTS 
Survival 
Logrank 
P-value 
P > 0.2 
P > 0.2 
P < 0.001 
P < 0.01 
0.1 < P< 0.2 
0.05 < P< 0.1 
P < 0.001 
P < 0.001 
Hazard 
ratio 
1.10 
1.17 
0.47 
1.55 
0.77 
1.45 
2.75 
2.08 
The life-span of mice in which MIST was started at the age of 6 
months was not significantly different from the life-span of mice in which the 
same treatment-protocol was started at late adult age (data not shown). The 
treatment-protocol of group A, azathioprine and prednisolone, affected the 
life-span neither of young nor of adult mice as compared to the PBS-control 
group D (Table 1). The young immunosuppressed mice in group B had a 
shorter life-span compared to the PBS treated control group. While assessing 
differences between the CsA/prednisolone treated group B and the Cremophor 
EL treated group C, it became apparent that young mice in the control group 
C had a significantly shortened life-span as compared to young mice treated 
with the immunosuppressants. This was not the case in adult mice, but both 
young and adult mice treated with Cremophor EL had a significantly 
shortened life-span as compared to group D (P<O.OOI) (Fig. I). 
Because of these adverse effects of Cremophor EL in group C, 
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additional experiments were performed, although with a different batch of 
Cremophor EL. Only when given a 4 times higher dose of Cremophore once 
a week (group CR2), the life-span of the mice was significantly shortened 
(P<O.OOI; Hazard Ratio 2.76). None of the other groups of the second 
experiment showed differences in survival compared to PBS/lO% ethanol 
control groups. No differences were detected in life-spans of the PBS-control 
group D of the first experiment and the PBS/ethanol control groups Kl and 
K2 in the second experiment (data not shown). 
Homogenolls immllllogioblllin compollents 
The frequency curve of H-Ig (Fig.2) and its slope of the control mice 
receiving only PBS did not differ much from those in untreated normal 
C57BLIKa mice as seen in numerous previous experiments [12]. The H-Ig 
frequency curve of mice receiving azathioprine followed more or less that of 
its control group, being only slightly higher in the beginning of the treatment. 
The frequencies of H-Ig in group C and even more in the CsA/prednisolone 
treated group B were clearly higher than that of group D for several months 
after initiation of the treatment. At the end of the observation period, which is 
in fact determined by the natural ending of the lives of the animals, the 
frequencies of H-Ig were similar in all groups, reaching values above 70%. 
The characterization of the H-Ig components (Table 2) showed that the pattern 
of MM as detected in high resolution serum electrophoresis was seen in 5 % of 
the mice in each of the groups A, B, and C, which was a ten times higher 
incidence than was expected (P<O.OOOI, one-proportion frequency analysis). 
Also transient small H-Ig components were most frequently seen in these three 
groups. No difference in the incidences of BMG was found. In group A the 
incidence of unclassified H-Ig was significantly lower than in the control 
group D. Over all, no differences were detected in H-Ig incidence and 
characteristics between groups Band C. 
In the additional experiments on the effect of Cremophor EL, heavy 
H-Ig components with the characteristics of MM were detected in one case in 
group CRI and one in group CR4. Thus the incidence of MM in the later 
experiments in all Cremophore groups together was 3 % . 
H-Ig isotypes alld specificity 
Testing the isotypes of H-Ig revealed that 11 of the 17 MM were of 
the IgG2b isotype. Of the remaining 6 MM, 4, 1 and 1 belonged to the 
IgG2a, IgGI and IgG3 subclasses, respectively. All of them were of the kappa 
light chain type. The most frequent isotype of the H-Ig in the BMG group was 
Table 2. Frequency of monoclonal gammopati1ies in C57BLlKaLwRij mice submitted to two maintenance immunosuppressive treatments. 
H-Ig (%) 
Experimental group n" + MMb BMGb 
A: azathioprine/prednisolone 95 80 20 5' 37 
B: CsA/prednisolone 97 89 11 5' 41 
C: Cremophore ELI!O% ethanol 97 89 11 5' 36 
D: PBS 53 87 13 0 51 
Number of mice suitable for evaluation. 
b Percentage of mice within this category of monoclonal gammopathy. 
c P<O.OOOI as tested in a one proportion frequency analysis, using the expected frequency of 0.5% for lv1M. 
d Yates corrected P value = 0.004 when compared to group D. 
Yates corrected P value = 0.015 when compared to group D. 
f Yates corrected P value = 0.007 when compared to group D. 
1: Yates corrected P value = 0.001 when compared to group D. 
Transient 
H_Igb 
26\1 
23' 
25t' 
6 
Unclassified 
H-Ig' 
12' 
20 
23 
30 
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Figure 2. Frequency curves of H-Ig in mice treated f)"om the age of 5 months with 
Azathioprine/prednisolone (A), CsAiprednisolone (B), Cremophor EL (C), and PBS (D) in 
relation to the age (in months) of the mice. The 50% survival value of mice of the different 
groups is indicated by the vertical lines. The arrow indicates the lime at which the 
immunosuppressive treatments were started. 
IgG2a. H-Ig of the transient type were of various isotypes, including IgM. 
There was no clear-cut H-Ig of the IgA isotype found in any of the groups. 
Tests for the antibody specificity of individual H-Ig components to the 
antigen used for inm111nization revealed that one of 114 cases of BMG and one 
of 15 cases of MM had a positive anti-human IgG activity. The latter was a 
mouse (BL-59) from group A, treated with azathioprine/prednisolone. At the 
age of 22 months, this mouse developed an IgG2b-kappa paraprotein that 
reached within the remaining 5 months of life a concentration far above 10 
mg/ml (Fig 3). The epitope on human IgG recognized by this mouse myeloma 
protein (as tested by a number of human IgG paraproteins of different 
subclasses and light chain types) was shown to belong to a common 
determinant on the gamma chain. Similar specificity was also found when the 
BMG H-Ig was tested. In none of the cases a specificity to IgGl subclass, to 
lambda light chain type, or to the KAT -protein idiotype was detected. 
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Figure 3. Demonstration of the antibody activity to human IgG of the myeloma protein (BL59) 
by antigen-specific immulloblotting. The membrane on the left side was coated with the purified 
human IgG I-lambda myeloma protein (KAT) used for immunization of the mice prior to the 
start of immunosuppressive treatment; as a control, coating with ovalbumin was used on the 
right side. Serum of the BL59 mouse (MM S.) at the age of 27 months was tested in dilutions 
from 112000 up to 1120000. Normal mouse serum (dil. 1/1000) and ascites of a hybridoma 3-
I.l protein (± 5 mg/ml) with activity to a human IgG I epitape (dil.l!3000) were used as 
negative and positive controls, respectively. Anode and katode are indicated by + and -
symbols. 
Histopathological examination 
Hematopoietic neoplasms were common in all experimental groups 
(Table 3), whereas other neoplasms were rare and randomly distributed over 
the experimental gronps. The most common neoplasm was the follicular center 
cell lymphoma (FCCL), a slowly progressive malignancy of B cells [14]. In 
mice treated from young age with CsA/prednisolone (group B), the incidence 
of FCCL was significantly higher as compared to group C, but was not 
different when compared to the PBS control gronp D. 
Lymphoblastic lymphoma (LL) occurred significantly more in the 
group that had received Cremophore EL, but was rare in the other treatment 
groups. This unexpected high incidence of LL in group C was another reason 
to start the additional experiment. There were no LL found in mice of this 
latter experiment. 
Histiocytic sarcomas (HS) were moderately frequent in all groups. 
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Twelve mice had more than one hematopoietic tumor: four mice had FCCL 
and HS, six mice had FCCL and LL, one mouse had LL and HS, and one 
mouse had FCCL, LL and HS. 
FCCL was most frequently found in the mesenteric lymph node, but 
other lymph nodes, spleen and Peyer's patches were also commonly affected. 
The FCCL was characterized by nodular expansive growth and contained a 
mixed population of cells. The cells were small and large lymphoid cells 
mixed with variable numbers of plasma cells, macrophages, multinucleated 
cells and granulocytes. 
LL was characterized by infiltrative growth and was usually leukemic. 
Bone marrow involvement was common. The neoplasm was present 
throughout the peritoneal cavity and neoplastic cells infiltrated the abdominal 
viscera from the serosal surface or hematogenously. The neoplasm consisted 
of homogenous population of non-cohesively growing lymphoid cells with 
numerous mitotic figures. Neoplastic cells did not contain cytoplasmic 
immunoglobulin as demonstrated by iImnunoperoxidase histochemistry on 
paraffin sections (not shown). 
HS was primarily present in the liver, lung, lymph nodes and uterus. 
The tumor consisted of ovoid or spindle shaped histiocytic cells. 
Multinucleated cells and erythrophagocytosis were conunon. 
MM was characterized on light microscopy by the presence of 
multiple foci of pleomorphic plasmacytoid cells without distortion of the 
normal architecture of the bone marrow or osteolysis. These were most 
conunonly found in the pelvic bones and in the distal femur and proximal 
tibia. UltrastlUctural examination demonstrated typical plasmacytoid cells with 
abundant rough endoplasmic reticulum and a well developed Golgi-apparatus. 
DISCUSSION 
Short term studies evaluating the effects of MIST on the development 
of neoplasias showed an increased risk of the treated persons for malignancies, 
often of lymphoid cells [1-5). Only little is known about the late effects of 
long-lasting MIST. Literature review (5) and preliminary data from our 
studies on kidney recipients (10) indicated increased frequencies of MM and 
BMG that were related more to the higher age than to the duration of MIST. 
This led to the hypothesis that MIST accelerates and potentiates the 
development of an age-related inmlUnodeficiency and eventually leads in 
susceptible individuals to benign and malignant neoplasias mainly of the B 
cells. This hypothesis seems to be corroborated by the present experiments for 
at least the increased incidence of MM. A tenfold increase in the incidence of 
Table 3. Incidence of hematopoietic neoplasms in C57BLIKa mice submitted to two maintenance immunosuppressive treatments. 
Experimental groups 
A B C D 
Neoplasm / age of mice (Aza/pred) (CsA/pred) (Cremophore EL) (PBS) 
No.(%) ,) No.(%) No.(%) No.(%) 
Follicular center cell lymphoma (FCCL) 
young b) 4116 (25) 10116 (63) 0) 2/16 (13) d) 417 (50) 
old 8116 (50) 9/16 (56) 7116 (44) 3/8 (43) 
total 12/32 (38) 19/32 (59) 0) 9/32 (28) 7115 (47) 
Lymphoblastic lymphoma (LL) 
young 0/16 (0) 1116 (6) D 9/16 (56) 117 (13) 
old 2116 (3) 1116 (6) g) 8/16 (50) h) 0/8 (0) 
total 2/32 (6) 2/32 (6) i) 17/32 (53) j) 1115 (7) 
Histiocytic sarcoma (lIS) 
young 1116 (6) 1116 (6) 4/16 (25) 117 (14) 
old 2/16 (3) 1116 (6) 4116 (25) 0/8 (0) 
total 3/32 (9) 2/32 (12) 8/32 (25) 1115 (7) 
a) Number of mice with neoplasm/total number of mice in which postmonem examination was performed; b) Age at statt of maintenance 
immunosuppression; c) Yates corrected P value = 0.011 when compared to group C; d) Two-sided P value = 0.045 as given by 
Fisher's Exact test when compared to group D; e) Yates corrected P value = 0.023 when compared to group C; f) Yates corrected P 
value = 0.008 when compared to group C; g) Two-sided P value = 0.015 as given by Fisher's Exact test when compared to group C; 
h) Two-sided P value = 0.022 as given by Fisher's Exact test when compared to group D; i) Yates corrected P value = 0.0001 when 
compared to group C; j) Two-sided P value = 0.006 as given by Fisher's Exact test when compared to group D. 
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MM was observed in both treatment regimens. The incidence of BMG, a 
benign B-cell neoplasia, was not increased. However, BMG is a typical 
phenomenon of old age and therefore, the shortened survival of the mice in 
some of the experimental groups may have influenced the results. 
The frequency distribution of isotypes within H-Ig of the different 
categories was comparable with that seen in other experiments [11,12]. While 
the most frequent isotype of H-Ig in BMG was IgG2a, in MM, typically, the 
IgG2b isotype was clearly dominant. An interesting finding was the anti-IgG 
specificity of one MM and one BMG to the protein used for immunization 
prior to the MIST initiation. Both paraproteins recognized a conml0n 
determinant on the human IgG I-lambda protein. This indicated that both BMG 
and MM developed from B-cell clones responding to a specific antigenic 
stimulation, even long before the disorder developed. As also our other 
previous experiments indicated [11,15], it may be the memory B cell that 
becomes target for oncogenic events. 
As far as the other malignancies are concerned, there was no 
significant difference in the occurrence of HS among the four groups. Young 
mice in group C had the lowest incidence of FCCL, even less than control 
group D. Since FCCL is a disease of old age, the shortened survival of these 
mice can explain this finding. Although malignant LL was detected in a few 
mice of the MIST treated groups and once in the PBS-control group D, 53 % 
of mice (P<O.006, Table 3) in the Cremophore control group Chad 
histologically confirmed LL. 
The effect of Cremophor EL unexpectedly complicated the whole 
study. Due to its highly carcinogenic effect (MM, LL) in the first experiment, 
it was further tested in additional experiments. There, the incidence of MM 
was found to be 3 %, but that of LL was not increased. The second lot of 
Cremophore EL diminished the survival probability significantly only in high 
doses (experiment 2, data not shown). The only plausible explanation for our 
findings leading to the development of malignant LL in a high frequency and 
causing the shortened survival of the mice, would be the presence of an 
unknown contaminant in the first lot of Cremophor EL with carcinogenic 
properties. Our search for some additional information on the previous lot of 
Cremophore EL remained unsuccessful. It may well be that the effect of 
Cremophore EL in the first experiment was an example of (co-) clastogenic 
effects of Cremophore, which is the enhancement of genotoxicity by 
Cremophore in the presence of a carcinogenic substance [19]. The mechanism 
by which Cremophore, a derivative of Castor-oil and ethylenoxide, enhances 
carcinogenicity is not known. It is used as a solvent for hydrophobic drngs, 
such as CsA and paclitaxel. It possibly facilitates carcinogenic substances to 
cross the cell membranes. The incomplete reversal of multiple drng resistancy 
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by Cremophore may also be a mechanism by which this solvent induces 
cytotoxicity or even malignant transformation [20]. Our observation stresses 
the importance of well defined control groups. While Cremophore is being 
used as a solvent for intravenous application only for a short period in the 
begiIming of MIST, it itself or its derivatives used for peroral treatment may 
not be innocent solvents, especially when carcinogenic contaminants could be 
present. 
In this study using a mouse model, azathioprine/prednisolone were 
shown to be the least harmful drugs for MIST when considering life-span and 
incidence of hematopoietic neoplasms. Only the incidence of MM was 
increased, but this was also the case in the CsA/prednisolone treated group. In 
this latter group, it is not clear whether Cremophore contributed to the 
increased incidence of MM and this should further be studied. In humans, the 
question should be addressed whether the genetically determined increased 
susceptibility for the development of MM could be predicted and, 
consequently, whether any long-term inullunosuppression protocols could be 
avoided or adapted to minimize the risks. 
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SUMMARY 
The 5T series of multiple myelomas (MM) and Waldenstrom's 
macroglobulinemia-like lymphomas (WM), which developed spontaneously in 
ageing mice of the C57BLIKaLwRij strain, shows clinical and biological 
features that closely resemble their corresponding human diseases. In order to 
compare the patterns of somatic mutation in V H genes of mouse tumors with 
those of human counterparts, we have determined and analyzed sequences of 
immunoglobulin (Ig) V H genes of five cases of murine MM, two of WM and 
one of biclonal benign monoclonal gammopathy (BMG). Four of five MM and 
212 WM cases used V H genes of the large J558 family; 1 MM used a gene of 
the VGAM3.8 family and both clones of the BMG used genes of the 36-60 
family. N-region insertions were observed in all cases, but D-segment genes 
were only identified from 6/9 cases, which were all from the D-SP family and 
translated in reading frame 3. Compared to human MM, in which the VII 
genes have been found to be consistently hypermutated (mean% ± SD = 8.8 
± 3.2), the degree of somatic mutation in the murine tumors was significantly 
lower (mean% ± SD = 2.9 ± 2.3). There was no significant evidence of 
clustering of replacement mutations in complementarity-determining regions 
(CDR), a feature considered to be characteristic of antigen selected sequences. 
* Published in: Immunology 1998, 93:162-170. 
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However, one clone of the biclonal BMG case showed intraclonal variation, a 
feature described in some cases of human BMG. These results indicate that 
murine VII genes in mature tumors differ from human counterparts in the level 
and distribution of somatic mutations, but support the concept that BMG may 
be distinct from MM. 
INTRODUCTION 
Monoclonal B cell proliferative disorders are a common feature in the 
elderly, both in humans and in laboratory animals [1]. Benign and malignant 
forms are able to produce large quantities of monoclonal immunoglobulins, 
which are detectable in the serum. Multiple myeloma (MM) is the most 
connnon malignant plasma cell tumor, producing IgG, IgA, IgD or IgE. 
However, there is a benign counterpart of MM that also involves plasma cells, 
but with stable levels of the monoclonal immunoglobulin and no clinical 
characteristics of malignant disease. This benign form has been designated as 
BMG or monoclonal gammopathy of undetermined significance (MGUS), the 
latter term being used on the grounds that only time will show whether a 
monoclonal disorder is truly benign or will develop into malignant disease. In 
fact, the rate of conversion from MGUS to MM is approximately 15 % within 
a median time of 9.6 years [2]. In humans, Waldenstr6m's macroglobulinemia 
(WM) is a relatively rare low grade lymphoma involving lymphoplasmacytoid 
cells that secrete monoclonal IgM. The course of disease tends to be 
influenced by the molecular nature of the IgM, with hyperviscosity or 
cryoglobulinaemia as common features. 
In human disease, illUnunoglobulin (lg) V gene sequences of various 
B-cell tumors have been investigated extensively. Recent data indicate that the 
malignant cell of MM is a B cell that has passed the germinal centre and 
undergone somatic hypermutation [3-5]. Both Ig VII and V L genes are 
extensively mutated and do not show intraclonal variation, indicating that the 
malignant plasma cells are no longer able to accumulate further mutations. 
Furthermore, there is clustering of replacement mutations in CDR regions in 
VII genes in 25% of cases [5,6], consistent with a role for antigen in selecting 
V II sequences. Clustering has also been found in V L in some cases [6]. The 
lack of intraclonal variation might be a distinctive feature of MM, since data 
from human MGUS studies demonstrated that a proportion of cases of MGUS 
showed intraclonal variation, indicating that the tumor cell may still be under 
the influence of a mutation mechanism [7]. There have been fewer studies of 
VH Ig gene sequence analysis of /IIurine MG I1S 
WM, but the limited sequence data on V H and V L genes show evidence for 
somatic mutation and intraclonal homogenity [8]. 
The ST series of MM and WM, which developed spontaneously from 
ageing mice of the CS7BLlKaLwRij strain, shows clinical and biological 
features that closely resemble those of the corresponding human diseases and 
could be used as experimental models [9,10]. Studies on the influences of T-
cell function, antigenic stimulation, and genetic background on monoclonal 
gammopathy (MG) development have been described previously [11,12]. In 
this paper, we report sequences of Ig VH genes for S MM, 2 WM and 1 
biclonal BMG. The sequences are analyzed in comparison with hnman disease 
counterparts. 
MATERIALS AND METHODS 
Cells 
Spontaneously developed mouse MM and WM lines have been maintained and 
propagated by intravenous transfer of bone marrow or spleen cells for several generations in 
syngeneic C57BL/KaLwRij recipients. Their cytogenetic abnormalities arc relatively stable, as 
reported previously [13]. In this study, we used spleen cells of mice in terminal phase with high 
levels of serum monoclonal proteins, as detected by serum electrophoresis. The following 
established tumor lines were studied: 5T2, an IgG2aK-secreting myeloma; 5T7. an IgG2bK-
secreting smouldering myeloma; 5Tl3 and 5T33, both IgG2bK~secreting, aggressive myelomas; 
5T14, an IgGIK~secreting, moderately aggressive myeloma; 5TIO and 5T16, both aggressive, 
IgMK~secretillg WM. 
The biclonal BMG arose in a long-term immunosuppressed old C57BL/KaLwRij 
mouse [11]. Both paraproteills, JgG2aK and IgG2bK, were detectable in the serum for more than 
6 months without clinical signs of progression, and can therefore be considered as BMG rather 
than MGUS. Bone marrow cells were flushed out of the femura and tibiae of the mouse and 
subsequently used in this study. 
cDNA sYJlthesis ami amplificatioJl 
Total mRNA was extracted from the cells by RNAzol B (Ciuna Biotex Labs Inc, 
Houston, TX). Single-stranded cDNA was synthesized lIsing oligo (dT) primer in a Reverse 
Transcription system (RT) (Promega, Madison, WI). The Ig VII genes were amplitied by 
polymerase chain reaction (PCR) lIsing Taq DNA polymerase and a 5' universal FRI VH 
primer, or a mixture of 5' primers specific for each of the VII leader sequences in combination 
with a mix of 1" primers, or an appropriate 3' constant region primer (Table 1). The conditions 
of the peR amplification after initial denaturation of the cDNA at 94°C for 5 min, comprised 
30 cycles of 1 min at 94 °C, followed by 1 min at 60 °C, decreasing in the first 5 cycles with 
I °C each cycle to 55 °C, and a final 1 min at 72 °C. The PCR products were run in a 1.5% 
agarose gel, and the bands were cut out and purified using the Geneclean kit (Bio 10 1 Inc, 
Vista, CA). The purified products were ligated into pGEM-T vector (Promega). The lig,ltion 
mixture was used to transform JM109 competent cells. Plasmid DNA was prepared from over~ 
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Table 1. Primers used in mouse VB gene amplification. 
VH FRI consensus: 
L-J558: 
L-VGAM: 
L-lIc: 
L-Va: 
MHALTl: 
MHALT2: 
MHALT3: 
JHl: 
JH2: 
JH3: 
JH4: 
5Tl3 FRl: 
5Tl3 CDRl: 
VH heptamer: 
5'-AGG TSM ARC TGC AGS AGT CWG G-3' 
5'-ATG GRA TGG ASC TGG RTC 1'1'1'-3' 
5'-ATG GAA TGG CTG TGG AA-3' 
5'-ATG AAA TKC AGC TGG RTY AT-3' 
5'-ATG ATR GTG YTR AKT cn YTG-3' 
5'-TGG RAT GSA GCT GKG TMA TSC TC-3' 
5'-ATG RAC TTC GGG YTG AGC TKG G-3' 
5'-ATG GCT GTC TTG GGG CTG CTC-3' 
5'-TGA GGA GAC GGT GAC CGT GGT CCC-3' 
5'-TGA GGA GAC TGT GAG AGT GGT GCC-3' 
5'-TGC AGA GAC AGT GAC CAG AGT CCC-3' 
5'-TGA GGA GAC GGT GAC TGA GGT TCC-3' 
5'-GGC TGA GCT TGT GAA GCC TGG-3' 
5'-ACC AGC TAC TGG ATG CAC TGG-3' 
5'-ATG TGG TTR CAA CRC TGT GTC-3' 
5'-CAC AGG RRC CAG TGG ATA GAC-3' 
5'-GCT erc GCA GGA GAC GAG GGG GA-3' 
IUPAC-IUB codes for nucleotides are used. 
night cultures using QIAprep Spin Plasmid kit (QIAGEN GmbH, Hilden, Germany). At least 6 
clones were sequenced for each case. 
Screenillg of ST13 V,rreiated germ liue gene 
C57BL genomic DNA was amplified by peR using 5'-primers based on 5Tl3 VH 
FRI and CDRl region sequences together with a 3'-primer based round the heptamer 
recombination sequence Cfable 1). The peR conditions were as above except Ihat the final 
annealing temperature was 50 °C. The peR products were purified, cloned and sequenced. 
Sequencing and sequence assigllments 
The nucleotide sequences of amplified VII genes were determined by the 
dideoxynucleotide chain termination reaction using the SequenaseTIl kit (United States 
Biochemicals Corp, Cleveland, OR) or the T7 Sequencing kit Til (phannacia Biotech Inc.). Both 
T7 and SP6 promoter primers (promega) were used for sequencing. Sequence alignment 
analysis was carried out by searching the Entrez databases of the National Center for 
Biotechnology Information (NCB!) using the BLAST program [14], 
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RESULTS 
Five MM, two WM and one BMG were studied. The disease 
phenotypes and V H gene usage are summarized in Table 2. Comparison of the 
sequences with the NCBI's Entrez database was made, and the most 
homologous germ line genes were considered as the germ line donors. In 
some cases, sequences were aligned to rearranged genes for best match, since 
the closest germ line genes were far less homologous and probably not the 
actual germ line counterparts. 
MM VH sequence analysis 
VH gene sequences. The VH gene sequences derived from the S MM 
cases are shown in Figure 1. ST2 used a gene from the VGAM3.8 family, but 
the other 4 cases all used distinct V H genes derived from the largest JSS8 
family (for a review of mouse VH gene family, see ref. IS). The best germ 
line match for ST2 is VGK7 [16). There were six nucleotide substitutions, of 
which three were silent and three replacement. ST7 was almost identical to the 
germ line gene S1.2 VH [17], with one silent substitution in FR2 and one 
replacement substitution in CDR2, changing Ser to Asn. ST33 was highly 
homologous to an expressed V H gene from a monoclonal antibody directed 
against carcinoma-associated antigen 17-1 A [18). One nucleotide difference 
was found in FR3, resulting in an amino acid change. Although ST33 was 
aligned against an expressed gene, the fact that ST33 V Hand 17-IA VB were 
highly homologous strongly indicates that they were derived from a common 
germ line gene. STI3 VH and ST14 VH were less well matched to known germ 
line genes. The closest germ line match of STI4 found in the Entrez database 
was the V102.1 gene [19). STl4 had nine nucleotide differences, introducing 
one silent and seven replacement mutations. 
The known germ line gene in the database to which ST13 V H was 
most homologous was VHI24 [20). Compared to VH124, ST13 VB had 14 
nucleotide substitutions that resulted in 11 replacement amino acid changes. 
This low percentage homology between ST 13-derived V H gene and the closest 
germ line gene could be due either to somatic mutation of a germ line gene, 
or to the presence of a novel germ line gene yet to be identified. Therefore, 
the corresponding germ line gene of ST 13 VB was investigated further by 
screening PCR products amplified from genomic DNA isolated from a CS7BL 
mouse using two ST13-specific S'-primers and the consensus heptamer 3'-
primer. The first ST13-specific primer is located in FRl, and the second in 
CDRI. Both primers had two mismatches with VHI24 (Table I and Figure 
I). In total, 11 clones amplified with FRI primer and 8 clones with CDRI 
Table 2. Analysis ofMM-.,WM-. and BMG-derived VH gene sequences. 
Proliferative disorder Isotype VH family 
MM5T2 IgG2a-k VGAM3.8 
MM5T7 IgG2b-k J558 
MM5T13 IgG2b-k J558 
MM5T14 IgGl-k J558 
MM 5T33 IgG2b-k J558 
WM5T10 IgM-k J558 
WM5T16 IgM-k J558 
BMG 4.1Ca IgG2a-k 36-60 
BMG4.1Cb IgG2b-k 36-60 
* The best matched germ line V H genes in the Entrez database. 
** The best matched rearranged V H genes in the Entrez database. 
DH 
D-SP2.5 
D-SP2.3 
D-SP2.5 
D-SP2.2 
D-SP2.2 
D-SP2.2 
JH Most homologous V H genes % homology 
JH 3 VGIG 97.5 
JH 2 S1.2VH* 99.6 
JH 3 VH124* 92.3 
JH 4 VI02.1 * 96.6 
JH 2 17-lAVH** 99.3 
JH 1 VH205.12* 95.9 
JH 2 MUSIHCVRA ** 98.5 
JH 2 6D6VH** 95.6 
JH 3 VJUvfRB9** 98.9 
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primer were sequenced. Of the 11 FRI clones, 9 were identical to VH124, the 
others were different and had even lower homology to ST13 VII' Of the 8 
CORl clones, 4 were identical to VH124, one differred from VHl24 by two 
nucleotides, and the remaining 3 clones were different and less homologous as 
compared to ST 13 V H' VHl24 was therefore considered to be the genuine 
donor of 5T13 V H' 
The distribution of the somatic mutations in MM-derived V H genes is 
shown in Table 3. Analysis of the distribution of somatic mutations in each 
sequence was carried out by the method of Chang and Casali [21]. In this 
method, each V gene sequence is analyzed codon by codon for significance of 
deviation from the germ line sequence. A modification of the binomial 
distribution model is then used to calculate whether the probability (p) of an 
excess (in CDR) or scarcity (in FR) of replacement mutations resulted by 
chance alone. ST7 and ST33 were not included, as the numbers of mutations 
were too small. In all 3 cases, the observed and expected numbers of 
mutations were not significantly (p> 0.05) different in either FR or CDR, 
indicating no evidence for antigen selection in the V H sequences. 
CDR3 and If{ sequences. The COR3 of ST2 was composed of OSP 2.5 
o segment and JH3 gene. Both 0 and J segments were used in germ line 
configuration. N-region nucleotide insertions, either G or C, were observed at 
both VH-O and O-JH junctions. The COR3 of ST7 was short with 6 amino 
acids and the JII2 gene was utilised. The nucleotides between V Hand JH could 
be derived either entirely from N additions or contributed partially by a 0 
segment too short to be identified with certainty. The COR3 sequence of ST14 
was also short, and again there was no clearly identifiable 0 gene. In this 
case, however, it was more likely that the VH was rearranged directly to the 
JII4 gene, and the 6 nucleotides between VII and JH were derived entirely from 
N-region insertions, since the nucleotides are exclusively C and G, which 
have been found to be predominant in N regions [22]. The COR3 of ST 13 
was composed of the OSP 2.3 0 segment and JH3 gene. There were N 
insertions at both VwO and O-JH junctions. The COR3 of ST33 VH was 
formed by the OSP 2.5 0 segment and JII2 gene. N additions were only seen 
at the VH-O junction. In all cases, there were no mutations in JII segments, 
and N-region nucleotide insertions were predominantly G and C. In the 3 
cases where the 0 segments were identifiable, reading frame 3 was used 
exclusively. 
WM VH sequence analysis 
VH gene sequences. Two WM cases, STlO and STI6, were investigated. 
120 
VGK7 
5T2 VH 
VGK7 
5T2 VB 
vGK7 
5T2 VB 
VGK7 
5T2 VB 
Q I Q L V Q S G PEL K K P GET V K I S C K A S G Y T F T 
TCCAGTTGGTGCAGTCTGGACCTGAGCTGAAGAAGCCTGGAGAGACAGTCAAGATCTCCTGCAAGGCTTCTGGGTATACCTTCACA 
CAGA--------------------------------------------------------------------------------------
CDRl CDR2 
TAG M Q W V Q K M P G K G F K WIG WIN T H S G V P K Y 
ACTGCTGGAATGCAGTGGGTGCAAAAGATGCCAGGAAAGGGTTTGAAGTGGATTGGCTGGATAAACACCCACTCTGGAGTGCCAAAATAT 
--------------------------------------------T----------------------------------A----------
*F *E 
A E D F K G R F A F S LET S A S T A Y L Q INN L K NED 
GCAGAAGACTTCAAGGGACGGTTTGCCTTCTCTTTGGAAACCTCTGCCAGCACTGCCTATTTGCAGATCAACAACCTCAAAAATGAGGAC 
--------------------------------------------------------------A-----A-G-------------------
MAT Y F C 
ACGGCTACATATTTCTGT 
--------G---------GCGAGA GG 
A R G 
CDR3 
D-SP2:"5""" 
*S 
JH3 
CTATGGTAACTAC CCC GCCTGGTTTGCTTACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCA 
Y G N Y PAW FAY W G Q G T L V T V S A 
Figure 1. Nucleotide and deduced amino acid sequences of V H genes derived from MM. Comparisons were made with the closest germ line or 
expressed VH genes. Dashes represent identity with the representative germ line sequence. Replacement amino acids are starred. 
S1.2VH 
5T7 VH 
S1.2VH 
5T7 VH 
S1.2VH 
5T7 VH 
S1.2VH 
5T7 VH 
E V Q L Q Q S G PEL V K P GAS v K I S C K A S G Y T F T 
GAGGTCCAGCTGCAACAATCTGGACCTGAGCTGGTAAAGCCTGGGGCTTCAGTGAAGATATCCTGTAAGGCTTCTGGATACACGTTCACT 
CDR! CDR2 
D Y Y M K W V K Q S P G K S LEW I G DIN P N N G G T S Y 
GACTACTACATGAACTGGGTGAAGCAGAGCCATGGAAAGAGCCTTGAGTGGATTGGAGATATTAATCCTAACAATGGCGGTACTAGCTAC 
--------------------------------A----------------------------------------------------A----
*N 
N Q K F K G KAT LTV D K S SST A Y M Q L N S L T SED 
AACCAGAAGTTCAAGGGCAAGGCCACATTGACTGTAGACAAGTCCTCCAGCACAGCCTACATGGAGCTCCGCAGCCTGACATCTGAGGAC 
CDR3 
S A v Y Y CAR D JH2 
TCTGCAGTCTATTACTGTGCAAGAGAT 
--------------------------- GAAAGGTT CTTTGACTACTGGGCCCAAGGCACCACTCTCACAGTCTCCTCA 
E R F F D Y W A Q G TTL T V S S 
Figure 1. (Continued). 
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VH124 
5T13 VH 
VH124 
5T13 VB 
VH124 
5T13 VB 
VH124 
5T13 VH 
FRI Primer 
Q V Q L Q Q S G A E L V K P GAS V K L S C K A S G Y T F T 
CAGGTCCAACTGCAGCAGCCTGGGGCTGAGCTTGTGAAGCCTGGGGCTTCAGTGAAGCTGTCCTGCAAGGCTTCTGGCTACACCTTCACC 
-------T------T-------------------A--------------------G-----------
*F *M *M *0 
CDRl CDR2 
S Y W M H W V K Q R P G Q G LEW I GEl D P S D S Y T N Y 
AGCTACTGGATGCACTGGGTGAAGGAGAGGCCTGGACAAGGCCTTGAGTGGATCGGAGAGATTGATCCTTCTGATAGTTATACTAACTAC 
-----------A--T--------A---------C------------------------------------------CC------T-----
*I *R *T *y 
N Q K F K G KAT LTV D K S SST A Y M Q L S S L T SED 
AATCAAAAGTTGAAGGGCAAGGCCACATTGACTGTAGACAAATCCTCCAGCACAGCCTACATGCAGCTCAGCAGCCTGACATCTGAGGAC 
-----------T-G---------------------T-------------A----------------------------------------
*R 
$ A V Y Y CAR 
TCTGCGGTCTATTACTGTGCAAGA 
---------------------G--
*G 
*N 
COR3 
D-$P2.3 JH3 
TCG GGTTACGAC GAC GCCTGGTTTGCTTACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCA 
S G Y D D A W FAY W G Q G T L V T V S A 
Figure L (Continued). 
vI02.1 
5TH VH 
vl02.1 
ST14 VH 
VI02.! 
5Tl4 VH 
VI02.1 
ST14 VH 
Q v Q L Q E S G PEL V K P GAS V K L S C K A S G Y T F T 
CAGGTTCAGCTGCAGCAGTCTGGACCTGAGCTGGTGAAGCCTGGGGCTTCAGTGAAGTTGTCCTGCAAGGCTTCTGGCTACACCTTCACA 
-----------------------------C---------------A--------------------------------------------
*0 *T 
CDR! CDR2 
S Y DIN W V K Q R P G Q G LEW I G W I Y P R D G S T K Y 
AGCTACGATATAAACTGGGTGAAGCAGAGGCCTGGACAGGGACTTGAGTGGATTGGATGGATTTATCCTAGAGATGGTAGTACTAAGTAC 
--------------G-----------------------------------C----------------------------C----------
*K *C *T 
N E K F K G KAT LTV D T S SST A Y MEL H S L T SED 
AATGAGAAGTTCAAGGGCAAGGCCACATTGACTGTAGACACATCCTCCAGCACAGCGTACATGGAGCTCCACAGCCTGACATCTGAGGAC 
-------GA-----------------------------------------------AG----------------------T---------
*R *v 
CDR3 
S A v Y F CAR JH4 TCTGCGGTCTATTTCTGTGCAAGA ____________________ ~2-____________________ __ 
------------------------ GGCGGG TATGCTATGGACTACTGGGGTCAAGGAACCTCAGTCACCGTCTCCTCA 
G G YAM D Y W G Q G T S V T V S S 
Figure L (Continued). 
123 
124 
17-1AVH 
ST33 VH 
17-1AVH 
5T33 VB 
17-1AVH 
ST33 VH 
17-1AVH 
5T33 VB 
Q v Q L Q E S G A E L V R P G T S V K V S C K A S G Y AFT 
CAGGTCCAGCTGCAGCAGTCTGGAGCTGAGCTGGTAAGGCCTGGGACTTCAGTGAAGGTGTCCTGCAAGGCTTCTGGATACGCCTTCACT 
CDRl CDR2 
N Y LIE W V K Q R L G Q D LEW I G V I N P G S G G T N Y 
AATTACTTGATAGAGTGGGTAAAGCAGAGGCTTGGACAGGACCTTGAGTGGATTGGGGTGATTAATCCTGGAAGTGGTGGTACTAACTAC 
--------------------------------------------------------A---------------------------------
N E K F K G KAT L TAD K S SST A Y M Q L S S L T S D D 
AATGAGAAGTTCAAGGGGAAGGCAACACTGACTGCAGACAAATCCTCCAGCACTGCCTACATGCAGCTCAGCAGCCTGACATCTGATGAC 
--------------------------------------------------------------------------------------G---
S A V Y F CAR 
TCTGCGGTTTATTTCTGTGCAAGA 
*E 
CDR3 
D-SP2.S JH2 
GAGGeT TATGGTAACTGC TTTGACTACTGGGGCCAAGGCACCACTCTCACAGTCTCCTCA 
E A Y G N C F D Y W G Q G TTL T v S S 
Figure 1. (Continued). 
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Table 3. Distribution of mutations in MM-, MW-, and BMG-derived VH genes. 
observed expected 
Tumor Region R S R:S R:S p 
ST2 FR 2 4 O.S 3.4 0.08 
CDR 0 3.6 0.39 
5TI3 FR 6 3 2 2.9 0.06 
CDR 4 3 1.3 5.4 0.21 
STl4 FR 4 2 2 3.0 0.13 
CDR 3 I 3 4.8 0.18 
5TlO FR 5 I 5 3.1 0.17 
CDR 3 2 1.5 4.9 0.22 
5TI6 FR 3 I 3 3.4 0.16 
CDR 0 0 3.8 0.43 
4IC-A FR 5 2 2 2.9 0.10 
CDR 5 I S 4.2 0.07 
4IC-B FR 2 0 2.9 0.36 
CDR 2 0 4.7 0.15 
The expected theoretical inherent R:S mutation ratio and the probability (P) that observed R 
mutations resulted from chance only were calculated according to Chang and Casali [21]. 
Again, genes from the J558 family were used in both cases. The VII sequences 
aligned to the best matched sequences in the Entrez database are shown in 
Figure 2. 5T10 was 96% homologous to the germ line gene VH205.12 [23]. 
5TlO had 11 nucleotide substitutions, two were silent mutations and nine 
replacement. 5Tl6 was closest to an expressed V H sequence derived from a 
hybridoma producing anti-human procollagenase antibody (24). There were 
four nucleotide differences, resulting in 3 amino acid changes. 
The distribution of the somatic mutations in WM-derived VII genes 
was also analyzed according to Chang and Casali (Table 3). Again, there was 
no significant evidence of antigen selection in either case (Table 3). 
CDR3 and J/I sequences. 5TlO had a long CDR3 sequence that was 
composed of the D-SP2.2 D segment and JHl gene. The stretch of nucleotides 
126 
VH20S.12 
5T10 VH 
VH20S.12 
ST10 VH 
VH20S.12 
STlO VH 
VH20S.12 
5T10 VH 
ST10 VH 
FRI Primer 
E V Q L Q Q S G PEL V K P GAS V K I S C K A S G Y T F T 
GAGGTCCAGCTGCAACAATCTGGACCTGAGCTGGTGAAGCCTGGGGCTTGAGTGAAGATATCCTGTAAGGCTTCTGGATACACGTTCACT 
-------------------------------------------------------------C---T-
*L *1 
CDRl CDR2 
D Y Y M N W V K Q S H G K S LEW I G D T N P K N G G T D Y 
GACTACTACATGAACTGGGTGAAGGAGAGCGATGGAAAGAGCCTTGAGTGGATTGGAGATATTAATCCTAACAATGGTGGTACTAGCTAC 
-------------------------------------------------------------A---------G-------A-----AT---
*N *n *N 
N Q K F K G KAT LTV D K S SST A Y MEL R S L T SED 
AACCAGAAGTTCAAGGGGAAGGCGACATTGACTGTAGACAAGTCCTCCAGCACAGCCTACATGGAGCTCCGCAGCCTGACATCTGAGGAC 
------------------------G---------------------------------C-G-----------------------------
*A 
S A V Y Y CAR 
TCTGCAGTCTATTACTGTGCAAGA 
--------------------T--- GGCCCTCCT 
G P P 
T V S S 
ACCGTCTCCTCA 
*S *V 
CDR3 
D-SP2.2 JHl 
TATGATTACGAC GAGGGAAAA TACTTCGATGTCTGGGGCAAAGGGACCACGGTC 
Y D Y D E G K Y F D V W G K G T T V 
Figure 2. Nucleotide and deduced amino acid sequences of V H genes derived from WM-like lymphomas. Comparisons were made with the closest germ 
line or expressed V H genes. Dashes represent identity with the representative germ line sequence. Replacement amino acids are starred. 
FR! Primer 
E v K L Q E S G G G L V Q P K G S L K L SeA A S G F T F N 
MUSIHCVRA GAGGTGAAGCTGCAGGAGTCTGGTGGAGGATTGGTGCAGCCTAAAGGGTCATTGAAACTCTCATGTGCAGCCTCTGGATTGACCTTCAAT 
ST16 VH -----------------------------------------------------------G-------
*S 
CDR! CDR2 
T YAM N W V R Q A P G K G LEW V A R IRS K S N N Y A T 
MUSIHCVRA ACCTACGCCATGAACTGGGTCCGCCAGGCTCCAGGAAAGGGTTTGGAATGGGTTGCTCGCATAAGAAGTAAAAGTAATAATTATGCAACA 
ST16 VH ------------------------------------------------------------------------------------------
Y Y ADS V K D R F TIS R DDS Q S M L Y L Q M N N L K T 
MUSIHCVRA TATTATGCCGATTCAGTGAAAGACAGGTTCACCATCTCCAGAGATGATTCACAAAGCATGCTCTATCTGCAAATGAACAACTTGAAAACT 
5T16 VH --------------------------A----------------c-------G--------------------------------------
MUSIHCVRA 
5T16 VH 
Figure 2. (Continued). 
EDT AMY Y C V R 
GAGGACACAGCCATGTATTACTGTGTGAGA 
*A *E 
CDR3 
D-SP2.2 JH2 
C ATGATTACG ACTTTGACTACTGGGGCCAAGGCACCACTCTCACAGTCTCCTCAGAGAGT 
H D Y D F D Y W G Q G TTL T V SSE S 
127 
128 
606VH 
41Ca-l VH 
41Ca-2 VH 
41Ca-3 VH 
606VH 
41Ca-l VH 
41Ca-2 VH 
41Ca-3 VH 
6D6vH 
41Ca-l VH 
41Ca-2 VH 
41Ca-3 VH 
606VH 
41Ca-l VH 
41Ca-2 VH 
41Ca-3 VH 
FRl Primer 
Q V Q L Q E S G P G L A K P S Q T L S LTC S V T G Y SIT 
CAGGTGCAGCTGCAGGAGTCAGGACCTGGCCTGGCAAAACCTTCTCAGACTCTGTCCCTCACCTGTTCTGTCACTGGCTACTCCATCACC 
-------------------------------------------G-----------------------
-------------------------------------------G------------G----------
-------------------------T-----------------G-----------------------
*8 *A *C 
CDR1 CDR2 
S D Y WNW IRK F P G K K LEY M G Y I S Y S G STY Y N 
AGTGATTACTGGAACTGGATCCGGAAATTCCCAGGGAATAAACTTGAGTACATGGGGTACATAAGCTACAGTGGTAGCACTTACTACAAT 
-A----A-------------------------------G-------------------------A----------GC-------------
-A----A-------------------------------G-------------------------A----------GC-------------
-A----A--------------------C----------G-------------------------A----------GC-------------
*N *N *L *N *A 
P S L K SRI SIT R D T S K N Q Y Y L Q L N S V T TED T 
CCATCTCTCAAAAGTCGAATCTCCATCACTCGAGACACATCCAAGAACCAGTATTACCTGCAGTTGAATTCTGTGACTACTGAGGACACA 
----------------A-G-------A-------------------------T-------------------------G-----------
----------------A-G-------A-------------------------T-------------------------G-----------
----------------A-G-------A-------------------------T-------------------------G--------T--
*Q *V *F *A *$ 
CDR3 
A T Y Y CAR D-SP2.2 JH2 
GCCACATATTACTGTGCAAGA CT G 
---------------------T TCTATAATAATTAC CCA TACTTTGACTACTGGGGCCAAGGCACCACTCTCACAGTCTCCTCA 
F Y N N Y P Y F D Y W G Q G R T LTV S S 
Figure 3. Nucleotide and deduced amino acid sequences of V H genes derived from mouse BMG. Comparisons were made with the closest germ line or 
expressed V H genes. Dashes represent identity with the representative germ line sequence. Replacement amino acids are starred. 
VHMRB9 
41Gb VH 
VHMRB9 
41Cb VH 
VHMRB9 
41Cb VH 
VHMRB9 
41Cb VH 
FRI Primer 
D V Q L Q E S G P G L V K P S Q S L S LTC S V T G Y SIT 
GATGTACAGCTTCAGGAGTCAGGACCTGGCCTCGTGAAACCTTCTCAGTCTCTGTCTCTCACCTGCTCTGTCACTGGCTACTCCATCACC 
CDRl CDR2 
S G Y Y WNW IRQ F p G N K LEW M G Y I S Y D G S N N Y 
AGTGGTTATTACTGGAACTGGATCCGGCAGTTTCCAGGAAACAAACTGGAATGGATGGGCTACATAAGCTACGATGGTAGCAATAACTAC 
------------------------------------A------------------------------------G-----A----------
*R *G *N 
N P S L K N R I SIT R D T S K N Q F F L K L N S V T TED 
AACCCATCTCTCAAAAATCGAATCTCCATCACTCGTGACACATCTAAGAACCAGTTTTTCCTGAAGTTGAATTCTGTGACTACTGAGGAC 
CDR3 
TAT Y yeA S JH3 
ACAGCCACATATTACTGTGCAAGT 
-----------------------A GGGGGGCCG GCCTGGTTTGCTTACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCA 
*R G G PAW FAY W G Q G T L V T v S A 
Figure 3. (Continued). 
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between V and D and D and J could not be assigned to any D segments, and 
were presumably derived from N additions. By contrast, the CDR3 sequence 
of 5T16 was very short and formed by D-SP2.2 and JH 2. 
BMG VH sequence allalysis 
The BMG had two paraprotein bands, and V H gene analysis also 
showed that there were two distinct groups of sequences, both derived from 
the small 36-60 family (Figure 3). In the first group, 41 Ca, a number of 
sequences were closely similar to each other with an identical V -D-J junction 
sequence, indicating that they originated from the same clone. It is unlikely 
that the nucleotide heterogeneity was introduced by Taq DNA polymerase, 
since it was not seen in the other cases, and the Taq DNA polymerase error 
rate in our system is much lower « 115000 bases). All intraclonal nucleotide 
variations led to change in amino acid sequence. The best matched gene found 
in the database for this group of sequences was a gene used in an anti-MPO 
antibody (Gilbert et al., unpublished data, accession Z37144). 41Ca clones 
were different from this gene by between 12 to 15 nucleotides, which were 
located in FR as well as in CDR. The D segment used matched equally well 
to D-SP2.2 and D-SP2.9, both with 1 silent and 2 replacement nucleotide 
changes. The D segment was rearranged to JH2 gene in germ line 
configuration. The second clone, 41Cb, was most homologous to the gene 
VHMRB9, which was used in an anti-histone antibody [25]. There were three 
nucleotide differences, one in FR2 and two in CDR2, all resulting in amino 
acid changes. No intraclonal variation was observed. The CDR3 was short, 
with no identifiable D segment. The JH3 germ line gene was used. The 
nUcleotides between V and J were exclusively G and C, probably derived 
entirely from N additions. 
In both cases, there was no evidence of antigen selection, since no 
significant difference was found in the observed and theoretically expected 
numbers of mutations in either FR or CDR. 
DISCUSSION 
We have determined and analyzed Ig V H gene sequences derived from 
five cases of MM, two of WM and one of biclonal BMG. In contrast to 
corresponding human diseases, in which V H genes have consistently been 
found to be extensively mutated with a mean% ± SD of 8.8 ± 3.2 [5], the 
rate of somatic mutation in the mouse tumors studied here was significantly 
lower (two-sample t test, p<O.OI), with a mean% ± SD of 2.9 ± 2.3. In the 
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five mouse MM, ST2, ST7 and ST33 had only a limited number of mutations. 
In contrast, ST13 and ST14 were considerably different from the closest germ 
line genes, with 11 and 7 amino acid replacement mutations, respectively. 
Although mouse Ig V H repertoire has not been fully sequenced and seems to 
be more complicated, with estimates varying between 100 to 1000 members 
[15], we could not find a better-matched germ line donor for ST13 by 
sequencing PCR products amplified with ST13-specific primers. We believe 
therefore that the low homology between ST13 V Hand VH124 is due to 
somatic hypennutation. 
Recent studies indicate that in humans the neoplastic cell of MM is a B 
cell that has passed the germinal centre and undergone somatic hypennutation 
[3-S]. Both Ig V Hand VL genes are extensively mutated and in a proportion of 
cases (- 2S %) there is evidence for antigen selection, as significant clustering 
of replacement mutations has been observed in CDR regions in either V H or 
VL [6,7]. In the mouse, however, the origin of MM cells is less clear, since 
the mutation rate of VII genes varies from case to case. ST13 and ST14, which 
have numerous nucleotide substitutions, may originate from B cells that have 
been exposed to the hypermutation mechanism in the germinal centre, possibly 
memory cells. However, there is no clear evidence for antigen selection, as 
the mutations were not clustered in the CDR regions. In contrast, ST2, ST7 
and ST33 have only a small number of mutations. It is possible therefore that 
they originated from naive cells that had not undergone somatic mutation 
process. On the other hand, it is generally believed that the rate of somatic 
mutation of mouse V genes is lower, especially in old animals [26]. It can not 
be ruled out that the precursor cells of ST7 and ST33 were at the same 
differentiation stage as ST13 and ST14, but failed to accumulate further 
mutations. It is interesting to note that in mouse B-cell lymphomas, BCLl 
[27], 38Cl3 and A3l [28], the V H genes have just one (BCLl) and no (38C13 
and A31) somatic mutation [our unpublished data]. 
Compared to human MM, the CDR3 regions of mouse MM are less 
complex. Unlike human MM, no D-D fusion and D segments in reverse 
orientation were observed and the D segments identified were all in germ line 
configuration. There was evidence of N-region additions in all the murine 
tumors investigated; however, it is difficult to compare the degree of N 
additions to that of the human tumors because of the complexity of the D 
segment usage of the latter. Interestingly, in 2 murine MM cases the CDR3 
regions seemed to be contributed mostly by N insertions with no apparent D 
segments involved. However, the possibility that very short or mutated D 
segments were used could not be ruled out. 
Similar variations in the somatic mutation rate of V H genes were also 
observed in the two cases of WM and the biclonal BMG. The two BMG 
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clones both nsed VII genes from the much smaller 36-60 family. The clone 
41Ca was more mutated and intraclonal nucleotide variations were observed, 
snggesting that the tumor cells may still be undergoing somatic mutation. In 
this aspect, mouse BMG is similar to the human counterpart, as intraclonal 
variation has been observed in a number of human cases [7]. The degree of 
somatic mutation in the clone 41 Cb was much lower with only 3 nucleotide 
substitutions. Similar low frequency of somatic mutation in one case of BMG 
has been observed previously [29]. 
The 5T series of MM and WM-like lymphomas is, in many aspects, 
closely similar to corresponding human diseases. However, the rate and 
pattern of somatic mutation of VII genes in some cases are quite different. 
Obviously, the findings have implications in using the 5T series of mouse 
tumors as experimental models, especially in anti-idiotypic therapy studies, 
where it might be anticipated that the number of idiotypic determinants arising 
from somatic mutations and genetic complexity in CDR3 will be more limited 
than in the human disease counterparts. 
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CHAPTER 6 
GENERAL DISCUSSION 
6.1 B-ceU subsets and their involvement in monoclonal gannnopathies 
The studies described in this thesis attempt to give insight into some 
basic pathogenetic aspects of the development of monoclonal gammopathies 
(MG). Chapter 2 shows that the recently acknowledged subset of B-cells in the 
coelomic cavities, the B-1 cells, can be responsible for MG. 
In the I-',K-transgenic C57BLl6 (Sp6) mice two populations of B-cells 
have been identified that differed in the expression of transgenic (Tg) and 
endogenous IgM [1]. The majority of the peripheral B-cells expressed 
exclusively the Tg IgM of 1-" allotype. However, a small proportion of B-cells 
showed endogenous, i.e. non-transgenic, IgM expression of 1-'" allotype, 
usually concomitant with Tg IgM. This B-cell subset possessed a B-1 
phenotype: expression of CDllb, CDS, and low levels of IgD. In addition, 
they were especially enriched in the peritoneal cavity, and they could not fully 
reconstitute endogenous IgM-positive B-cells in irradiated recipient mice. We 
therefore assumed that monoclonal B-cell proliferative disorders arising from 
the B-1 cell population in these aging Tg mice would result in a homogenous 
immunoglobulin component (H-Ig) of endogenous isotype. A major advantage 
of this study was that we were able to detect B-1 cell derived H-Ig without 
prior disruption of the ill vivo experimental model. 
In fact, all H-Ig that we detected in the Tg mice (n=58) were of 
endogenous origin: one multiple myeloma (MM), six benign monoclonal 
gammopathies (BMG), five transient MG, and 10 unclassifiable H-Ig (Chapter 
2.2). Consequently, these MG were all of B-1 origin. The aging Tg mice 
showed half as many MG as their normal littennate (LM) counterparts. 
From these results we can certainly not conclude that all mouse MG 
are derived from the B-1 cell population. In this transgenic mouse model the 
B-1 cell population is the only B-cell subset that can shape the actual antibody 
repertoire, resulting in extensive activation of this B cell compartment [2,3). 
The frequency of the B-1 cell derived H-Ig in the aging Tg mice is therefore 
probably not similar to the frequency of those in normal LM mice, but 
exaggerated due to this activation. The B-2 cells, on the other hand, were 
functioning properly after encounter of the relevant antigen TNP [4). The I-',K 
inununoglobulin (Ig) transgene encoded for this specificity. Since the Tg mice 
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were not innnunized with TNP-conjugates, the B-2 cell compartment was in a 
relatively resting state. We can hypothesize from the results of this study that 
without extensive (antigenic) activation no B-2 cell derived MG will occur in 
this mouse model. 
This is in accordance with some previous studies on the role of antigen 
in the development of MG. It has been shown that repeated innnunization of 
mice at young age resulted at old age in a number of MG with H-Ig specific 
for the antigen used in the immunization procedure [5,6,7]. Results of studies 
on the accumulation of somatic mutations in the irmnunoglobulin heavy-chain 
variable region (Ig V H ) gene complementarity-determining regions (CDR) 
also reveal a role for antigen in the process of a B-cell clone becoming larger 
and persistent and giving rise to MG [8,9,10]. Although antigen is likely to be 
a major contributing factor in the development of MG, it is not known what 
antigens caused the excessive monoclonal B-1 cell proliferations in the Sp6 Tg 
mouse model. Almost all infectious diseases and other pathological conditions 
have been excluded as causative factors in this study, suggesting that the 
stimuli that initiated the development of the monoclonal B-cell proliferative 
disorders might very well be physiological ones. Candidate antigens probably 
come from the murine intestinal flora. Antibodies produced by B-1 cells have 
been shown to bind microbial antigens, such as phosphatidylcholine, 
phosphorylcholine, dextran, pneumococcal polysaccharide, lipopolysaccharide, 
and others [reviewed in 11]. Furthermore, in anti-red blood cell autoantibody 
transgenic mice it was shown that bacterial colonization of the murine gut was 
responsible for the expansion of the B-1 cells [12]. 
In the second study we used immunoglobulin heavy-chain (IgH) 
allotype-congenic mouse chimeras to study the same experimental question: do 
MG originate from both B-cell lineages or not? Again, a long-term study was 
performed. The C57BL mice under investigation were lethally irradiated and 
reconstituted with bone marrow (BM) cells and IgH allotype congenic 
peritoneal wash cells. The cells from the peritoneal washes provided for the 
precursors of the B-1 cells, while the BM cells gave rise to the B-2 cells [13-
15]. The cell lineage origin of the H-Ig that developed at old age could thus 
be determined by Ig-allotyping of the H-Ig component in the serum. 
A great disappointment in the outcome of this study was the markedly 
decreased survival time of the irradiated mice. Histopathological examination 
of necropsy material showed that this was not caused by any infectious disease 
due to an impaired innnune system, nor by radiation induced tumors. It 
appeared that severe renal damage, as a late effect of irradiation, resulted in a 
protein loosing disorder of the affected mice, leading to their relatively early 
death. The steep decline in the survival curves indicated that the mice were 
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severely ill for only a short time. Clinically their deaths could hardly be 
predicted, since the only early sign of disease was a generalized edema, 
followed in a few days to almost two weeks by marked discomfort and fast 
progression of the illness. A subsequent study with allotype-congenic mouse 
chimeras that received a 1 Gy lower radiation dose (8.5 Gy) than the first 
groups did not improve the survival times significantly and was therefore left 
out of the study. 
As a consequence, fewer MG could be studied, most of them were 
BMG and transient MG, and only one MM. This MM could be identified as 
having the BM derived allotype of the IgG2a isotype. Determination of the 
IgM-allotypes of the H-Ig in the aging chimeras revealed that most of these H-
Ig originated from the peritoneal B-cells and were therefore of B-1 cell origin. 
Our experiments, presented in chapters 2.2 and 2.3, showed that B-1 
cells can be responsible for age-related MG in a susceptible mouse strain. The 
MG were mainly transient and benign (BMG) of character. Only one 
malignant MG of B-1 cell origin, a IgG2b-kappa producing MM, was detected 
in a !',K-transgenic mouse. The B-1 cell derived MG that we detected in the 
allotype-congenic chimeras produced IgM, the isotype that is secreted in large 
amounts by B-1 cells. This is in contrast to the findings in the !"K-transgenic 
mice in which we detected almost no H-Ig of IgM isotype. It is speculative 
that this is the result of the extensive activation of the B-1 compartment in the 
Tg mice, leading to a relatively high rate of class-switch of the B-1 cells. 
There are also other experimental approaches that might be employed 
to study the differential involvement of the B-1 and B-2 cells in the 
development of MG. Xid mice, in which the B-1 cells are selectively depleted, 
can be used as recipients for IgH allotype congenic peritoneal wash cells 
without the in our model necessary total body irradiation. It was shown by 
Gueret et al. [16] that C57BLlXid mice had a low incidence of H-Ig 
compared with the 50% incidence in the control mice. Unfortunately, these 
mice did not live long enough to develop full-blown MG of neoplastic origin. 
Selective and permanent depletion of the B-1 cells can also be accomplished 
by intraperitoneal injections of anti-IgM antibodies [17]. Mice treated this way 
can function as recipients of allotype congenic B-1 cells. Several other 
treatment protocols of mice, similar to the fonner one, can be used, e.g. 
intraperitoneal injections of anti-IL-IO [18] or anti-mouse CD19 [19] 
antibodies. Once the peritoneal B-1 cells are depleted and restored by donated 
B-1 cells, the original B-1 precursor cells will be inhibited by a feedback 
mechanism [20]. 
B-1 cells in the peritoneal cavity (PerC) have been recognized as a 
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separate B-cell compartment, with a distinct phenotype and localization, 
restricted Ig repertoire, and self-replenishing properties [21-26]. B-1 cells ill 
vitro [27] and ill vivo [28] grow preferentially on peritoneal stromal cells, 
indicating that the microenvironment contributes to the growth, survival and 
anatomical distribution of peritoneal B-1 cells. Still a matter of debate is 
whether the B-1 cells are a different lineage or a subset of B-cells that 
expresses a B-1 cell phenotype after activation by antigen [29-32]. Although 
we thiuk that the cell transfer experiments propose the strongest argument of 
the different B-cell lineages [21-26,29,33], definitive proof is lacking, mainly 
because a unique identifier of these cells still has to be found. Progress is 
being made, however, as appears from the different transcription factor 
induction in B-1 cells [34], the non-constitutive expression of apoptosis-
associated Fas receptor on B-1 cells [35], and especially the constitutive 
activation of STAT3 (signal transducer and activator of transcription-3) in 
normal B-1 cells [36]. The latter study showed that prolonged stimulation of 
conventional B-2 cells with anti-Ig, a treatment sufficient to induce CD5 
expression, did not result in sustained STAT3 activation, suggesting that 
ST AT3 is a specific nuclear marker for B-1 cells. 
Aging affects the levels and clonality of the B-1 cells in mice: numbers 
of CD5 + cells increase with aging, together with oligoclonal expansions of 
these cells. The clones could be detected at the cellular level in the peritoneal 
cavity and spleen, later in lymph nodes, peripheral blood and BM [37]. There 
are indications that the frequencies of CD5 + B cells in the PerC and the 
spleen are in part under separate genetic control [38]. At the subcellular level, 
clonal expansions of B-cells could be detected in old mice, using a PCR-based 
technique [39]. The latter study did not focus on the B-1IB-2 dichotomy of the 
B-cell compartment. None of these studies did investigate and reveal Ig 
spectrum abnormalities as a result of the clonal expansions. 
A role for B-1 cells in human lymphoproliferative diseases has been 
established in B-cell chronic lymphocytic leukemia (B-CLL), although 
impressive differences exist between normal and malignant CD5 + B-cells 
[40]. Furthermore, CD5 expression has been found in small lymphocytic 
lymphoma, and lymphocytic lymphoma of intermediate differentiation or 
mantle zone lymphoma [41]. CD5 + immunoregulatory B-cells have been 
found in the peripheral blood and spleen from MM patients [42,43]. These 
cells inhibited the Ig production in a pokeweed mitogen driven assay. In some 
cases the CD5+ CDI9+ or CDllb+ B-cells may have been a part of the 
malignant process [44,45,46], while other studies showed a reduced number 
of CD5 + B-cells in MM patients [47]. In patients with Waldenstrom's 
macroglobulinemia (WM) monoclonal CD5+CDllb+ B-cells have been 
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found in the peripheral blood [48]. Although there is as yet no functional 
evidence that clearly defines these monoclonal B-cells as a malignant part of 
the WM, their monoclonality and morphology suggested indeed malignancy. 
When using phenotypical features of malignant B-cells to define their normal 
counterparts, it is necessary to have information as to whether the expression 
of certain antigens is induced by the malignancy itself. As yet there is no such 
information on the regulation of CDS or CDllb expression on B-cells. 
Furthermore, the use of the expression of these two antigens to define a 
normal B-cell in humans as originating from the B-1 cell lineage is an equally 
dangerous undertaking. As discussed before, expression of these antigens on 
B-cells outside the PerC is not sufficient evidence to place these B-cells into 
the group of B-1 cells, since the expression of these markers can be induced 
in B-2 cells as well. In the human situation it is hardly possible to investigate 
the peritoneal resident B-cells. This makes it even harder to find a definitive 
lineage marker and to investigate the normal physiology of this B-cell subset. 
However, a study on peritoneal lymphocytes from patients starting continuous 
ambulatory peritoneal dialysis and from women undergoing bilateral tubal 
ligation suggested that the phenotype of human peritoneal B cells is similar to 
that of B-1 cells in mice [49]. 
Because of the self-replenishing properties and the tendency to become 
clonally restricted with aging, the B-1 cells might be prone to a higher chance 
of malignant transformation. Among the age-related MG, some could be of B-
1 cell origin. Knowledge of the B-cell lineage origin might be helpful for 
correct diagnosis and timely efficient treatment of malignant forms of MG. 
6.2 Is clonal dominance in antibody responses the basis for 
development of monoclonal gammopathies? 
To elucidate the process that takes place prior to the development of a 
stable monoclonal B-cell clone, we started the experiments that are described 
in Chapter 3. We studied the effects of age at time of immunization, the 
genetic background, and an impaired T-cell system on the levels and the 
heterogeneity of the specific antibody response to dinitrophenylated human 
serum albumin (DNP-HSA). This heterogeneity can be envisaged as the 
capacity of the immune system to recruit the available antigen-specific 
clonotypes directly after iuununization. An exaggerated response of one or a 
few clones could result in the so called clonal dominance. With the use of 
sensitive immunoblotting techniques, these H-Ig, as products of the dominant 
clones, can be detected in the serum. 
In this study we used two inbred mouse strains: the CS7BLlKaLwRij 
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(C57BL), which has a high incidence of spontaneonsly developing MG, and 
the CBA/BrARij (CBA), which in contrast shows a low incidence of these B-
cell proliferative disorders. Similarly, clonal dominance was scarce in CBA 
mice, but frequent in C57BL mice. This observation could not be related to 
the number of spectrotypes in the mice: young intact members of both strains 
had an equal number of spectrotypes. Furthermore, non-immunized mice of 
both strains have been shown to possess equal numbers of DNP-specific B-
cells in the spleen [50], which ruled out the number of available responding 
B-cell clones as an explanation for the resnlts from this study. 
In the C57BL mice innnunized with DNP-HSA at old age, smaller 
amounts of specific antibodies were produced by fewer clones, while the 
incidence of DNP-HSA-specific H-Ig (produced by the dominant clones) was 
as high as in C57BL mice iIl11llunized with DNP-HSA at young age. This 
indicated that at old age the responding B-cell clones are more prone to 
become dominant in C57BL mice. Fewer responding clones in these 
experiments meant that more spectrotypes could be detected in less diluted 
serum in the isoelectric focussing (IEF) procedure. 
Neonatal thymectomy had a little effect on the levels and the 
heterogeneity of the antibody response in our experiments, probably because 
the T-cell system was only moderately impaired and/or a part of the DNP-
specific antibody response could have been T-cell independent. However, 
Benjamini et al. [51] concluded from their study that clonality of the antibody 
response is neither due to a restricted B-cell repertoire, nor to a reduced 
function of antigen specific TH cells. The clones will be randomly selected for 
by the antigen from a larger pool of available B-cell clones, and these 
responding clones eventually become immuno-dominant, thus establishing the 
clonal characteristics of the response. This response was shown to be what 
they called "locked-in" for the life of the immunized individual, meaning that 
non-responsiveness after the first set of immunizations was maintained after 
the second set of immunizations. In analogy also positive responsiveness was 
maintained after a subsequent set of immunizations. In other words: the 
development of clonal dominance was intrinsic to the B-cells. Specificity 
maturation was not determined in this study. This mechanism can not explain 
the restriction in the specific antibody responses since it was found that clonal 
dominance was present even before significant amounts of specific antibodies 
were found in the sera. Some animals showed clonal dominance even before 
immunization [52, and our data]. The inability of the study of Benjamini et al. 
[51] to show T-cell influence might be an antigen based problem or a specific 
trait of the involved inbred mouse strain, in this case the C3H.SW mouse. 
Furthermore, the size of the individual responding clones and number of 
spectrotypes were not established. Both parameters might give insight into the 
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effect of an impaired T-cell system. However, this study and our data together 
strongly suggest that the T-cell system might not be the most important factor 
in the initiation of clonality of the antibody response, but it certainly plays an 
important role in the progression into bigger clones and subsequent 
development of MG [53-57]. 
Our observation of the tendency to respond in a specific antibody 
response with a restricted set of B-cell clones parallels the genetic 
susceptibility to develop spontaneously MG in a high frequency in C57BL 
mice. The importance of this observation is extended by a study from Nooij et 
at. [6]. in which it was established that age-associated MG could produce an 
H-Ig with antibody specificity to the antigen (again DNP-HSA) used for 
inununization at young age. While most of the MG that developed in the CBA 
mice were transient and of a low concentration, the majority of MG in C57BL 
mice had characteristics of a BMG. Interestingly, some of the clonal products 
had the same mobility and similar spectrotypes as dominant clonal products at 
the peak of the antibody response. This strongly indicates a close relationship 
between expanded dominant clones after immunization and BMG appearing 
later in life. In the same study a clear effect of neonatal thymectomy was 
found in the old CBA mice, resulting in a higher frequency of MG. This 
emphasizes the conclusion at the end of the former paragraph. 
Thus, clonal dominance in antibody responses is a genetically 
determined trait of the B-cell compartment. Control over dominant clones is 
exerted by immuno-regulatory factors, such as the T-cell system. Imbalances 
in this control mechanism allow for the preferential outgrowth of the dominant 
B-cell clones and precede the development of MG in mice. As yet there are 
no studies available that suggest a similar mechanism in humans. 
6.3 A long-term impaired T-cell system: submissive for the 
development of malignant monoclonal ganmlOpathies 
The occurrence of H-Ig in the serum of immunosuppressed patients is 
not uncommon [58-60]. Most of these H-Ig, about 75%, are of transient 
nature, but persistent MG are certainly present [58,61-63]. The incidence of 
lymphoproliferative disorders of B-cell origin that do not produce an H-Ig (or 
only rarely in a low concentration) is greatly enhanced in immunosuppressed 
patients [64,65]. These B-cell lymphoproliferative disorders are non-Hodgkin 
lymphomas (NHL) , associated with Epstein-Barr virus (EBV) reactivation. 
However, as yet there are only few observations of a malignant MG 
developing in immunosuppressed patients. They can be divided into 
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extramedullary plasmacytomas [66-68] and multiple myelomas [63,69-71]. In 
some of these malignancies an EBV association has been established. Because 
of this low incidence there is no information as to whether an extramedullary 
plasmacytoma frequently ends up as an MM in these patients. Analogously, 
other causes of immunosuppression have been shown to increase the incidence 
of B-cell NHL and paraproteinemias, e.g. in patients with HIV-infection [72-
77]. 
Our animal model was employed to perform a long-term investigation 
of the effects of maintenance immunosuppressive treatment on the 
development of transient and persistent MG (Chapter 4). Although the 
proportion of mice with H-Ig in the immunosuppressed groups was equal to 
the proportion of mice with H-Ig in the PBS control group, remarkable 
differences were observed between the incidences of the individual categories 
of MG. The transient MG reached a four to five times higher incidence in the 
mice of the immunosuppressed groups as compared to the mice of the PBS 
control group. No differences were detected in the incidences of BMG, but a 
remarkable ten times higher incidence of MM occurred in the 
immunosuppressed groups. 
This is an important observation with regard to the etiology and 
pathogenesis of the individual categories of MG. Would it be that transiently 
present mono- or oligo clonal B-cell proliferations, responding to certain 
antigenic stimulations, were a foregoing event in the development of a BMG, 
we should have expected to find an equal increase in the incidence of BMG 
similar as in the incidence of transient H-Ig. This we did not find. The 
incidence of MM that we observed in our experiments was increased to more 
or less the same order as transient H-Ig. It is tempting to conclude from these 
data that MM results directly from a transformed "overshooting" B-cell clone 
and not from a persistent, but non-progressive, BMG. The long-term 
immunosuppression probably resulted in the outgrowth of usually small and 
undetectable antigen responding B-cell clones. These normally functioning 
dominant clones could subsequently be detected in the serum by their H-Ig 
product. The accumulation in time of multiple genetic aberrations might than 
have transformed these normally occurring B-cell clones into malignant MG 
like MM. The exact nature of these transforming processes is as yet unknown. 
As mentioned before, the incidence of BMG was not significantly 
changed in the immunosuppressed groups treated with either 
azathioprine/prednisolone or cyclosporin /prednisolone as compared to the 
PBS control group. To interpret this observation adequately, we should bear 
in mind that the cumulative frequencies of H-Ig components, as given in 
Chapter 4, table 2, were collected after the death of the mice. When we 
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analyze the data from table 2 together with the data from figure 2, which 
depicts the frequency of H-Ig in relation to the age of the mice, we can 
conclude that the total number of MG, and more specifically of BMG, was the 
same in all groups. However, the mice receiving immunosuppressive 
treatment showed an earlier onset of the MG in general. This finding is in 
accordance with a study in immunosuppressed patients after renal 
transplantation [58] where a correlation was found of the frequency of H-Ig 
and the age of the patient. This earlier onset of the development of the various 
categories of MG was also found in athymic nude C57BL mice during aging 
[56]. These studies strongly indicate that an intact T-cell system is required 
for a normal heterogenous Ig spectrum. Impairment of the T-cell system 
results in an earlier onset of age-related MG, and increases the incidences of 
malignant forms of MG, especially MM, and of transient MG. 
Furthermore, tests for the antibody specificity of individual H-Ig to the 
antigen used for immunization (a human myeloma IgG I-A) revealed that one 
of the 114 cases of BMG and one of the 15 cases of MM had a positive anti-
human IgG 1 activity. This observation is in accordance with previous studies 
on antigen specificity of H-Ig in MG [5-7]. Moreover, studies in HIV-infected 
patients showed that monoclonal Ig detected in the serum of some of these 
patients were specific for parts of the HIY [73,74,76]. 
6.4 Imlllunogiobulin V H gene seqnence analysis of spontaneous Illurine 
monoclonal gannnopathies 
Although all MG are excessive plasma cell proliferations, the 
progenitor cells might be less differentiated B-cells that circulate in the 
peripheral blood [78-80]. These progenitors might even be different for the 
individual MG categories, including B-1 cells in the peritoneal cavity as 
precursors for certain types of extramedullary plasmacytomas and part of the 
BMG. The presence of shared idiotypes between IgM-expressing pre-B 
lymphocytes and the cells of a myeloma clone suggested the existence of such 
a progenitor cell [81]. However, others showed that anti-idiotypic antibodies 
in MM can be cross-reactive to other, different, Ig in the same patient [82]. 
The third complementarity-determining region (CDR3) sequences and somatic 
mutations of V -region Ig genes are more potent clonal markers of malignant 
B-cells and plasma cells. This method can help to identify the normal 
counterparts of these cells [9,83]. 
For MM, numerous studies in humans have shown that the malignant 
plasma cell has undergone extensive somatic mutation [8-10]. Analysis of both 
V H and V L gene sequences revealed no intraclonal variation, indicating that the 
146 Chapter 6 
malignant cells were no longer able to accumulate further mutations. 
Furthermore, the clustering of replacement mutations in CDR regions of the 
VII genes is consistent with a role for antigen in selecting V H sequences. After 
encounter, or several encounters, of antigen in the germinal center the B-cell 
accumulates somatic mutations [10]. Somewhere between the germinal center 
and the BM a final event transformed the antigen specific B-cell into a 
malignant plasma cell that is ill1ll1ortal, generating an MM or a WM. 
Although thus far sequence data indicate a common pathway for MM and 
WM, it is not known why the progenitor cells of MM, in contrast to those in 
WM, can still make an isotype switch: in case of MM, IgM-positive 
progenitor cells with identical V H sequence to the isotype-switched cells have 
been detected in the BM [84,85]. 
Our sequence data from spontaneous murine MM, WM, and BMG did 
not show such extensive somatic mutations in the Ig VH-regions (Chapter 5). 
This does not necessarily mean that the progenitor cells of MG in the mouse 
are different from man. It has been shown that the rate of somatic mutations 
in mouse VII genes is lower, especially in old animals [86]. Furthermore, the 
gene pool that constitutes the V H-repertoire in mice is estimated to be 
approximately ten times larger as in humans [87]. Thus, old mice probably 
can rely more on their repertoire of VII genes for antigen specific Ig responses 
and thus do not necessarily employ extensive somatic mutation. Sahota et at. 
demonstrated that if significant clustering of replacement mutations was 
present in human MM cells, it was either in V H or in V L but not in both. 
Therefore, deductions concerning a role for antigen selection in any B-cell 
proliferative disorder may require both V H and V L sequences for validation 
[88]. In our study on mouse MG we did not analyze the VL sequences. 
Therefore we camlOt conclude whether the accumulation of somatic mutations 
in V genes of mouse MG indeed is smaller than in human MM. 
There is otherwise evidence from our own studies that in mouse MG 
antigenic selection occurs preceding the malignant transformation. In Chapter 
4 we mentioned that one MM and one BMG produced an H-Ig with specificity 
to the antigen used in the inununization procedure (human IgGl-)"). Together 
with previously published studies [5-7] these results show a strong relationship 
between the antigen used for immunization at young age and the development 
of specific H-Ig later in life. 
The 5T2 MM tumor produces an antibody with specificity to DNP. 
The antigenic specificity of the other 5T tumor products is unknown. In 
humans a large amount of data is available on antibody activity of myeloma 
proteins [89]. In addition, a recent study of Rettig et al. [90] showed that the 
VII gene usage in human MM is unique compared to other malignant and non-
malignant B-cell populations, and that the physiological process of clonal 
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deletion resulted in the removal of rearranged V H genes that are capable of 
expressing antibodies with anti-self specificity. Assuming that clonal deletion 
is a process that occurs only during antigen driven stages of B-cell 
differentiation, this implies that the final oncogenic event in MM occurs in a 
terminal step of plasmacytic development. This would be in accordance with 
the data of somatic mutations in human myeloma Ig. 
Studies on somatic mutations in V H-genes of MG of undetermined 
significance (MGUS) in humans demonstrated that a proportion of these B-cell 
proliferative disorders showed intraclonal variation [91], indicating that the 
clone might still be part of a dynamic process that can respond to an antigen. 
This could be a useful marker to distinguish MM from benign counterparts. 
Follow-up studies are necessary to show whether these benign clones can 
develop into malignancies. Although data on murine BMG mostly parallels the 
data on human MGUS, too few mouse BMG have been analyzed to state that 
these disorders are comparable at the molecular level. Their biological 
behaviour, however, strongly suggest similarity. 
The use of specific V H CDR3 region probes can help in the further 
identification of the progenitor cells of MG in general. Using RT-PCR 
techniques it is possible to detect small B-cell clones in different organs and to 
further characterize them and their cellular envirOllllent [39,92-94, and Dr 
Roland Gueret, personal communication]. Such sensitive techniques can reveal 
T-cell clonalities as well, with frequencies increasing with age [95-97]. A 
possible link between reduced clonal heterogeneity at the B-cell and T-cell 
level in the aging individual should be anticipated. This subject has to be 
investigated further. 
6.5 Three-stage hypothesis on the development of benign monoclonal 
gannnopathies 
At the end of this discussion we will attempt to review the hypothesis 
on the stages of development of BMG as has been postulated by Radl in 1979 
[98], and add to it new information as is described in this thesis. Radl 
suggested that the development of BMG is the result of age-related immune 
dysfunction. 
Stage 1,' During aging, the function of the cellular immune system becomes 
impaired. This is illustrated by involution of the thymus and a restricted 
repertoire of T-cell receptors in aged individuals [95] and the unbalanced 
development CD4+ and CD8+ T-cell clones [96,97]. The onset, extent and 
progress of this regulatory T-cell malfunction can be influenced by extrinsic 
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factors, such as long-term immunosuppressive treatment (chapter 4) and viral 
infections, as is seen in HIV-infected patients [72-77]. 
Stage 2: The stage-one condition has a profound effect on normal B-ce11 
responses. Excessive B-cell clonal proliferations will result after antigenic 
stimulation, due to the improper helper and suppressor T-cell functions. The 
physiological phenomenon of clonal dominance in antibody responses is now 
relatively out of control, and a monoclonal Ig product can be detected in the 
serum. Clonal dominance and its relation to genetic background and the 
development of age-related MG have been discussed in chapter 3. This second 
stage is still reversible and the MG are transient in character (category 3 MG; 
see Chapter 2.1, table 1). 
Stage 3: Repeated and prolonged mono- or oligo clonal expansions result in a 
higher probability for genomic mutation. Part of the susceptibility to this 
failure of proliferative control is genetically based. Proliferation of the clone 
has become independent from external signals, because now there is an 
intrinsic B-cell defect, as was illustrated by the transplantation experiments of 
BMG cells into congenic recipients. This third stage, BMG (category 2 MG; 
see Chapter 2.1, table 1), is irreversible. Although inhibition of proliferation 
can no longer be exerted by normal T-cell functions, the BMG progenitor 
cells probably have still an intact somatic mutation mechanism (chapter 5). It 
is not known whether this mechanism in BMG is directed by antigen. 
The development of MM and WM may involve some of the steps 
mentioned above. Certainly the intracellular defects are more complex, and 
the cells can no longer somatically mutate their Ig V-regions. As was 
suggested before, these MG probably develop directly from stage 2. 
We have not yet fit in into this hypothesis the occurrence of MG 
derived from the B-1 cell population (chapter 2). There is hardly any 
information about T-cell influences on this B-cell subset. Still, with aging the 
B-1 cell popUlation becomes restricted in heterogeneity [37]. Also antigenic 
stimuli from the gut mucosal surfaces might have an impact on the 
proliferative responses of this subset. Although transient MG and a few BMG 
of B-1 cell origin have been detected, it still has to be elucidated whether 
these B-1 cell clones can evolve into malignant MG in otherwise normal 
individuals. In humans, certain extramedullary plasmacytomas, WM, and 
BMG might be the offspring of such a B-1 cell proliferative disorder, apart 
from numerous transient MG. 
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SUMMARY 
Monoclonal gammopathies (MG) are B-cell proliferative disorders at 
the differentiation stage of a plasma cell. They often prodnce relatively large 
quantities of monoclonal or homogenous innnunogiobulins (H-Ig), that are 
detectable in the serum. This heterogenous group of monoclonal B-cell 
proliferative disorders can be classified into several categories of MG. 
Category 1 comprise the B-cell malignancies that give rise to an H-Ig. The 
most important representatives of this category are multiple myeloma (MM), 
Waldenstrom's macroglobulinemia (WM), and (extra-) medullary plasma-
cytoma. Category 2 represent B-cell benign neoplasia. This common B-cell 
proliferative disorder is also known as benign monoclonal gammopathy 
(BMG). Category 3 comprise MG due to immunodeficiency with T-cellfB-cell 
imbalance, including primary immunodeficiencies, as well as secondary, such 
as aging, viral infections, innnunosuppressive treatment, and others. Category 
4 is represented by the MG due to particular antigenic stimulation, as is seen 
. in response to certain haptens and polysaccharides, and in some autoimmune 
diseases. 
Although a large amount of clinical data is available on MG of 
neoplastic origin (categories 1 and 2), there is still not much known about the 
exact etiology of these B-cell proliferative disorders. The possible relationship 
among the different disorders, the location and stage of differentiation of the B 
cell at the time of neoplastic transformation, and the causes of this 
transformation are among the questions that asked for a suitable animal model. 
It turned out that a particularly useful mouse strain was the CS7BLlKaLwRij 
mouse. Aging mice of this strain spontaneously develop MG of all four 
categories, with characteristics that are similar to their human counterparts. 
Based on cell surface phenotype, anatomical localization, function and 
origin, B-cells in mice can be divided into two lineages: the predominantly in 
thoracal and peritoneal cavities localized B-1 cells, expressing the CD 11 b 
molecule, often in conjunction with CDS expression, and the conventional, 
bone marrow (BM) derived B-2 cells, which express neither CDS nor CDllb. 
The B-1 cells comprise a self-replenishing population that becomes 
increasingly restricted with aging of the individual. This phenomenon might 
account for a relatively high chance of neoplastic transformation within these 
cells. Therefore they form a pool of potential precursor cells of MG. 
Although CDS expression has been found on the malignant cells of B-CLL in 
humans and in certain mouse B-cell lymphomas and cell lines, no information 
was available on the lineage origin of the more mature B-cell proliferative 
disorders (BMG, WM, MM). Two experimental approaches have been used to 
investigate this latter question (Chapter 2). 
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First, a life-long follow-up study of !"K-transgenic Sp6 mice was 
started (Chapter 2.2). The innnunogiobulin (lg) transgene encoded for TNP 
specificity. Peripheral B-cells in these mice expressed exclusively the 
transgenic (Tg) IgM of I" allotype. Only a small proportion of B-cells showed 
endogenous !,b allotype expression. These B-cells possessed the B-1 cell 
phenotype and characteristics. We therefore assumed that MG arising from the 
B-1 cell population in these aging Tg mice would result in an H-Ig of 
endogenous isotype. In fact, all H-Ig that we detected in the Tg mice (one 
MM, six BMG, five transient MG, ten unclassifiable MG) were of 
endogenous origin. Consequently, these MG were of B-1 cell origin. 
Second, we used IgH allotype-congenic C57BL mouse chimeras in 
order to be able to evaluate the H-Ig that developed from the B-1 cell lineage 
separately (Chapter 2.3). The C57BL mice under investigation were lethally 
irradiated and reconstituted with BM cells and IgH allotype-congenic 
peritoneal wash cells. The cells from the peritoneal washes provided for the 
precursors of the B-1 cells, while the BM cells gave rise to the B-2 cells. The 
cell lineage origin of the H-Ig that developed at old age could thus be 
determined by Ig-allotyping of the H-Ig component in the serum. Due to late 
effects of the total body irradiation, the life-span of the chimeras was reduced 
and consequently the number of H-Ig detected in this study was less than 
expected. Determination of the IgM-allotypes of H-Ig in aged chimeras 
revealed that most of these originated from the B-1 cell popnlation. The 
experiments, presented in Chapters 2.2. and 2.3, showed that B-1 cells can be 
responsible for age-related MG in a susceptible monse strain. The MG were 
mainly of transient and benign (BMG) character, but one malignant MG of B-
I origin (an MM) was detected in a !"K-transgenic mouse. 
To elucidate the process that takes place prior to the development of a 
stable monoclonal B-cell clone, we started the experiments that are described 
in Chapter 3. We investigated the effects of age at time of immunization, 
genetic background (CBA and C57BL inbred mouse strains) and impaired T-
cell system (using neonatal thymectomy) on the levels and the heterogeneity of 
the specific antibody response to dinitrophenylated human serum albnmin 
(DNP-HSA). This heterogeneity can be envisaged as the capacity of the 
immune system to recruit the available antigen-specific clonotypes directly 
after innnunization. Using isoelectric focussing (IEF) , the specific antibodies 
can be divided into discrete bands, the so-called spectrotypes or clonotypes. 
An exaggerated response of one or a few clones could result in so-called 
clonal dominance. This clonal dominance was scarce in CBA mice, but 
frequent in C57BL mice. Age at time of immunization and neonatal 
thymectomy had little if any additive effect on the incidence of homogenous 
antibody components (H-Ab) in the sera of either mouse strain. In old C57BL 
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mice smaller amounts of specific antibodies were produced by fewer clones. 
Still, the incidence of H-Ab in this group was the same as in the group of 
young C57BL mice. This indicated that at old age the responding B-cell 
clones are more prone to become dominant clones in C57BL mice. This 
tendency correlated with the high incidence of spontaneously developing 
monoclonal gallUl10pathies in aging C57BL mice. In conclusion, clonal 
dominance in specific antibody responses appears to be a genetically 
determined trait of the B-cell compartment. Control over dominant clones is 
exerted by inillmnoregulatory factors, such as the T-cell system. Imbalances in 
this control mechanism allow for the outgrowth of dominant B-cell clones and 
precede the development of MG in mice. 
Long-term immunosuppressive treatment has been shown to increase 
the risk for the development of early B-cell malignancies, especially non-
Hodgkin lymphomas. Little is known about the late effects of maintenance 
immunosuppressive treatment (MIST) on the development of MG. This we 
studied in the C57BLlKaLwRij mouse model of MG, as is described in 
Chapter 4. Two widely used immunosuppressive treatment protocols in 
humans (azathioprine/prednisolone, and Cyclosporin A/prednisolone) were 
tested in young and adult mice. Both regimens were shown to increase ten-
fold the incidence of spontaneous MM. Transient MG reached a four to five 
times higher incidence in the mice of the inl1l1unosuppressed groups as 
compared to the mice in the PBS control groups. No differences were detected 
in the incidences of BMG. The proportion of total MG was the same in all 
groups, however, mice receiving inillmllosuppressive treatment showed an 
earlier onset of MG. This study strongly indicated that an intact T-cell system 
is required for a normal heterogenous Ig spectrum. Furthermore, a long-term 
impaired T-cell system is submissive for the development of malignant MG. 
The 5T series of mouse MM and WM that developed spontaneously in 
aging mice of the C57BLlKaLwRij strain show clinical and biological features 
that closely resemble their corresponding human diseases. In order to compare 
the patterns of somatic mutation in VII genes of these 5T tumors with those of 
human counterparts, we determined and analyzed the Ig V H sequences of five 
cases of MM, two of WM, and one of a biclonal BMG. This study is reported 
in Chapter 5. Compared to human MM and WM the degree of somatic 
mutation in the mouse tumors was significantly lower. There was no 
significant evidence of clustering of replacement mutations in CDR, a feature 
considered to be characteristic of antigen-selected sequences. However, one 
clone of the biclonal BMG case showed intraclonal variation, suggesting that 
the tumor cells may still be undergoing somatic mutation. In this respect, 
mouse BMG is similar to the human counterpart. 
The continuing search for unique identifiers of malignancy in the 
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clonal B-cells of MG and the unravelling of the mechanisms that lead to the 
malignant transformation of the B-cells is necessary for discrimination of 
benign and malignant MG at an early stage of the disease. 
SAMENVATTING 
Monoklonale gammapathieen (MG) zijn proliferatiestoornissen van B-
cellen in het differentiatiestadium van piasmacellen. Gewoonlijk produceren zij 
relatief grote hoeveelheden van een monoklonaal of homogeen inununo-
globuline (H-Ig), dat detecteerbaar is in het serum. In deze heterogene groep 
van monoclonale B-cel proliferatiestoornissen kunnen vier categorieen worden 
onderscheiden. Categorie 1 bestaat uit de B-cel maligniteiten welke een H-Ig 
produeeren. De voornaamste vertegenwoordigers uit deze eategorie zijn 
multiple myeloom (MM) , Waldenstrom's macroglobulinemie en (extra-
)medullair plasmacytoom. Categorie 2 omvat de benigne B-cel neoplasie. 
Deze veel voorkomende B-eel proliferatiestoornis wordt ook weI benigne 
monoklonale ganmlapathie (BMG) genoemd. Categorie 3 omvat de MG welke 
door immunodeficienties met T IB eel dysbalans worden veroorzaakt, waarbij 
zowel prima ire als secundaire immunodeficienties betrokken knnnen zijn. 
Secundaire immunodeficienties treden bijvoorbeeld op bij veroudering, virale 
infecties en immunosuppressieve behandeling. Categorie 4 omvat MG welke 
zijn ontstaan na een bepaalde, vaak langdurige, antigene stimulatie, zoals in 
reactie op bepaalde haptenen en polysacchariden, en in sonmlige 
autoinmluunziekten. 
Hoewel er een overweldigende hoeveelheid klinische gegevens 
beschikbaar is over MG van neoplastische origine (categorieen 1 en 2) is er 
nog steeds weinig bekend over de etiologie van deze B-cel proliferatie-
stoornissen. De mogelijke relaties tussen de diverse eategorieen MG, de 
localisatie en het differentiatiestadium van de B-cel ten tijde van de 
neoplastische transformatie, tezamen met de mogelijke oorzaken van deze 
transformatie, stimuleerde de ontwikkeling van een geschikt proefdiermodel. 
Uit eerdere studies bleek dat de C57BLlKaLwRij muis als proefdiermodel 
voor MG zeer geschikt was. Verouderende muizen van deze inteeltstam 
ontwikkelen spontaan MG van aIle vier eategorieen, met eigenschappen die 
sterk lijken op de MG die bij de mens worden gevonden. 
Op basis van het fenotype van de ceIlen, hun anatomische localisatie, 
funetie en oorsprong, knlmen B-eellen in de muis worden onderscheiden in 
twee subpopulaties: de voornamelijk in de thoracale en peritoneale holten 
gelocaliseerde B-1 eeIlen, die CD 11 b op de celmembraan tot expressie 
brengen, vaak samen met CD5 expressie, en de conventionele, uit het 
beenmerg afkomstige B-2 cellen. Deze B-2 eellen brengen CD lIb en CD5 
niet tot expressie. De B-1 eellen ontstaan uit unieke vooriopercellen in de 
peritoneale holte. Het Ig repertoire van de B-1 cel populatie wordt met het 
toenemen van de leeftijd minder divers. Daarom zouden B-1 cellen mogelijk 
een grotere kans hebben op het ondergaan van maligne transformatie en 
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potentiele voorlopereellen voor MG kunnen zijn. Hoewel CD5 expressie is 
gevonden op de maligne eellen van B-CLL in de mens en op sonuuige muize 
B-ee1 Iymfomen en eellijnen, is nog onvoldoende bekend in hoeverre de B-eel 
proliferatiestoornissen van een rijper differentiatie-stadium (MM, WM, BMG) 
uit beide B-eel lijnen kunnen voortkolllen. Twee experimentele benaderingen 
werden gekozen om dit laatste te onderzoeken (Hoofdstuk 2). 
Ten eerste werd een levenslange follow-up studie gestart van /l,K-
transgene Sp6 muizen (Hoofdstuk 2.2). Het IgM-kappa transgen van deze 
muizen codeert voor een TNP specificiteit. Perifere B-eellen in deze muizen 
brengen aileen het transgene IgM van het /l' allotype tot expressie. Sleehts een 
klein deel van de B-eellen braeht /lb tot expressie. Deze B-eellen hadden een 
B-1 eel fenotype en de daarbij behorende karakteristieken. Daarom werd 
aangenolllen dat MG, welke in deze verouderende transgene muizen uit de B-1 
eellen zouden ontstaan, een H-Ig zouden produeeren van een endogeen 
isotype. Deze studie resulteerde in de deteetie van een groot aantal H-Ig in het 
serum van de transgene muizen (1 MM, 6 BMG, 5 MG van voorbijgaande 
aard, 10 niet-klassificeerbare MG). Al deze H-Ig waren van endogene 
oorsprong en zullen daarom van de B-1 cellen afkomstig zijn geweest. 
Ten tweede werd gebruik gemaakt van IgH allotype-eongene C57BL 
ehimeren om de van de B-1 eellen afkomstige H-Ig afzonderlijk te kullllen 
deteeteren (Hoofdstuk 2.3). De muizen in deze studie werden letaal bestraald 
en gereconstitueerd met beenmergcellen en IgH allotype-eongene cellen uit 
peritoneaal spoelsel. De cellen in het peritoneaal spoelsel leverden de 
voorlopercellen voor de B-1 cellen, terwijl de beenmergcellen voorzagen in de 
B-2 cellen. De oorsprong van de H-Ig in de verouderende chimeren kon 
worden vastgesteld aan de hand van Ig-allotypering. Door late 
bestralingseffecten was de levensduur van de chimeren geredueeerd met als 
consequentie dat er minder H-Ig konden worden bestudeerd dan waren 
verwacht. Vii analyse van de IgM-allotypen van de H-Ig in de oude chimeren 
bleek dat de meeste afkomstig waren van de B-1 cellen. De in de 
hoofdstukken 2.2. en 2.3 beschreven experimenten 1aten zien dat B-1 cellen 
verantwoordelijk zijn voor een dee1 van de MG in muizen welke gevoelig zijn 
voor de ontwikkeling van deze categorie van B-eel proliferatiestoornissen. De 
MG waren voornamelijk van voorbijgaande aard of chronisch-benigne (BMG) 
van karakter; slechts een maligne MG van B-1 oOl'sprong werd gevonden (een 
MM) in een /l,K-transgene llluis. 
Om de proeessen te kunnen bestuderen die plaatsvinden voor het 
ontstaan van een stabiele lllonokionale B-ce1 kloon, werden de experimenten 
uitgevoerd zoals beschreven in hoofdstuk 3. Het effect werd bestudeerd van de 
leeftijd van de muizen ten tijde van inullunisatie, de genetische achtergrond 
(CBA en C57BL inteelt muizenstamlllen) en een verminderd functionerend T-
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cel systeem (middels neonatale thymectomie) op de concentratie en de 
heterogeniteit van de specifieke antistofvorming op DNP-HSA. Deze 
heterogeniteit kan worden voorgesteld als het vermogen van het 
inmmunsysteem om de beschikbare antigen-specifieke B-cel klonen te 
activeren direct na immunisatie. Middels de isoelectrische focussering techniek 
(IEF) konden de specifieke antistoffen worden gescheiden in een discreet 
bandenpatroon, de zogenaamde spectrotypen of klonotypen. Een 
disproportioneel grote reactie van een of enkele klonen resulteert dan in 
klonale dominantie. Deze klonale dominantie was zeldzaam in CBA muizen, 
maar frequent in CS7BL muizen. De leeftijd op het moment van immunisatie 
en neonatale thymectomie had nagenoeg geen additief effect op de incidentie 
van H-Ig in de sera van de muizen van beide stammen. In oude CS7BL 
muizen werden geringere hoeveelheden specifieke antistoffen geproduceerd 
door minder klonen. Toch was de incidentie van H-Ig in deze groep geIijk aan 
die in jonge CS7BL muizen. Dit duidt erop dat oude CS7BL muizen een 
grotere nelgmg hebben tot klonale dominantie in de specifieke 
antistofvorming. Deze tendens correleerde met de hoge incidentie van MG in 
verouderende CS7BL muizen. Concluderend kan worden gesteld dat klonale 
dominantie in de specifieke antistofvorming een genetisch bepaald kenmerk 
van B-cellen Iijkt te zijn. Controle op deze dominante klonen wordt 
uitgeoefend door inul1unoregulatoire systemen, zoals het T-cel systeem. 
Verstoringen in dit controlesysteem kunnen ervoor zorgen dat dominante B-cel 
klonen kUlmen uitgroeien tot grotere klonen, een stadium dat voorafgaat aan 
het ontstaan van MG in muizen. 
Langdurige inul1unosuppressieve therapieen verhogen het risico op B-
cel maligniteiten, met name van non-Hodgkin Iymfomen. Slechts weinig is 
bekend over de late effekten van immunosuppressieve onderhoudstherapieen 
op het ontstaan van MG. In hoofdstuk 4 werden twee veelgebruikte inununo-
suppressieve behandelprotocollen, azathioprinefprednisolon en Cyclosporine 
Afprednisolon, bestudeerd in zowel jonge als oude CS7BLIKaLwRij muizen. 
Beide behandelmethoden verhoogden de incidentie van MM tienvoudig. MG 
van voorbijgaande aard bereikten een vier tot vijf maal hogere incidentie in de 
behandelde groepen ten opzichte van de PBS controle groep. Er werden geen 
verschillen gevonden in de incidenties van BMG. De incidentie van MG was 
ongeveer gelijk voor de verschillende behandelde groepen en de 
controlegroep, maar de muizen in de behandelde groepen Iieten eerder een 
toename zien van MG. De resultaten van deze studie benadrukken dat een 
intact T -cel systeem noodzakeIijk is voor een normaal heterogeen Ig spectrum 
en dat een langdurig, c.q. levenslang, verminderd functionerend T-cel systeem 
predisponerend werkt voor het ontstaan van maligne MG. 
De ST muize MM en WM, welke spontaan ontstaan in verouderende 
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C57BLIKaLwRij muizen, hebben klinische en biologische kenmerken die sterk 
lijken op de corresponderende humane ziekten. Om de patronen van 
somatische mutaties in de V H genen van deze 5T-tumoren te vergelijken met 
die van de analoge afwijkingen bij de mens, werden de Ig V H sequenties 
bepaald en geanalyseerd van 5 MM, van 2 WM, en van 1 biklonale BMG. Dit 
werd beschreven in hoofdstuk 5. Vergeleken met humane MM en WM is de 
mate van somatische mutatie in de muize MM en WM significant geringer. Er 
waren geen duidelijke aanwijzingen voor de groepering van aminozuur 
volgordeveranderende mutaties in de zogeheten "complementarity-determining 
regions" (CDR). Zo'n groepering wordt beschouwd als een karakteristiek van 
antigen-geselecteerde sequenties. Echter, in een kloon van de biklonale BMG 
bleek intraklonale variatie aannemelijk, hetgeen suggereert dat de tumorcellen 
nog onder de invloed van het somatische mutatiemechanisme stonden. Wat dit 
betreft lijkt de muize BMG erg op de humane analoge B-cel proliferatie-
stoornis. 
Verder onderzoek naar unieke kemnerken van maligniteit in de klonale 
B-cellen van MG en het ontrafelen van de mechanismen die lei den tot de 
maligne transfortnatie van de B-cellen is noodzakelijk voor het onderscheiden 
van benigne en maligne MG in een vroeg stadium van de ziekte. 
ABL 
ADIBA 
Ag 
AP 
B-ALL 
B-CLL 
BM 
BMG 
BSA 
BSS 
C-region 
CDR 
CsA 
DAB 
D" 
DNP 
EBV 
FCCL 
FR 
GALT 
GaM 
H-Ab 
H-chaill 
HS 
HSA 
H-Ig 
HIV 
IEF 
Ig 
IgH 
IP 
I" 
Il-
L-chain 
LL 
LM 
LPS 
MALT 
M-Ig 
MIST 
MG 
MGUS 
MM 
MR 
NHL 
ABBREVIATIONS 
antigen-specific immunoblotting 
antigen-specific dot-immunobinding assay 
antigen 
alkaline phosphatase 
B-cell acute lymphocytic leukemia 
B-cell chronic lymphocytic leukemia 
bone marrow 
benign monoclonal gammopathy 
bovine serum albumin 
balanced salt solution 
constant region of the immunoglobulin molecule 
complementarity determining region(s) 
Cyclosporin A 
3,3' -diaminobenzidine telrahydrochloride 
D gene segment of the immunoglobulin heavy chain gene cluster 
dinitrophenyl 
Epstein-BaiT virus 
follicular center cell lymphoma 
framework region(s) 
gut-associated lymphoid tissue 
goat anti-mouse 
homogenous antibody 
heavy chain of the immunoglobulin molecule 
histiocytic sarcoma 
human serllm albumin 
homogenolls immunoglobulin component(s) 
human immunodeficiency virus 
isoelectric focussing 
immunoglobulin 
immunoglobulin heavy chain 
idiopathic paraproteinemia 
J gene segment of the immunoglobulin heavy chain gene cluster 
J gene segment of the immunoglobulin light chain gene cluster 
light chain of the immunoglobulin molecule 
lymphoblastic lymphoma 
liuermate 
lipopolysaccharide 
mucosa-associated lymphoid tissue 
monoclonal immunoglobulin component(s) 
maintenance immunosuppressive treatment 
monoclonal gammopathies 
monoclonal gammopathy of undetermined significance 
multiple myeloma 
multi reactive immunoglobulin 
non-Hodgkin lymphoma 
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NMS 
NTx 
PB 
PBS 
PCR 
PerC 
PMA 
PO 
PVDF 
scm 
ShaM 
STAT3 
T 
TBI 
Tg 
TNP 
VH 
VL 
W 
WABL 
WM 
Abbreviations 
normal mouse serum 
neonatal thymectomy 
peripheral blood 
phosphate-buffered saline 
polymerase chain reaction 
peritoneal cavity 
phorbolmyristateacetate 
peroxidase 
polyvinylidcne difluoride 
severe combined immunodeticiency 
sheep anti-mouse 
signal transducer and activator of transcription-3 
Tween-20 
total body irradiation 
transgenic 
2,3,6-trinitrophenyl 
variable part of Ig heavy chain 
variable part of Ig light chain 
Wieme agar-electrophoresis 
Wieme agar-electrophoresis and antigen specific immunoblotting 
Waldenstrom's macroglobulinemia 
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einde te brengen. Mijn dankbaarheid betreft niet aileen het bereiken van het 
eindresultaat in de vonn van dit proefschrift, maar juist ook aile 
(leer)ervaringen die niet in de voorafgaande delen van dit boekje verwoord 
konden worden. 
Pleunie van den Berg was een van de doorgewinterde ana listen die mij 
de weg leerde in het laboratorinm. Zij werkte het langst van aile analisten aan 
de monoklonale gannnapathieen in mens en dier. Helaas kan zij dit laatste 
proefschrift in de Radl-cyclus over MG niet meer lezen: zij overleed vlak na 
haar pensionering. 
Vanaf het eerste uur waren ook Lia Nottelman-Hoogeveen en Frank 
Hopstaken de peilers van ons kleine groepje. Naast jullie getrouwe en 
goedgehumeurde inzet voor de analyse van de honderden sera waren jullie 
mijn leermeesters in het laboratorium en, niet te vergeten, de levende 
databanken in het labyrint van ongezuiverde antisera, gezuiverde antilichamen, 
conjugaten, ingevroren cellen, en sepharosekolommen. Frank was daarbij de 
absolute muizemeester in Leiden en later de ELISA expert. Wat hebben we 
getobt met de standaarden! Heel veel dank voor je geduld en voor je 
Brabantse gezelligheid. 
Vanaf het begin was het duidelijk dat een groot deel van het werk 
verricht moest worden op het terrein van de proefdierpathologie. Willem, 
Herman, Frits, Erik, en Plonie: jullie hulp en goede raad zal ik nooit 
vergeten. Helaas konden door pijnlijke reorganisaties tal van plannen geen 
dOOl'gang vinden en moest ik ook jullie (hulp) uiteindelijk missen. Via een 
omweg kon Plonie gelukkig nog het sectiemateriaal bewerken van de Sp6-
muizen. Dit kostbare materiaal is daarom niet verloren gegaan. Dank je wei 
voor je bereidwilligheid, en dank ook aan de Afdeling Klinische Pathologie 
van het St. Fransiscus Gasthuis te Rotterdam. De coupes werden nauwgezet 
beoordeeld door dr Chris Zurcher. Chris, we hadden het ons allemaal anders 
voorgesteld, maar je hebt er toch nog heel wat informatie uit kUllllen slepen. 
Dank je wei voor je inspamlingen. 
Een bijzander avontuur was het cohort transgene Sp6-muizen, dat 
gefokt en gehuisvest was in Groningen. De geruchten als zau het een 
Mycoplasma besmette muizenpopulatie betreffen, zargden ervoor dat ik 
regelmatig de trein naar Groningen moest nemen voor het opzetten van het 
experiment en voor het 'tappen' van de luuizen in de follow-up periode. Toch 
waren deze reisjes alleszins de moeite waard. Bij dr Nico Bos en dr Frans 
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Kroese yond ik steeds luisterende oren en frisse ideeen. Had ik maar meer van 
jullie knowhow gebruik gemaakt. In die zin was het jammer dat de muizen 
uiteindelijk in Rotterdam geplaatst werden. Dank voor jullie gastvrijheid! 
Voor de transgene muizen werd het echter niet slechter. Gehuisvest in 
de isolatoren, verstopt in de catacomb en onder het ThoraxcentlUm van het 
AZR, werden zij vertroeteld door Helen Kok. We hebben daar heel wat tijd 
doorgebracht om uit te vinden hoe het allemaal zou moeten: de verzorging, 
het tappen en noem maar op. Je annen waren eigenlijk te kort om overal goed 
bij te komen, maar je motivatie zorgde dat alles tot in de puntjes geregeld 
werd en je dierenliefde zorgde ervoor dat niets zich aan je oog onttrekken 
kon. Helen, dank je weI voor je vrolijke en onbaatzuchtige inspanningen! 
Elders in de medische faculteit, op de Afdeling Immunologie, regeerde 
de ongekroonde koning van de dierenverzorgers: Joop Brandenburg. Joop, 
wat jammer dat je zo vaak gelijk had Ge begrijpt weI wat ik bedoel) en wat 
fijn dat je me de dingen leerde die noodzakelijk zijn voar het verantwoord 
kunnen uitvoeren van een dierproef. De tegenslagen bij mijn proeven waren 
zeker groter geweest als jij niet steeds beschikbaar was geweest en tot raad en 
daad bereid was. Dank je weI, Joop! 
Acllteraf is het niet goed mogelijk uit te leggen welk een ongelofelijke 
hoeveelheid werk het is geweest om de chimeercohorten tot stand te brengen. 
Miranda Baert was mij hierbij zeer behulpzaam en samen vervolmaakten we 
de kunst van het 'buikspoelen' bij muizen en het transplanteren van de 
gelsoleerde cellen. Ook de andere medewerkers van het lab van Huub 
Savelkoul waren steeds tot hulp bereid. Ik dank Huub voor zijn niIruner 
aflatende gastvrijheid en bereidwilligheid tot het geven van goede raad. 
1 never forget the hospitality of Prof. dr Freda Stevenson and all her 
cO-lVorkers of the Molecular Ill1Il1unology Group at the Tenovus Laboratory, 
Southampton University Hospitals. It has been a priceless experience to be 
able to work in a lab that has accomplished important results in the field of B-
cell proliferative disorders. With the help of dr DeliIl Zhu 1 was able to 
continue the work at Leiden. Apart from the many lessons on molecular 
biology of the Ig genes, my stay in Southampton was also a brief introduction 
into the history of the southern part of the UK. But I still don't understand 
cricket ... 
De ingrijpende reorganisatie van het gezondheidsonderzoek van TNO 
resulteerde in een weI heel plotselinge en grote uitbreiding van het aantal 
collega's. Naast de wetenschappelijke verbreding die dit veroorzaakte, bracht 
het een van levensbelang zijnde gezelligheid en collegialiteit. Belangrijke 
hoogtepunten voor mij waren met name het Eerste Retraite-team (met Marc, 
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Margret, Frank, MaIjan), de Brabantse borrels (met Frans, Frank, Margret), 
de bijna wekelijkse borrels (met iedereen), de Glazenwassers (met Marc en 
Jeffrey en een enkele golfspeler), de Kitty-curves (enkel begrepen door Kitty), 
de Duvel (in de vriendelijke gedaante van Kitty), de klimavonturen (met Stip 
als Jane), het alomtegenwoordige a-B-crystalline (met Arianne, Stip, Hans, 
Jeffrey, en opeens ook Sacha, en eigenlijk iedereen), de biodetectiestripjes en 
enge virus sen (met Hans, Ernst, Netty), interleukines uit aile cellen die willen 
groeien (Lex, Margret, Jeroen, Bep, Sandra, Anette), mondige stagiaires 
(Christa en Sacha), de buurvrouw (Mar lies) , protocollen, bestellingen, ISO-
9001, SJL muizen (met Carla, Louis, Marc, 2x Gerrit), de Lactobacillen-
meisjes (Marie-Joan, Chantal, Conny, Kitty), even FACSen (Margret, Frans), 
de reddende engelen bij de fax (Finka en Karin), de vertrouwenscommissie 
(zodat Marc het aan Jon kon vertellen en vice versa). Dat dit stel zonderlingen 
zich vaak moeizaam liet leiden zal dr Cees Lucas kmmen beamen. Dank je 
weI dat ik in deze kweekvijver van jonge wetenschappers mocht mee-
zwemmen. Het was helaas voor mij van korte duur dat dr Wim Boersma zich 
met mijn project kon bemoeien. Maar in die korte tijd heeft hij mij opnieuw 
kunnen motiveren tot wat uiteindelijk de eindsprint kon WOrdell. Wim, dank je 
weI voor je bemoedigende persoonlijklleid. 
De oOl'sprong van dit project, van proefschrift en aio-schap samen, lag 
in het vertrouwen van Prof. dr Rob Benner. Zonder zijn praktische kijk op het 
uitvoeren en beoefenen van onderzoek was het onmogelijk geweest dit project 
tot een goed einde te brengen. Beste Rob, de afstand Leiden-Rotterdam heb je 
door je betrokkenheid altijd klein knnnen houden. Dank je voor je 
vertrouwen. 
Het meeste dank ik dr Jirka Rad!. Hij was degene die mij inwijdde in 
het vakgebied en mij met zijn onschatbare hoeveelheid kennis en ervaring 
steeds terzijde stond. Beste Jirka, ik zou nog zoveel van je willen leren. Dank 
je weI voor je vaderlijke bijstand bij de vele tegenslagen, voor je 
voorzichtigheid en zuiverheid bij de interpretaties van resultaten, en voor de 
aansporingen om vooral vol te houden. 
Twee van mijn Noodlottige vrienden, en mede-promovendi, zijn mijn 
paranimfen. Nick en Ralph, wij schrijven historie, vooral ook buiten onze 
boekjes. De relativiteit van het al geldt niet voor onze lijfspreuk: Sapere aude. 
Tot slot, lieve Marjanne, deze egojstische periode is nu achter de rug, 
ook omdat jij van volhouden wist. Dank je voor je onbegrip (als ik liever wat 
anders deed dan wetenschap). Onze volgende avonturen zullen we samen 
kiezen. 
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